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Abstract 
Gene therapy is a promising tool in the treatment of genetic disorders. Viral vectors 
have a natural ability to genetically alter cells, however, concern over their immunogenic 
and mutagenic effects has led to the development of safer non-viral alternatives, such as 
ultrasound and microbubble mediated gene transfection (UMGT). UMGT causes cellular 
bioeffects leading to uptake of genetic material; however transfection efficiencies in vivo are 
poor. It was the aim of this project to investigate key factors that affect UMGT in vivo. A 
Model Protocol was created with techniques capable of characterising the acoustic 
response and stability of microbubbles, as well as their population statistics and ability to 
transfect the heart of six to eight week old, CD1, female mice with a luciferase plasmid. This 
was used to investigate the effect of needle gauge and microbubble formulation on 
transfection. 
It was found that the needle gauge used to systemically deliver SonoVue 
microbubbles affected microbubble number and transfection. 29G needles caused a 
decrease in microbubble concentration and transfection, whilst 25G needles caused no 
microbubble destruction and resulted in significantly greater transfection. 
Albumin microbubbles are more effective than lipid microbubbles at transfection, 
but are not optimised. It was found that altering the dextrose and albumin content of an 
albumin microbubble affected their acoustic and transfection properties. A link between the 
attenuation behaviour of a microbubble and its transfection efficiency was found, 
suggesting that optimising acoustic behaviour could improve transfection. 
DNA-loaded, cationic lipid microbubbles have shown greater transfection ability than 
neutral microbubbles due to co-localisation of DNA at the site of microbubble activation. 
Albumin microbubbles have not been fully investigated for this effect. A novel, potentially 
safe, microbubble formulation was created and fluorescence techniques used to 
demonstrate its loading capability. 
This project has identified needle gauge and microbubble acoustic behaviour as key 
factors affecting the effectiveness of UMGT.  
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1. Introduction 
In this chapter, a background on gene therapy is given, with a focus on the non-viral 
techniques. Ultrasound is then covered in both history and basic physics, along with 
ultrasound contrast agents. The current uses of ultrasound contrast agents are discussed in 
both imaging and therapy. Key microbubbles parameters that affect their transfection 
efficiency are discussed. The hypothesis and aims of this project are then stated. An overview 
of the following chapters is presented at the end of this chapter. 
 
1.1. Gene therapy 
Gene therapy is the treatment of a hereditary or acquired genetic disease by the 
delivery of therapeutic DNA. In many cases, these diseases cause lifelong complications and 
have high mortality rates. A recent report by Macmillan Cancer Support[1] highlighted that, 
although in general cancer survival has increased six fold since the 1970s, certain cancers 
still have a median survival time after diagnosis of less than a year. The same is found for 
hereditary diseases, such as Duchenne Muscular Dystrophy[2] and Cystic Fibrosis[3]; life 
expectancy has improved but is still low. There is great need for new clinical tools for the 
treatment of these diseases. Gene therapy is a particularly attractive tool in that it has the 
potential to not just treat the symptoms, but also cure the underlying pathology. 
Viral vectors have been used in pre-clinical and clinical gene therapy trials to 
investigate the possibility of treating a number of acquired or hereditary disorders for over 
20 years[4-8]. Viruses are effective transduction agents against mammalian cells and can be 
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modified to carry therapeutic DNA to a variety of target cells. However, there are potentially 
severe immunological and oncogenic side effects associated with viral vectors which have 
hampered development in the field. The first such serious adverse event occurred in 1999, 
when a patient in a clinical gene therapy safety trial suffered a fatal immunological response 
to the adenovirus used[9, 10]. 
A further clinical trial in 2000 was aimed at treating X-linked severe combined 
immunodeficiency (X-SCID)[11]. Mutations in the interleukin 2 receptor gamma gene (IL2RG) 
results in absent or non-functional common gamma chain protein[12], which is a common 
subunit of many interleukin receptors[13]. Loss of the common gamma chain protein leads to 
a lack of growth and differentiation of lymphocytes resulting in a deficient immune system. 
Sufferers rarely survive beyond the first years of life due to recurrent infections, with 
treatment limited to bone marrow transplants. This trial demonstrated the potential of gene 
therapy by successfully curing three young children afflicted with the disease[11]. The 
treatment was then used in further X-SCID patients, successfully treating 10 out of 11 
children, however problems then arose. In 2002, the group involved reported that patients 
under treatment had developed a leukaemia-like disease[14, 15].  By 2011, four of the original 
patients have developed leukaemia, linked to either the overexpression of IL2RG[16, 17] or 
insertional mutagenesis of oncogene LMO2 regulatory elements[14, 18, 19]. 
Viral gene therapy is still on-going with several new successes being reported, in the 
treatment of cancer[20], inherited retinal disease[21] and HIV[22]. However, the potential 
issues have led to increased interest in the safer non-viral vectors, such as plasmid DNA. 
These are well-tolerated by host organisms and cause no induction of the immune 
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response[23]. Additionally, plasmids are incapable of actively integrating with the genome, 
reducing the chance of insertional mutagenesis.  
However, expression from plasmid DNA is generally transient, due in part to its 
bacterial origin[24, 25]. Therapeutic or reporter plasmids are typically modified forms of 
bacterial versions. Additionally, the simplest and most cost effective method for producing a 
high number of plasmids is by bacterial cloning. This requires bacterial genomic elements, 
such as the replication origin, and some form of selection factor, typically a bacteria-derived 
antibiotic resistance. Bacterial, fungal and viral DNA typically contains unmethylated 
cytosine-guanine dinucleotide (CpG) sites[26, 27]. These motifs are recognised by Toll-Like 
Receptor 9 (TLR 9) leading to methylation of the cytosine. Methylation of CpG sites is 
typically used in mammals to silence gene expression[28, 29].  
Plasmids can be modified to remove CpG sites and reduce the prevalence of other 
bacterial elements. This improves the expression transience but expression time is still 
limited by cell division “diluting” the plasmid load and eventual destruction of the plasmid 
by intracellular nucleases[24, 30]. This can be combated by construction of episomal plasmids, 
which contain eukaryotic genomic elements allowing their replication and persistence inside 
the nucleus of a transfected cell[30-32]. These changes can however, complicate the 
production of a sufficiently high number of plasmid copies for effective transfection[25, 33].  
Despite these improvements, plasmid DNA has a poor transfection performance, as 
mammalian cells are not designed to facilitate the entry of foreign DNA. Early studies 
demonstrated that DNA can be simply transfected in target tissues by direct injection, 
however, this gives variable results with generally poor transfection[34-37]. Additionally, 
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plasmid DNA can only effectively transfect actively dividing cells as passage to the nucleus, 
the site of transcription, is hindered by the nuclear envelope outside of mitosis. Further 
techniques are therefore required to effectively transfect a cell with plasmid DNA. These 
work by either permeabilising the cell membrane, or, transporting the DNA molecule across 
the cell membrane, or a combination of the two. The techniques fall into two major 
categories, Chemical or Physical. 
 
1.1.1. Chemical Techniques 
The earliest chemical techniques to enhance uptake of genetic material in bacterial 
cells were demonstrated in the 1970s[38, 39] and improved upon in the 80s[40]. Incubation of 
Escherichia coli with a cold calcium chloride solution, followed by a short heat shock, can 
result in plasmid entry. This process, technically called transformation, is commonly used to 
create bacterial strains containing desirable plasmids or DNA.  
A similar process can be performed for eukaryotic cells using calcium phosphate[41]. 
This can bind up DNA and be taken up by cells; however, transfection is poor and limited to 
tissue cultures. For in vivo purposes, more sophisticated chemicals are required. One of the 
key group of chemicals used for transfection are the cationic polymers[42]. These positively 
charged molecules electrostatically interact with DNA, neutralising the negative phosphate 
charges on its sugar backbone. This causes condensation of the DNA to a nanoparticle, 
allowing easier transit across the membrane, typically by endocytosis[43]. The complex must 
then escape the endocytic vesicle before it is trafficked to the nucleus. Polyethylenimine 
(PEI) is a commonly used cationic polymer. In 1995, Boussif demonstrated that PEI could be 
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used to transfect a variety of tissue cell lines and be used to transfect cells in vivo by direct 
injection[44]. PEI is a heavily protonated branched molecular capable of condensing DNA and 
has a strong buffering ability vital in escape from the endocytic vesicle after endocytosis[45]. 
However, PEI is very cytotoxic, causing both cell and mitochondrial membrane damage 
which has hindered its use[46]. A less toxic cationic polymer is chitosan composed of 
repeating units of D-glucosamine and N-acetyl-D-glucosamine and produced by 
deacetylation of chitin – the primary component of the exoskeletons of arthropods and 
found in the cell walls of fungi. It has low cytotoxicity, low immunogenicity and is 
biodegradable; however the transfection efficiency is worse than PEI[47-49]. Improvements to 
the chitosan molecule have involved grafting it to PEI, to combine the best of both 
molecules, with encouraging results[49].  
Despite improvements, cationic polymers have yet to make it to clinical relevance. 
There are few clinical trials for cationic polymer gene therapy, including a PEI based trial for 
the treatment of pancreatic ductal adenocarcinoma and a cyclodextran based trial for the 
treatment of solid tumours (information from www.clinicaltrials.gov). Instead, the focus has 
been on the related cationic lipids[50]. These consist of a positively charged head group, 
typically of an amine group based design, which, like the polymers, can electrostatically bind 
to DNA. Unlike the polymers, cationic lipids also contain a hydrophobic tail region which 
causes the lipids to assemble into liposomes (Fig. 1.1). These liposomes can protect their 
internal contents from potential attacks from nucleases in vivo and deposit bound DNA into 
the target cell’s cytosol by fusing with the cell membrane. Research has gone into improving 
the head groups DNA loading efficiency[51-53] and the fusogenicity of the liposome[54, 55]. 
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Liposomes can also be loaded with targeting molecules and peptides to improve localisation 
to specific tissue types[56, 57]. 
Unlike the polymers, cationic lipids have found themselves the subject of several 
clinical trials, for instance in the treatment of cystic fibrosis and cancer[58-62], however 
expression levels have generally been poor and transient. Other chemical techniques can 
include directly conjugating the therapeutic DNA to a lipid, polymer or other nanoparticle[63, 
64]. In these cases, the therapeutic DNA tends to be oligonucleotides or siRNAs rather than 
full plasmids and the lipids or polymers used can be modified to provide targeting, for 
instance, galactose targeting of hepatocytes[65]. These show promise but have yet to be used 
clinically. 
 
 
Figure 1.1. Self-assembly of lipids to form liposomes. Lipids are shown in blue with a 
hydrophilic head (circle) and a hydrophobic tail (lines). Water is shown as red (oxygen) and 
green (hydrogen) circles. 
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1.1.2. Physical Techniques 
Whereas chemical techniques tend to focus on transport of the genetic product over 
the membrane, physical techniques are based primarily on disruption of the membrane 
allowing internalisation of the genetic product. One of the most popular and effective 
techniques is electroporation, sometimes referred to as gene electrotransfer. When short 
pulses of electricity are applied to cells, the charge difference across the membrane is 
altered leading to instability, pore formation and an increase in permeability. Any molecules 
near or attached to the cell membrane can then enter the cells, including drugs and genetic 
materials[35, 66, 67]. The electric field can also have an electrophoretic effect on charged 
molecules like DNA, bringing them close into contact with the cells and potentially 
improving trafficking to the nucleus[68]. Whilst commonly used in vitro on difficult to 
transfect cell types, it has also found use in vivo for a number of tissue types[69-72]. One area 
of particular interest is the transfection of skeletal muscle fibres, particularly for DNA 
vaccination[73, 74]. Muscle fibres do not divide over an individual’s lifetime, allowing 
persistent expression of a delivered genetic product. Electroporation has already been used 
for clinical trials into cancer[75] and DNA vaccination[76]. Electroporation did historically have 
issues with resultant tissue damage[66] and targeting tissues non-proximal to the surface of 
the organism, however new electrode designs and pulse sequences have made these less of 
a concern[72]. 
Other physical techniques used in vivo include laser or optical transfection and 
hydrodynamic delivery. Laser transfection uses a highly focused beam of optical light to 
create pores in cell membranes[77]. It is not typically used in vivo due to the highly focused 
beam and limited penetration of laser energy into organisms, however the effect can be 
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enhanced by using absorbers of laser energy which themselves can permeabilise 
membranes by acoustic emission[78]. For hydrodynamic delivery, a large volume of liquid 
containing the therapeutic agent is rapidly administered, effectively flooding the tissue with 
agent. The pressure and high concentration of the agent leads to uptake. The technique is 
very effective in certain organs, particularly the liver in mice models[79, 80], however other 
organs require more invasive procedures and clinical application may be limited[81, 82]. 
The non-viral transfection technique in use in this project is ultrasound and 
microbubble mediated gene transfection (UMGT). Microbubbles oscillation under the 
influence by ultrasound causes transient bioeffects in surrounding tissues, including 
permeabilisation of the blood vessel and individual cell membranes[83, 84]. It has been shown 
that any co-delivered genetic product transfects cells in the treated area but with limited 
uptake outside of it[85-87]. The transfection can also be focused at different tissues at 
different depths by altering the ultrasound settings[86-90]. The ability to target transfection to 
specific sites combined with only transient damage makes this an attractive non-viral gene 
therapy technique[91, 92]. However, transfection efficiencies still compare unfavourably with 
other therapy techniques, requiring further optimisation before it reaches clinical 
significance[70, 93, 94]. 
 
1.1.3. Transfection Efficiency 
A commonly used indicator for the success of a gene therapy technique is its 
transfection efficiency; however there is confusion in the term’s exact meaning. For in vitro 
work, transfection efficiency is simply defined as the percentage of positively transfected 
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cells compared to total cell count[95, 96]. A similar approach can be used for in vivo work if the 
transfected cells can be identified, e.g. by histology, and is typically performed per organ, 
rather than total organism[89, 97]. Bioluminescence approaches are not typically treated in 
this way without further labelling to identify the transfected cells, for example a fusion GFP-
luciferase protein[98].  
Transfection efficiency also has a looser meaning to indicate transfection success[94, 
99-101]. For instance, if a particular cationic liposome formulation causes an increase in the 
expression of a reporter gene compared to another formulation, this could be described as 
having a higher transfection efficiency. It should be noted that without histological analysis, 
it is difficult to know whether this is due to an increase in transfected area, an increase in 
drug uptake, or both. In this project, where transfection efficiency is mentioned, it is this 
qualitative meaning that has been used throughout. 
While useful as a guide, defining the transfection efficiency for gene therapy 
techniques is complicated. The parameters, target, and therapeutic agent have a strong 
effect on the resultant transfection. For instance, Molnar et al. investigated a number of 
different factors affecting the transfection efficiency of electroporation of a β-galactosidase 
encoding plasmid into the tibialis anterior (TA) muscle[102]. The study demonstrated that the 
electroporation factors, the mouse strain, the mouse age, pre-treatment with pro-
permeabilisation agents and plasmid size all had a significant effect on the levels of 
transfection efficiency, defined in their work as β-galactosidase positive muscle fibres per 
muscle.  
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From their study, for CD1 mice, using the pCBLacZ plasmid, pre-treatment with 0.4 
U/µL hyaluronidase and optimal electroporation settings with a pad surface electrode (8 
pulses, 20 ms pulse length, 1 s pulse intervals, 175 V/cm), a transfection efficiency of 1600 
β-galactosidase positive fibres per muscle was achieved. A similar study by Donà et al. also 
focused on electroporating the TA muscle of CD1 mice with a β-galactosidase reporter 
plasmid. Using the pCMV-β-gal plasmid, no hyaluronidase pre-treatment and optimal 
electroporation settings with spatula like electrodes (5 pulses, 20 ms pulse length, 200 ms 
pulse interval, 50 V/cm), yielded a ~75% transfection efficiency, defined by positively 
transfected fibres per total muscle fibres[103]. Interestingly, the Donà et al. paper measured 
approximately 1000 fibres per muscle, suggesting that a 75% transfection efficiency would 
be 750 positively transfected fibres per muscle. Even between relatively similar studies, 
there are differences in reported values due to methodological differences. As such, 
calculating the transfection efficiency for a technique is useful for a research group to 
determine how their techniques compare across the field and to chart improvements in 
their own methodology, however it is impractical and inaccurate to define a transfection for 
an entire field without consideration to each individual method. The example given here has 
been electroporation however similar considerations exist across all gene therapy 
techniques. 
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1.2. Ultrasound 
1.2.1. History 
Medical diagnostic ultrasound began with the work of Dr Karl Dussik in Austria. In 
the late 1930s and early 40s he attempted to use cranial ultrasound to detect brain 
tumours. While technically unsuccessful due to misinterpretation of the strong attenuation 
and reflection patterns found in cranial ultrasonography, the potential of the ultrasound 
was recognised. In 1942, the first abdominal ultrasound was used by Dr George Lewig at the 
University of Pennsylvania, to diagnose gallstones in the gallbladder, and later on, worked 
on the diagnosis of kidney stones with ultrasound. Over the two decades, a number of 
different groups around the world developed practical applications and improved 
technology. One notable early pioneer of the field was Professor Ian Donald in Scotland, 
who refined the technology for obstetrics and gynaecology and published one of the most 
famous papers in the field (information taken from a history on Ultrasound by Dr Joseph 
Woo)[104, 105]. 
In the decades that followed, progress in the development of electronics and 
microchips rapidly advanced the technology leading to its commercial exploitation. New 
applications and techniques for image analysis were developed leading to widespread 
uptake of ultrasound as a vital tool for medical imaging. After over 40 years of use, its safety 
profile when used appropriately is exemplary[106-108]. Its low cost, portability, real time 
imaging, high spatial resolution and well characterised safety make medical ultrasound an 
attractive option for any diagnostic imaging work, with over 8.5 million ultrasound scans 
performed in England over the year 2010-2011 (information taken from Department of 
Health, KH12 data, published 10th August 2011). 
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1.2.2. Basic Physics 
Medical ultrasound works on the principle of generating high frequency sound 
waves in the 1-20 MHz range by electrical stimulation of piezoelectric crystals in a 
transducer. The waves cause oscillation of particles, creating areas of high and low pressure. 
These waves reflect back off objects or boundaries caused by changes in density or 
elasticity. In organisms, these changes occur at tissue boundaries, allowing non-invasive, 
internal visualisation of the body at the scanned section[107]. Tissues under ultrasound 
stimulation can also oscillate with the pressure waves creating harmonics of the original 
frequency. While single element transducers can be used to develop an ultrasonic image 
from the reflection information, diagnostic ultrasound machines use arrays of elements to 
detect and analyse the returned echoes to construct spatial images, producing the 
characteristic B-mode scan image of ultrasound. These array transducers allow adaptive 
focusing of the ultrasound by staggered emission maximising the resolution at specific 
depths, and also can give rise to more complex beam formation for specific techniques, such 
as power or colour Doppler which can be used to measure blood flow[109, 110]. 
 
1.2.3. Limitations 
A limitation of ultrasound is that of attenuation or energy loss which limits how deep 
within a tissue an ultrasound wave can propagate and return with meaningful signal. 
Increasing frequency increases the resolution but also attenuation, resulting in a trade-off 
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between resolution and depth. Increasing the amplitude can compensate but leads to more 
energy deposition within tissues potentially leading to tissue damage[111], particularly at 
tissue-bone boundaries[112]. Tissue-bone boundaries effectively halt the continued 
propagation of an ultrasound wave, leading to poor imaging of bone-encapsulated tissues 
such as the brain. The thoracic cavity is also complicated to image due to the ribs and the 
presence of the lungs. The lungs contain air which, like bone, creates a large impedance 
mismatch resulting in strong reflection of the wave. The same applies for the gut, which 
contains swallowed air and metabolic waste gas released from gut flora. Additionally, 
mechanical cavitation of these gas bubbles can occur at sufficient negative pressures and 
wave duration, leading to cellular damage by shear forces, high temperatures, high 
pressures and free radicals[111, 113]. To prevent users from exceeding the pressures required 
to cause thermal or mechanical damage, two safety indices have been defined; the Thermal 
Index (TI) and the Mechanical Index (MI). The TI is concerned with the energy absorption of 
tissues and heat generation while the MI is concerned with mechanical and cavitation 
effects of ultrasound. There are also a number of image artefacts in ultrasound imaging 
which must be understood by the user to ensure their appropriate diagnostic value[114]. A 
diagnostic ultrasound machine arguably provides the user with a greater amount of control 
over the final image than other medical imaging modalities. As such, users of 
ultrasonography require a greater amount of training for effective imaging and knowledge 
of the underlying physics is an advantage. 
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1.3. Ultrasound Contrast Agents 
A limitation in many forms of medical imaging is the similarity in structure of 
different tissues and certain disease states. For ultrasound, this similarity lies in the acoustic 
impedance for different tissues. As ultrasound relies on impedance mismatch for imaging 
purposes, identifying tissues or, more importantly, features of the tissue can be challenging. 
To improve the difference between tissues and features, contrast agents are commonly 
used. In Magnetic Resonance Imaging, these consist of paramagnetic particles like 
gadolinium, whereas X-ray contrast is provided by iodine or barium depending upon imaging 
regime. Ultrasound contrast agents (UCAs) are suspensions of gas microbubbles delivered 
systemically, which create a large impedance mismatch between blood and tissue.  
 
1.3.1. History 
The first commercial ultrasound contrast agent was Echovist, developed in 1982 by 
Schering AG, however the principles had been known since the late 60s from experiments 
with agitated saline[115]. Echovist was prepared by agitation of a solution of galactose 
crystals, which acted as nucleation sites for air bubble formation. It was effective at 
enhancing heart chambers when delivered systemically, but like the saline microbubbles it 
was not stable enough to survive passage through the fine capillary beds of the lungs 
limiting its use.  
Other first generation microbubbles, like Albunex and Levovist, attempted to 
stabilise microbubbles with the addition of a shell. Albunex (Infoson in Europe) was 
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produced from sonicated albumin, effectively trapping air bubbles in a shell of albumin. 
Levovist, like Echovist, consisted of an agitated galactose solution, but also contained 
palmitic acid, a lipid designed to stabilise the microbubbles formed on the sugar crystals. 
However, neither was particularly effective for imaging as the thin shells presented little 
barrier to diffusion of gases and the air gas core was highly soluble in blood, causing the 
bubbles to rapidly disappear after administration[116]. 
To solve this problem, the second generation of microbubbles utilised a high 
molecular weight gas as the core. Optison, the earliest second generation microbubble, 
used sonicated albumin, however the gas core consisted of the heavy gas, 
octafluoropropane. This drastically improved the performance of microbubbles, allowing 
multiple passes through the pulmonary capillary bed and an extended duration after 
administration. This allowed development of novel microbubble based diagnostic strategies, 
such as monitoring ablation success[117] or metastatic spread to the liver[118]. 
Perfluorocarbons and sulphur hexafluoride – the gas core of the lipid-based, second-
generation, commercial microbubble SonoVue – with their low solubility and low diffusion 
coefficients result in extended microbubble duration in vivo, but full microbubble clearance 
still occurs within 10 minutes. Unfortunately, commercial development of third generation 
ultrasound contrast agents stalled after a series of fatal adverse events linked with 
microbubble use led to a black box warning being issued by the Food and Drug 
Administration (FDA) in 2007 for both Optison and Definity, a second-generation, lipid-
shelled microbubble of octafluoropropane. Usage of Optison dropped from almost 100,000 
patient exposures per year for the years prior to 2008, to just 27,000 per year afterwards 
(information taken from the FDA Optison Post-Marketing Safety Data Summary, 2010). 
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1.3.2. Safety of UCAs 
The black box restrictions put in place by the FDA were relaxed in 2008 after 
consultation with companies and a publication analysing the mortality of patients 
undergoing echocardiography involving the use of UCAs[119]. A number of studies have since 
followed, investigating the potential risk to patients posed by UCAs with favourable results 
indicating their safety[120-122]. However, these consider cases within standard and approved 
clinical use of UCAs. In research settings, their experimental use will fall outside of the 
manufacturer’s indications so some considerations must be given to the potential and 
reported safety issues. 
UCAs are microbubbles which are injected directly into the circulatory system. The 
presence of large quantities of gas bubbles in the circulation can lead to gas emboli in key 
areas of the microvasculature, potentially resulting in myocardial infarction or stroke. This 
risk is minimal with the low concentrations and small diameter size of microbubbles used in 
clinical settings, however, in preclinical experimentation, particularly for gene transfection, 
greater quantities of microbubbles may be administered which can lead to mortality[123].  
In clinical use, there are also reports of other minor adverse events. Transient 
discomfort at the injection site, altered taste and vasovagal episodes has been reported[124]. 
When used in conjunction with ultrasound, UCA cavitation will occur, producing the desired 
diagnostic images but also potential bioeffects. This has led to safety recommendations for 
UCA use[125, 126], however for preclinical use these will likely be ignored to increase bioeffects 
such as extravasation and membrane damage[84, 85]. 
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1.3.3. Current uses 
When administered in vivo, microbubbles of gas create an extreme impedance 
mismatch with the surrounding liquid or tissue, causing strong reflection of an ultrasound 
wave. Additionally, the gas nature and thin, flexible nature of the microbubble makes them 
highly compressible. Under the influence of the ultrasound pressure wave, the microbubble 
can oscillate in size, effectively scattering ultrasound. This oscillation is especially 
pronounced as microbubbles of diameters 1-10 µm have a natural resonant frequency 
approximately equal to frequencies used in diagnostic medical ultrasound. This strong 
reflection and scattering of sound means that even single microbubbles can be detected 
during an ultrasound scan despite being smaller than the resolution of the ultrasound 
system, appearing as bright echoes of returned sound. 
The oscillation of a microbubble can also become asymmetrical and complex under 
increasing acoustic pressure amplitude. This can give rise to harmonic and subharmonic 
signals in the scattered sound. Transmitting at the fundamental and imaging at the 
harmonic can be used to provide further contrast as the tissue component of returned 
echoes are primarily linear[127, 128].  
Imaging at the harmonic is perhaps the most basic of the UCA imaging strategies. 
There has been further development of ultrasound imaging techniques, such as pulse 
inversion, which work to remove the tissue component completely, leaving behind only the 
non-linear microbubble signals. These techniques, although computationally more 
demanding, have resulted in a high sensitivity and specificity for detection of the UCAs. As 
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UCAs are confined to blood vessels, excellent diagnostic imaging of the vasculature is 
possible, useful for clinical classification of liver lesions[129], myocardial blood flow[130] and 
plaque vulnerabilities[131, 132].  
There has also been great interest in the targeted visualisation of pathological 
features. It has been known for some time that certain microbubbles are susceptible to 
immunological clearance[133]. Kupffer cells, specialised immune cells found in the liver, 
phagocytose a number of different UCAs, particularly Optison and Sonazoid[134, 135], leading 
to potentially useful delayed parenchymal contrast enhanced images[136]. Attachment of 
ligands to the outer shell of microbubbles is also under investigation for potential 
improvements in imaging of specific pathologies[137, 138] and treatment localisation[139]. 
Typically targeted microbubbles have had trouble with potential immunogenic responses 
due to the protein based targeting antibodies and bubble-antibody linkages used[140], 
however the first human trial of targeted microbubbles was recently performed using BR55 
(Bracco), a microbubble targeted at the vascular endothelial growth factor (VEGF) 2 
receptor, an angiogenesis marker for aggressive prostate cancer (information taken from 
www.clinicaltrials.gov). 
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1.4. UMGT in gene and drug therapy 
1.4.1. Ultrasound only 
It is established that high intensity ultrasound at low frequencies can cause transient 
pores in cell membranes in vitro due to shear stresses caused by ultrasound waves[91, 141, 142]. 
The process, called sonoporation, creates pores have been shown to be short-lived and non-
lethal with the majority resealing within seconds or minutes[91, 92]. Large or hydrophilic 
molecules, such as DNA, otherwise excluded by the cell membrane, are able to pass through 
these pores[90, 96, 143]. The concern around these mechanical effects of ultrasound led to the 
introduction of the safety guidelines of ultrasound mentioned earlier, specifically the 
Mechanical Index. 
The first demonstration of the potential power of the technique was the electron 
microscopy images of sonoporated cells taken by Tachibana and colleagues[144]. Human 
leukaemia cells (HL-60) were sonicated with continuous wave ultrasound (255 kHz, 0.4 
W/cm2) in the presence of the phototoxic drug, merocyanine 540 (MC 540), before 
examining them under electron microscopy. The pores created by sonoporation were 
clearly visible on the treated cells along with possible cytoplasmic extrusion (Fig. 1.2). The 
cell viability also dropped significantly compared to controls. The mechanism is not fully 
explained but it is suggested that increased porosity of the cells, combined with MC 540 
lead to rapid cell death. 
However, as mentioned, the intensities required are potentially damaging to 
tissues[145, 146]. Instead, it has been shown that UCAs can also cause these pore-like, non-
lethal bioeffects at lower acoustic intensities[92, 147-149]. 
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Figure 1.2. Scanning electron microscopy images of HL-60 cells irradiated with ultrasound in 
the presence of MC 540 (a to d), without MC 540 (f), and without ultrasound or MC 540 (e). 
(Reprinted with permission from Tachibana et al. (1999)[144]) 
 
1.4.2. Mechanism 
Microbubbles are known to cause a number of bioeffects in vivo; the formation of 
transient pores in a target cell[150], the breakdown of tight junctions between cells[151], 
extravasation from the blood vessel[84, 152-154] and uptake of co-delivered material[98, 155, 156]. 
f) e) 
d) c) 
b) a) 
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Studying the relationship between bioeffects and microbubble oscillation is technically 
challenging in vivo, so much of the understanding of transfection mechanisms have come 
from in vitro studies. While there may be some influence from the shell material on the 
target cells[157, 158], the effects appear to be caused primarily by the acoustic effect on 
microbubbles[152]. There are currently three potential models by which UCA may cause 
transfection; pore formation by inertial cavitation, pore formation by stable oscillation and 
activation of endocytosis pathways. 
 
1.4.2.1. Inertial Cavitation 
Inertial cavitation describes violent UCA collapse. As a microbubble oscillates in an 
acoustic pressure field, it is constantly being compressed during the positive phase of the 
wave and expanded during the negative phase. At high acoustic pressures or low 
frequencies, this behaviour can be extreme. Under a high negative pressure, the 
microbubble expands lowering the pressure of the gas core. As the acoustic wave region 
passes on, the higher pressure of the surrounding medium, e.g. the water, blood, saline, 
etc., along with the incoming high pressure phase causes the bubble to collapse. This 
compression causes a significant increase in the temperature of the gas, and eventually, if 
the microbubble is compressed far enough, the gas will violently dissipate into the 
surrounding medium, creating shockwaves and microjets. 
If sufficiently close to the vessel wall, these shockwaves and microjets can damage 
cells, disrupting their membranes[159] and puncturing the endothelium in vivo[84, 154]. Any co-
delivered membrane impermeable drugs or genetic material can then leave the blood pool 
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and enter cells[86, 92]. The extreme temperature and pressure rise, approaching several 
thousand degrees Kelvin and several hundred atmospheres, can also cause the production 
of free radicals and other chemical species, which may be of use in triggering endocytosis as 
discussed further on. 
Most in vivo optimisation studies into acoustic settings suggest that the most 
effective transfection is achieved at high acoustic pressures[85, 150, 160]. Additionally, most 
research groups investigating transfection use acoustic intensities which would likely cause 
microbubble destruction in vitro[87, 98, 157, 161]. This suggests that this form of microbubble 
behaviour might be the primary mechanism in transfection, however direct visualisation is 
difficult and the complex in vivo environment makes accurate modelling in vitro a challenge. 
 
1.4.2.2. Stable oscillation 
Stable oscillation describes a similar situation to the above, but the intensity of the 
acoustic wave is not sufficient to cause violent microbubble collapse. Instead, the 
microbubbles fall into a state of stable oscillation, expanding and contracting under the 
influence of the acoustic field. This state can persist for some time, but eventually gas 
dissolution and shell damage will cause the microbubble to dissipate non-violently.  
In the microenvironment around the oscillating microbubbles, fluid in the 
surrounding medium is undergoing physical movement. When oscillation occurs near a 
boundary, such a cell membrane, this causes shear stresses which can disrupt endothelial 
cell membranes[92]. The pores formed are thought to be smaller than those achieved with 
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inertial cavitation, and neither are the events severe enough to force co-delivered materials 
directly into the cell, like the microjetting events. However, as the microbubble survives a 
lot longer, pore formation is less transient, potentially allowing greater diffusion time across 
the membrane. Additionally, these constant shear stresses and small pore formation are 
implicated in the activation of endocytosis, as discussed next. 
 
1.4.2.3. Endocytosis 
More recent research has shown that oscillating microbubbles can activate 
endocytotic pathways causing uptake of macromolecules[162, 163]. Endocytosis encompasses 
the different processes by which a cell takes up material from its surroundings by 
invagination of its cell membrane[164]. Meijering et al. (2009) showed that large fluorescent 
dextrans, ~500kDa, taken up by cells insonified in the presence of SonoVue (Bracco, Italy) 
would be localised in discrete vesicle-like structures, whilst smaller dextrans, <10kDa, would 
end up distributed around the cell[162]. A similar effect with different sized genetic material 
was also demonstrated[165]. The conclusion was that the pores created by insonified 
microbubbles caused ion fluxes triggering endocytosis and that these pores were too small 
for large molecules to pass through. Additionally, shear stresses acting on the membrane of 
a cell, and the presence of free radicals[166], can also trigger endocytosis[167]. As all these 
effects are occurring with either inertial cavitation or stable oscillation, it is likely that 
endocytosis is activated potentially leading to uptake of co-delivered material. 
Although much work has gone into examining these mechanisms in vitro, bubble 
mechanics are technically challenging to investigate in vivo. The technique of intra-vital 
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microscopy has been applied to investigate this for some time[99, 153, 168], but the procedure 
is extremely invasive and animals are sacrificed afterwards, preventing investigation of the 
preferred mechanism for transfection. Instead, assumptions have to be made about the 
intensities used and the microbubble response in vivo. The work of Chen et al. (2003) 
suggests that ultrasound settings that cause the highest bubble fragmentation, i.e. inertial 
cavitation, give the highest transfection in vivo[85, 160]. Work by van Wamel et al. (2006) 
suggests that lower intensities, which promote stable oscillation, can also be used for 
effective transfection[92]. Both forms of microbubble dynamics have the potential to 
promote endocytosis of surrounding material[162]. It is likely that the mechanism will be a 
combination of the three proposed, with the relative contribution of each determined by 
the ultrasound parameters used, the target tissue and the microbubble’s inherent 
behaviour. 
 
1.5. Factors affecting UMGT 
1.5.1. Ultrasound 
The acoustic wave has a large number of controllable parameters which will have 
some effect on the microbubble response and potential transfection. As discussed above, 
the exact bioeffect mechanism of transfection relies on the microbubble response to the 
pulse. The primary parameters controlling this response are the frequency and the 
amplitude of the pulse. 
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1.5.1.1. Frequency 
As discussed earlier, the frequency of an ultrasound pulse affects the penetration of 
a wave. Higher frequencies are unable to penetrate deeply into tissues but provide finer 
resolution. The choice of frequency will also affect how a microbubble responds. 
Microbubbles have natural resonance in the same frequency range as medical ultrasound, 
causing oscillation and amplifying their back scatter. A microbubble close to resonance will 
undergo more complex oscillation, strongly emitting non-linear signals. Extreme 
microbubble behaviour may cause stronger bioeffects, however, it is typically found that the 
lower the frequency, the greater the transfection, likely due to inertial cavitation[85, 160, 169]. 
However, the deep penetration of a low frequency wave may cause transfection in non-
target tissues. For treatment of localised diseases with potentially toxic agents, such as 
chemotherapy of tumours, the delivery of the therapeutic agent off target may be highly 
undesirable and damaging. Additionally, any non-target transfection lowers the dose 
delivered at the therapeutic site. Higher frequencies have finer resolution and less 
penetration, which may enable delivery of therapeutics to a more defined area. A second 
way to overcome this issue is to use targeted microbubbles which should adhere only to 
therapeutic sites[139]; however these are still some time off being used clinically. 
As can be seen from Table 1.1. UMGT studies in vivo commonly focus on the lower 
ultrasound frequencies for effective transfection, around 1-3 MHz. One of the earliest 
investigations into the effect of several ultrasound parameters on UMGT in vivo was the 
Chen et al. paper (2003)[85]. Using different probes on the Sonos 5500 diagnostic ultrasound 
machine – the S3, S8 and S12 probes – it was possible to change the frequency used to 
transfect Zucker rats with a luciferase plasmid. They found that at a constant MI, the lower 
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the frequency, the greater the transfection, with the optimal frequency out of the three 
tested, being 1.3 MHz. There have, however, been few subsequent studies looking at how 
the frequency affects transfection in vivo. The simplest reason is that many of the 
ultrasound machines used for transfection are incapable of other frequencies due to being 
either dedicated transfection machines[82, 170-173] or therapeutic machines[89, 161, 174-177], both 
of which typically have a single element, single frequency transducer. Those groups that do 
use machines capable of multiple frequencies typically optimise their settings in vitro, 
before applying those settings in vivo[178]. In this way, they are able to reduce animal usage 
and associated ethical and cost considerations, however, in UMGT, in vitro results do not 
transfer well to the in vivo setting[148].  
As such, the Chen et al. (2003) paper is helpful in indicating that lower frequencies 
are also applicable in vivo with the reasoning that they firstly penetrate tissues further than 
lower frequencies, and secondly are more likely to cause inertial cavitation, the proposed 
primary mechanism of UMGT. However, there are some further considerations. In studies 
examining multiple frequencies[85, 178] typically have to use multiple probes to investigate a 
range of frequencies as the transducer elements are limited to a set frequency range due to 
their material properties and size. In the Chen et al. (2003) paper, three different probes are 
used, neither of which are equivalent; a point raised in their discussion by highlighting that it 
was not possible “to control pulse duration, line density, and beam width for the three 
different transducers,” although they do go on to state that the differences in these 
properties may result in approximately the same level of destruction.  
As such, when multiple probes are available for use, consideration has to be given 
not just to achieving the lowest frequency, but also the other properties particular to the 
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transducer probe. In the Alete thesis, the author investigated the restoration of dystrophin 
expression following UMGT using Optison and the exon skipping PMO designed to cause 
expression of truncated but functional dystrophin in an mdx mouse[123]. Three frequencies 
were investigated: 3.5, 5 and 7 MHz, using two probes on the Siemens Acuson Sequoia 
machine, the 7V3c (3.5 and 5 MHz) and the 15L8 (7 MHz). Additionally, all three frequencies 
were transmitting at different MIs, with 7 MHz having the lowest (0.71 MI) and 3.5 MHz the 
highest (1.03 MI). It would therefore be logical to assume that 3.5 MHz and 5 MHz should 
cause greater transfection due to the lower frequencies and higher amplitude. However, 3.5 
and 7 MHz caused equivalent transfection whilst the 5 MHz was significantly worse than 
either. It is commented on by the author that “the transducers used are different in size” 
and that the experiment may have been a “comparison of different transducer size, rather 
than…different ultrasound settings.”  
As mentioned, although there is a preference of low frequencies typically due to 
effective transfection in vitro, it is important to consider the in vivo therapeutic situation. 
Haag et al. (2006) also investigated the use of multiple frequencies in vivo to transfect an 
antisense oligonucleotide into prostate tumours implanted in mice, with the consideration 
that although low frequencies (1.75 MHz) produced the most effective transfection in vitro, 
the transrectal ultrasound probes used for clinical prostate examination do not use low 
frequencies[178]. By using two probes on the Acuson Sequoia, the 4C1 and 15L8, it was 
possible to investigate the effect of 1.5, 2.5 and 7 MHz ultrasound. No quantitative results 
are given however it is reported that all three ultrasound frequencies were capable of 
transfecting the tumours. Again though, the two probes used are very different and care has 
to be taken in their interpretation. 
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As such, although the consensus is to use a low frequency for UMGT, it is possible 
and sometimes more appropriate to employ a higher frequency depending upon the 
application. 
 
1.5.1.2. Amplitude 
In UMGT, the highest amplitude attainable without severe tissue damage is typically 
used. In diagnostic ultrasound machines, power output is limited by the maximum 
permissible MI setting, which is dependent on both frequency and focal depth. The 
amplitude affects how extreme the oscillation of a microbubble is and the potential 
mechanism of transfection, as discussed earlier. The highest pressures encourage more 
inertial cavitation which has been linked to greater transfection efficiency[85, 150, 160].  
As with frequency, one of the earliest investigations into the effect of power on 
UMGT in vivo was the Chen et al. (2003) paper[85]. Using the S3 probe on the Sonos 5500 
ultrasound machine, three different powers – 1.2 MI, 1.6 MI and 2.0 MI – were investigated 
for their ability to transfect rat myocardium with a luciferase encoding adenovirus or 
plasmid. It was found that as the MI increased, luciferase expression also increased, 
indicating greater transfection. Additionally, the higher powers also allowed deeper 
penetration of the ultrasound energy, causing increased transfection of the posterior wall of 
the heart.  
Other groups have also found the same connection between power and transfection 
in vivo. In the Alete thesis, dropping the MI from 1.8 to 1.0, significantly decreased the 
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reduced the number of dystrophin-positive skeletal muscle fibres in mdx mice after 
transfection of an exon skipping PMOs designed to restore dystrophin[123]. As mentioned 
previously, that the higher amplitudes result in greater transfection, and considering the 
behaviour of microbubbles under these pressures[141, 179, 180], does suggest that inertial 
cavitation may be the primary mechanism of UMGT. 
However, an unstable microbubble may dissipate at high negative pressures without 
a strong acoustic response. As high MIs or amplitudes run the risk of cellular damage[181] this 
may lead to excessive damage with little extra therapeutic effect[182]. Indeed, this has been 
seen in a number of in vivo studies. Sakai et al. (2009) found that transfection of a GAPDH 
siRNA into the parotid glands of rat increased was significantly increased using 1 MHz 
ultrasound at 1 or 2 W/cm2 in comparison to 0 or 0.5 W/cm2 powers. However, increasing 
the power up to 4 W/cm2 caused transfection to drop and resulted in a number of cytotoxic 
effects including apoptosis and inflammation of acini cells[177]. Similarly, Shen et al. (2008) 
found that peak negative pressures of 4.3 MPa would half luciferase expression in mouse 
liver after transfection with 1.17 MHz ultrasound, in comparison to 3 MPa. It was also 
accompanied by noticeable macroscopic damage of the liver, including haemorrhaging of 
blood vessels and ischemia[183]. Finally, when transfecting the carotid artery of rabbits with 
β-galactosidase and a 0.85 MHz HIFU ultrasound system, Huber et al. (2003) found that 
powers over 6.3 MPa would cause haemorrhages and vessel puncture events in the 
presence of microbubbles, however in this instance transfection was not strongly affected 
and any ultrasound inflicted damage resolved within 48 hours[143]. These adverse events 
were linked with cavitation of microbubbles as the 0.9% saline control resulted in no 
detectable damage with amplitudes up to 15 MPa. 
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Like frequency, groups typically optimise their amplitudes in vitro before moving to 
the in vivo situation[148, 170, 184]. For instance, Li et al. (2009) examined the efficiency of 
transfecting a GFP plasmid into HeLa cells using 1 MHz ultrasound over an amplitude range 
of 0.5 to 4 W/cm2, initially optimising the transfection in vitro before attempting to transfect 
an episomal luciferase plasmid into implanted tumour cells in vivo[170]. Again, this can 
reduce animal usage and may indicate safe, effective parameters for efficient transfection in 
vivo, however there are additional tissue and microbubble attenuation effects to take into 
consideration, which will reduce the amplitude of the wave hitting the target area. 
It is therefore desirable to choose ultrasound settings with a sufficiently high power 
to cause strong transfection and little damage; however such settings should still be 
optimised in vivo rather than in vitro. 
 
1.5.2. Microbubble 
1.5.2.1. Concentration 
The most apparent link between microbubbles and UMGT success is their 
concentration. It has been demonstrated that an increase in the concentration or the 
amount of microbubbles used can lead to an increase in transfection, likely due to the 
increased likelihood of a transfection/cavitation event occurring within close proximity to a 
vessel wall[97, 98]. In the Alter et al. (2009) paper, doubling the amount of Optison used for 
UMGT of dystrophin recovery by PMOs, increased the number of dystrophin positive 
cardiomyocytes in the mdx mice heart by ~250%[98]. A similar 2-fold improvement was also 
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seen when using neat Sonazoid compared to a 1 in 4 dilution. However, the concentration 
could not be increased indefinitely. When the concentration of Sonazoid was further 
doubled by concentrating the microbubbles after centrifugation, no further increase in 
transfection was observed. As no histological damage was noted, the lack of improvement 
may be due to either another limiting factor, e.g. the amount of plasmid, or the increase in 
attenuation caused by the high number of microbubbles in the target area.  
This was also seen in the Azuma et al. (2003) paper, where increasing the 
concentration of Optison solution in saline beyond 10% (v/v) resulted in no additional 
transfection of a luciferase plasmid into rat kidneys using ultrasound[155]. Indeed, it was 
actually found that at 50% (v/v) Optison the expression of luciferase was worse, albeit not 
significantly, than 10% or 25% (v/v) Optison. Instead of attenuation, this was associated with 
increased tissue damage. Like the amplitude of the ultrasound pulse, there reaches a point 
where further increases in microbubble concentration appear to cause irreversible cellular 
damage reducing transfection efficiency.  
However, this level is not easily defined. For Azuma et al. (2003), this appeared to 
occur at 25% (v/v) Optison, which in the 500 µL delivered volume is approximately 1.0 x 108 
microbubbles. For Alter et al. (2009), 2.4 x 108 microbubbles in the doubled dose, which 
resulted in improved transfection without histological damage. Additionally, Azuma et al. 
(2003) used rats which have 10 times the mass of the mice used in the Alter et al. (2009) 
experiment. Evidently, certain tissues, such as the kidneys, are susceptible to microbubble 
damage. In fact, in the Koike et al. (2005) paper, it was found during optimisation of the 
transfection of rat kidneys with a luciferase plasmid, that concentrations of Optison over 
50% (v/v) (~2.0 x 108 microbubbles delivered) would cause significant kidney damage[97]. 
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Damage by 25% (v/v) Optison may have been missed due to histology and blood function 
tests being performed 7 days after transfection rather than 4 days as in the Azuma et al. 
(2003) paper. However, the Koike et al. (2005) paper does complicate matters with the 
finding that transfection actually kept increasing from 0% to 100% (v/v) Optison, which may 
instead be linked to the different ultrasound parameters in use.  
Selecting an appropriate concentration from the literature is therefore a challenge. 
Differences in target site, ultrasound settings and animal model appear to have strong 
effects on resultant transfection efficiency. These differences also make the comparison 
between studies very complicated and can obscure which factor is actually the more 
important. 
 
1.5.2.2. Size distribution 
Theoretically, the size distribution of a microbubble population can also affect the 
transfection efficiency, primarily by altering its response to acoustic insonation[185, 186], 
however, actually investigating this is a challenge. So called “monodisperse” single sized 
lipid or albumin based microbubbles of a single size have yet to be successfully produced. 
Isolation of certain size ranges can be performed using centrifugation however this is 
damaging to microbubbles[187] (personal correspondence, Dr Charles Sennoga), reducing the 
concentration and potentially affecting the stability. Additionally, microbubbles undergo 
rapid gas exchange with their surrounding medium, which ultimately affects the size of the 
microbubbles[188, 189]. As such, the effect of the size of microbubbles on transfection has not 
yet been investigated, although it was noted in Alter et al. (2009), that Sonazoid and 
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SonoVue, two lipid-based microbubbles with similar size distributions but different gas 
cores, caused significantly different transfection of PMOs into skeletal muscle, suggesting 
that size is not important. However, as the author notes, it would need to be confirmed on 
the same bubble type as there are differences between the formulations[98].  
 
1.5.2.3. Shell component 
Microbubble shells are typically made of protein, lipids or polymers. Each has its own 
material properties which can affect how the shell responds to ultrasound. A strong rigid 
shell, like those made with fluorinated poly(L-lactic acid) (PLLA) polymers[190], will not have a 
high scattering behaviour due to its incompressibility but can withstand higher intensities 
than other shell materials. When its structural limit is reached, the shell tends to crack, 
causing gas jetting at the fault[191, 192]. The rigidity and strength of a polymer shell is usually 
based on its thickness; a thicker shell will be more rigid and require greater acoustic 
intensities to crack[190, 193]. Thinner shells will allow some flexibility, typically through 
indentation, and sound scatter but will be broken at lower intensities[190, 194, 195]. Polymeric 
microbubble production also allows preloading with a therapeutic drug or agent[193, 194, 196, 
197]. Polymer microbubbles have been used for transfection in culture cells[198, 199], although 
transfection in vivo is uncommon. In the Hauff et al. (2006) paper[200], the authors used a 
polylactide-co-glycolide to form a microbubble which carried DNA within the gas core, 
which was releasable by ultrasound[201]. This was shown to successfully transfect tumour 
cells in both rats and mice with either a β-galactosidase enzyme or an anti-tumour 
suppressor protein, p16. 
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Lipid microbubbles, such as Definity, typically consist of several lipid types to 
improve stability[202-204] (information concerning Definity was taken from the package insert) 
although there are exceptions[205]. Lipid microbubbles are manufactured primarily by 
agitation; the amphiphilic nature of the lipids cause them to self-assemble into a monolayer 
around the gas core to protect the hydrophobic tails[203, 206]. They are highly flexible 
microbubbles giving off strong scatter and are capable of complex non-linear behaviour[186, 
207, 208], but the process of oscillation can cause shedding of shell material, ultimately 
destroying the microbubble[180, 209, 210].  
Lipid microbubbles have been used extensively in both drug and gene delivery[89, 90, 
98, 99, 211]. Interestingly, differences in the lipid composition do lead to transfection 
differences, usually by changing a property of the microbubble. For instance, in the 
Nomikou et al. (2012) paper, different types of lipids were used to create neutral, cationic 
and biotinylated cationic microbubbles to deliver a luciferase plasmid in vitro and in vivo[172]. 
The microbubbles showed differing transfection abilities, with the cationic microbubble, 
designed to carry DNA, outperforming the neutral microbubble in vitro, but showed no 
significant difference when used in vivo. However, the biotinylated cationic microbubbles, 
designed to carry DNA but also carrying a biotin tagged lipid, produced significantly greater 
transfection than neutral microbubbles in vitro and in vivo. Interestingly, the authors note 
that the improvement of the biotinylated cationic microbubble over the cationic 
microbubble was unexpected, the biotin is only present to provide an adhesion site for 
streptavidin labelled targeting molecules, although they state some form of interaction 
between the biotin and cells may be taking place to improve localisation against the 
membrane, which may improve transfection. As for the lack of improvement in vivo for the 
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cationic microbubbles, the study was performed by intramuscular injection of the plasmid 
and microbubbles; resulting in all components being in close proximity to the target cells 
before ultrasound treatment, possibly removing the benefit of DNA loading. In a similar 
vein, the Alter et al. (2009) study compared two lipid based microbubbles, SonoVue and 
Sonazoid, made from different compositions of phospholipids[98]. As discussed further on in 
greater detail, these differences conferred differences in stability, which significantly 
affected their transfection potential. 
Protein microbubbles are exclusively manufactured from human albumin. Albumin 
has well-established purification protocols and is already used for clinical treatment of 
hypoalbuminemia, making it both cheap and safe to use[212]. Microbubbles made exclusively 
from albumin, tend not to be stable or provide strong contrast so are typically mixed with 
dextrose (glucose)[213]. This also reduces the amount of albumin needed, reducing the cost 
of manufacture. Both Albunex and Optison are commercial albumin based microbubbles, 
although neither contains a sugar component. Microbubbles are made by sonication, which 
creates microbubbles of gas surrounded by albumin. The increase in heat caused by energy 
deposition also denatures the albumin creating a fixed yet flexible shell around the gas 
core[214, 215]. If a sugar is added, this may react with the albumin forming glycation products 
on exposed lysine residues[216, 217]. The addition of the sugar component may also cause 
greater transfection[218]. Although it has only been investigated in vitro, Pislaru et al. (2003) 
found that a PESDA type microbubble would cause greater transfection of a luciferase 
plasmid than Optison in cell cultures[218]. Although there are several differences between 
the formulations, the most notable is that PESDA microbubbles are prepared with a glucose 
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(dextrose) component[213], unlike Optison, according to the manufacturer (information on 
Optison taken from product insert).  
The inclusion of dextrose is known to increase the stability of albumin based 
microbubbles. Du et al. (2002) found that microbubbles of increasing dextrose 
concentration showed greater longevity in both storage and under ultrasound[219]. In a 
separate study, Alter et al. (2009) demonstrated that the stability is linked to transfection 
efficiency in vivo[98]. By examining the stability of Optison, SonoVue and Sonazoid under 
ultrasound, and their ability to restore dystrophin in mdx mice by transfection of exon 
skipping PMOs, it was found that both Optison and Sonazoid where significantly more 
resistant to ultrasound and caused significantly more transfection than SonoVue, which was 
rapidly destroyed under ultrasound. Interestingly, Optison and Sonazoid are albumin- and 
lipid-based microbubbles respectively, suggesting that the constituents of the microbubble 
shell may not be as important as the characteristics they impart. 
However, there is also evidence to suggest that purely the albumin component is 
responsible and can act as an effective transfection agent for direct injections[157, 158]. When 
comparing the transfection ability of different commercial microbubbles on skeletal muscle 
in mice, Wang et al. (2005) found that Optison produced the same number of GFP positive 
fibres with or without the application of ultrasound[157]. This was unlike SonoVue, which 
showed significantly improved transfection under the influence of ultrasound. Wang (2011) 
then went on to look at the constituents of Optison to identify the transfective factor and 
found that heat-treated and destroyed Optison would cause GFP transfection of mouse 
skeletal muscle at an equivalent to Optison, with or without ultrasound[158]. Additionally, the 
use of albumin only also caused equivalent levels of transfection but only with ultrasound; 
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when injected without ultrasound, the transfection was significantly worse. As such, 
albumin appears to be the important factor in transfection, however why Optison, but not 
albumin, is capable of transfection without ultrasound not fully explained. The author 
suggests it may be linked to the presence of the perfluorocarbon gas which may still be 
present trapped within the remains of the heat-destroyed Optison. However it should be 
noted that this study was performed on skeletal muscle by direct intramuscular injection; it 
is unlikely to apply for systemic delivery where a lack of ultrasound typically results in 
significantly worse transfection for Optison microbubbles. 
Albumin based microbubbles have been shown to be highly effective at gene 
transfection, typically causing greater transfection with less damage in comparison to lipid 
based microbubbles[85, 157].  
The various materials of a microbubble shell strongly affect how a microbubble 
responds to ultrasound and its transfection performance. Changes in the flexibility, rigidity 
and thickness of the shell will change the resonant frequency as well as the amplitude 
response of the microbubble[190, 220]. It can be difficult to measure these parameters and as 
such, models of microbubble behaviour have been developed in an attempt to simulate 
them[221-224], however the unknown values for key terms and the complex nonlinear 
behaviour of microbubbles complicate their use. Detailed in vitro characterisation is needed 
to identify how the microbubbles properties change with materials and their resultant 
effects on transfection. 
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1.5.2.4. Gas core 
The gas core of a microbubble controls a microbubble’s compressibility and 
survivability. As mentioned previously, the first generation microbubbles were air bubbles 
which would rapidly dissolved into the solution due to their high solubility and diffusion 
constants. Second generation microbubbles replaced air with high molecular weight gases 
such as the perfluorocarbons or sulphur hexafluoride[202, 205] (information on Optison and 
Definity taken from product inserts). The effect of the gas cores on transfection has never 
been directly investigated; however there have been investigations into the differences 
between commercial microbubble formulations with different cores. Typically, the first 
generation microbubbles, such as Levovist and Albunex, show poor transfection ability 
compared with second generation microbubbles, such as Optison[85, 148, 152, 157]. In the Li et al. 
(2003) study, the transfection ability of Albunex, Levovist and Optison was compared using 
mouse quadriceps[148]. After intramuscular injection and ultrasound, they found that 
Optison resulted in a 10-fold increase in transfection in comparison to a no microbubble 
control. Albunex and Levovist caused no significant transfection. Both Albunex and Optison 
are albumin based, whilst Levovist is a galactose based microbubbles, suggesting that the 
difference in transfection is not linked to shell material. Instead, the difference in 
transfection stems from the difference in gas core; both Albunex and Levovist consist of an 
air filled core, whereas Optison contains octafluoropropane. This is supported by the greater 
haemolysis and sonoporation effect noted using Optison in comparison to Albunex in 
vitro[225, 226]. 
The improvement is likely to do with the improvement in stability and longevity of a 
microbubble in the circulation[227]. This allows a greater quantity of microbubbles to reach 
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the targeted site, the potential of multiple passes, a prolonged bubble response and a 
longer treatment time. Perfluorocarbons, particularly octafluoropropane and 
decafluoropropane, have been extensively used as the gas core in microbubbles, however 
larger and less soluble perfluorocarbons are limited by their higher-than-body-temperature 
boiling points (tetradecafluorohexane – 56oC). Although, some, such as 
dodecafluoropentane, did initially find use as ultrasound contrast agents[228] and have 
current potential uses as dissolved oxygen carriers[229]. 
 
1.5.3. Genetic Material 
The aim of transfection is to deliver a particular gene of interest or therapeutic value 
into a target tissue. The effectiveness of this procedure relies in part on the technique in use 
and the parameters chosen, as described in detail for UMGT above. However, the genetic 
material being delivered also plays a role in this and will itself affect the resultant 
transfection. This applies to not only to the use of so called “naked” DNA, e.g. plasmids, 
RNA, etc., but also the viral or modified genetic material in use. 
To return again to the Chen et al. (2003) paper, two forms of genetic material were 
used to transfect rat hearts, a luciferase encoding plasmid and a luciferase encoding 
adenovirus[85]. In all cases in which the adenovirus was used, detectable transfection of the 
liver was noted, typically at levels greater than the heart. This is not an uncommon finding 
when using adenoviral particles for genetic therapy, as they will be quickly sequestered by 
hepatocytes and Kupffer cells[230]. Besides the safety implications of delivering to the wrong 
target, there is also the loss of transfective particles from which will affect the dose 
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available in the target area and may reduce transfection. The plasmid was only delivered at 
a detectable level to the heart rather than other organs, however it should be noted that 
the adenovirus was still more effective than the plasmid at transfecting the heart. 
Interestingly though, in the Howard et al. (2006) paper, it was shown that inactivating 
adenoviral particles by exposure to complement system proteins would remove their 
undesirable site specificity yet retain their transfection ability, which may be an effective 
way of improving UMGT therapy[231]. 
Another consideration is the size of the genetic material. Although the therapeutic or 
reporter gene will have a defined, generally immutable size, the plasmids carrying these 
genes typically contain a number of other genes or promoters involved in the bacterial 
cloning of these particles, e.g. replication origin sites, antibiotic resistance genes, etc. 
Removing the unrequired parts produces a smaller plasmid, called a minicircle, with less 
potentially immunogenic regions, which should result in better transfection[25]. The use of 
minicircles was invested by Yoon et al. (2009) in the treatment of wounds in diabetic mice 
by transfection of plasmids or minicircles encoding VEGF to induce angiogenesis[173]. By day 
6 after wounding, the animals which had subsequently received UMGT therapy with 
minicircle DNA demonstrated greater wound closing (58.2%) than either control untreated 
mice (38.1%) or plasmid (49.0%). Since both plasmid and minicircle DNA encode the same 
VEGF gene under the same β-actin chicken promoter and SV40 terminal sequence, this 
suggests that minicircle DNA has better transfection ability than plasmid. 
However, there is a potential flaw with the Yoon et al. (2009) study which is also a 
consideration in other study using plasmids, especially when comparing results across 
different plasmids or genetic DNA. To transfect the wounded tissue of the diabetic mice, 20 
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µg of either plasmid or minicircle DNA was injected, with SonoVue, subcutaneously into the 
wounded area. However, the VEGF plasmid is 4.8 kb long, whilst the VEGF minicircle is 2.2 
kb. As such, there are over twice as many molecules of minicircle being delivered into the 
wounded area than plasmid. This is an important point in any transfection or transduction 
study as the number of transfective particles delivered will determine the effectiveness of 
the transfection. This is a curious oversight in this study as the difference in molecule 
number was taken into account during the in vitro studies performed on cell cultures. The in 
vitro work demonstrated that at an equal molecule concentration, the minicircles produced 
2.5 fold greater expression than the plasmid in NIH3T3 cells. The minicircles may still be 
more effective transfection agents, but this has not been suitably proved in vivo. Still, this 
point is important as it shows the difficulty in comparing transfection efficiencies from 
different studies utilising different techniques and materials. 
In the majority of UMGT work with plasmids, promoters derived from viruses are 
used to express the transfected gene of interest. Possibly the most commonly used is the 
CMV promoter[85-87, 176, 200, 232, 233] derived from the cytomegalovirus, part of the 
herpesviridae family, which provides strong constitutively activated expression of the 
transfected gene. However, the CMV promoter can cause varying expression levels in 
different cell lines in vitro, related not to the efficiency of the transfection technique, and 
has no cell specificity[234, 235]. In the Alete thesis, transfection of mouse myocardium using 
ultrasound and Optison was attempted using pEGFPLuc, a plasmid encoding a fusion protein 
of GFP and luciferase under the control of CMV[123]. The transfection was effective with high 
levels of luciferase expression detected in vivo in the heart region, however ex vivo analysis 
of the organs demonstrated that a large amount of transfection had occurred in the 
63 
 
intercostal muscles of the ribs. To improve the specificity of the transfection, the promoter 
was replaced with the alpha myosin heavy chain promoter (α-MHC), which is cardiac 
specific. This eliminated expression in the intercostal muscles, improving transfection 
specificity; however it was not stated whether the expression levels were improved. 
This form of plasmid promoter modification has also been performed to improve the 
targeting and expression in pancreatic β-cells of reporter and sugar metabolism genes. In 
the Chen et al. (2006) paper, the rat insulin promoter (RIP) was inserted into reporter 
plasmids and then transfected into the pancreas of rats[87]. It was found that the DsRed 
transfection efficiency of β-cells and the luciferase expression of the pancreas under the 
control of RIP were 3.5- and 4- fold greater respectively than their CMV controlled 
counterparts. However, it should be said in relation to the previous point about differences 
in plasmid size, it appears that the amount of plasmid used was determined by mass rather 
than number of molecules. The group then went on to investigate how much of the RIP 
sequence was required to improve transfection and specificity, by using smaller versions of 
RIP, however the finding was that the longest, original RIP sequence was the most 
effective[236]. 
As such, the type of vector, the size, the amount and the promoter will all play a part 
in the transfection efficiency of the gene of interest. Additionally, as mentioned earlier 
about CpG regions in bacterial plasmids, the origin of the vector can also affect the 
transfection efficiency. There are, therefore, several considerations when choosing a vector 
for transfection and should be employed when comparing between different vectors. 
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Table 1.1. List of UMGT studies performed in vivo involving ultrasound, microbubbles and genetic material (abbreviations at end) 
First author, 
Year, Citation 
Strain, Model, 
Target 
Delivered 
Material 
Microbubble 
(MB) 
Method Ultrasound settings Optimal or notable 
transfection characteristics 
Safety 
Shohet R.V.,  
2000, 
[237]
 
Zucker,  
Rat, 
Myocardium 
β-gal 
adenovirus 
PESDA Jugular vein 
infusion, 5 x 10
9
 
β-gal transgene 
units 
1.3MHz; 1.5MI; ECG 
triggered 3 frame burst 
every 4-6 cardiac 
cycles 
10 fold increase in β-gal activity 
with US + MB vs. adenovirus 
only  
Transfection in liver, 
no abnormal ECG 
readings 
Danialou G., 
2002, 
[89]
 
C57BL10, mdx,  
Mouse, 
TA muscle 
Β-gal 
plasmid 
Definity IM injection, 
25µg plasmid, 
hyaluronidase 
1MHz; 1.5W/cm
2
; 3ms 
pulse; interval 7ms; 
30% DC; 2 min exp. 
mdx mice: 22x increase using 
Definity + US vs. plasmid only 
No increase in muscle 
damage using 
Definity + US vs. 
plasmid only 
Taniyama Y., 
2002, 
[176]
 
Sprague-Dawley, 
Rat, 
Pretibial muscle; 
New Zealand, 
Rabbit, 
Ischemic hind 
limb 
Rat: Luc 
plasmid; 
Rabbit: 
HGF 
Optison Rat: IM 
injection, 20µg 
plasmid; 
Rabbit: IM 
injection, 250µg 
plasmid at 4 
sites (1mg total) 
1MHz; 2.5W/cm
2
; 1-16 
min exp.; 25%-100% 
Optison 
Peak luc expression in rats with 
1 min exp. + 75% Optison; 
significant increase in angio-
graphic score, vessel number, 
blood flow blood pressure ratio 
in rabbits with US + MB vs. 
plasmid only 
Not reported. 
Taniyama Y., 
2002, 
[238]
 
Sprague-Dawley, 
Rat, 
Balloon catheter 
injured carotid 
artery 
p53 or luc 
plasmid 
Optison Direct injection 
after carotid 
isolation;  
2.5W/cm
2
; 2min exp. 1000 fold increase in luc with 
MB + US vs. plasmid only; 
significant reduction in neo-
intima formation and DNA 
synthesis 
Not reported 
Azuma H., 
2003, 
[155]
 
Wister, Lewis, 
Rat, 
Kidney 
Luc plasmid,  
decoy ODN 
Optison Perfused in 
excised kidney, 
50µg plasmid or 
100µg ODN  
2MHz; 2.5W/cm
2
; 30s 
to 8 min exp. 
Peak transfection, least damage 
after 1 min exp. with 10% 
Optison 
Exp. times over 1 
min, concentration of 
Optison >10% caused 
tissue damage 
Bekeredjian 
R., 
2003, 
[86]
 
Sprague-Dawley, 
Rat, 
Myocardium 
Luc plasmid PESDA and 
lipid MBs 
containing 
plasmid 
Jugular vein 
infusion, 350µg 
plasmid on MB 
1.3MHz; 1.5MI; ECG 
triggered 4 frame burst 
every 4 cardiac cycles; 
20 min exp. 
Peak within 4 days, decrease of 
plasmid after 7 days, re-
transfection effective 
Sister study showed 
troponin leak but 
without functional 
changes
[239]
 
Li T., 
2003, 
[148]
 
BALB/c, 
Mouse, 
Quadriceps 
GFP plasmid Albunex, 
Levovist, 
Optison 
IM injection, 
25µg plasmid 
1MHz; 2.0W/cm
2
; 50% 
DC; 2 min exp. 
10 fold increase using Optison 
vs. no MB, Albunex or Levovist 
have no effect 
No inflammation of 
necrosis 
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First author, 
Year, Citation 
Strain, Model, 
Target 
Delivered 
Material 
Microbubble 
(MB) 
Method Ultrasound settings Optimal or notable 
transfection characteristics 
Safety 
Chen S., 
2003, 
[85]
 
Zucker, 
Rat, 
Myocardium 
Luc plasmid 
or 
adenovirus 
Liposome MB 
containing 
plasmid or 
virus 
Jugular vein 
infusion, up to 
600 µg plasmid 
or 0.25 x 10
12
 
virus pfu on MB 
1.3, 5, 12MHz; 1.6, 
2.0MI; continuous or 
ECG triggered 4 frame 
burst every 4 cycle; 20 
min exp. 
Plasmid expression similar to 
adenovirus expression at 
1.3MHz, ECG triggered, 2.0MI 
settings 
No LV dysfunction, 
same sister study as 
above 
Christiansen 
J.P., 
2003, 
[99]
 
Sprague-Dawley, 
Rat, 
Hind limb skeletal 
muscle 
Luc plasmid Cationic and 
neutral lipid 
MB, mixed 
with plasmid 
Femoral artery 
or vein infusion, 
20µg plasmid 
1.75MHz; 1.9MI; 
1.14MPa; 3 min exp. 
200 fold greater transfection via 
artery vs. vein 
No change in 
haemodynamics 
Huber P.E., 
2003, 
[143]
 
New Zealand, 
Rabbit, 
Carotid artery 
Β-gal 
plasmid 
Albunex Isolated and 
infused carotid, 
200µg plasmid 
0.85MHz; 0-15MPa; 
1Hz PRF; 50ms burst; 
42500 cycles; 5% DC; 
1min exp. 
17.5 fold increase using MB + 
6.3MPa vs. 0MPa 
Haemorrhages and 
vessel puncture at 
powers over 6.3MPa  
Lu Q., 
2003, 
[240]
 
C57BL10, 
Mouse, 
TA muscle 
GFP plasmid Optison IM injection, 
10µg plasmid  
1MHz; 3.0W/cm
2
; 
100Hz PRF; 20% DC; 
60s exp. 
Peak expression with 4 week 
old mice and Optison, with or 
without US 
Area of muscle 
damage significantly 
decreased with 
Optison 
Pislaru S.V., 
2003, 
[218]
 
Sprague-Dawley, 
Rat, 
Triceps brachii, 
gastrocnemius 
Luc plasmid  PESDA IM injections, 
20-200µg 
plasmid; via 
femoral artery, 
400µg plasmid 
Diagnostic machine: 
1.7MHz; PNP: 560kPa;  
CW machine: 1MHz; 
PNP: 410kPa;  
Both up to 7min exp.  
Peak expression with IM 
injection of triceps with PESDA 
and 100µg plasmid using 
diagnostic US  
Apoptotic nuclei 
detected. No 
difference in 
inflammation against 
control. 
Guo D., 
2004, 
[241]
 
BALB/c, 
Mouse, 
Myocardium 
Luc or β-gal 
plasmid 
PESDA type 
with unknown 
component 
IV tail injection, 
50 to 60µg 
plasmid 
1.3MHz; 1.5MI; 2 min 
exp. 
8.5 fold increase using US + MB 
vs. plasmid only 
Elevation of cardiac 
enzymes in blood 
Hauff P., 
2005, 
[200]
 
WAG/Rij, 
Rat, 
Implanted liver 
carcinoma; 
NMRI/nu, 
Mouse, 
SC tumour 
β-gal or p16 
plasmid 
poly(D,L-
lactide-co-
glycolide) MB 
containing 
plasmid 
stabilised with 
polylysine 
Rat: IA or IV 
injection, 20µg 
or 50µg β-gal 
plasmid; 
Mouse: IV 
injection, 1.2µg 
p16 plasmid 
IA rats: colour Doppler; 
1.0MI; 6min exp. 
IV rats: colour Doppler; 
0.9MI; 6min exp. 
Mouse: colour 
Doppler; 1.5MI; 12min 
exp. 
Strong increase in β-gal in IA rat 
tumour with US + MB vs. US, 
MB or plasmid only; Strongest 
β-gal after 3 days in IV rats; 
Significant decrease in doubling 
time of mouse tumours with US 
+ MB vs. control 
Not reported 
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First author, 
Year, Citation 
Strain, Model, 
Target 
Delivered 
Material 
Microbubble 
(MB) 
Method Ultrasound settings Optimal or notable 
transfection characteristics 
Safety 
Koike H., 
2005, 
[97]
 
Wister, 
Rat, 
Kidney 
Luc and GFP 
plasmid 
Optison IV injection via 
renal artery, 
50µg plasmid 
1MHz; 5% power 
output; CW; 60s exp. 
70-80% glomerulus transfected, 
~13 fold greater  transfection 
with 25% Optison vs. US only 
Histological damage 
at concentrations of 
Optison greater than 
25%. No change in 
blood function tests 
Sakakima Y., 
2005, 
[90]
 
BALB/c nude Slc, 
Mouse, 
SC hepatic 
tumour 
GFP or 
human 
interferon-β 
plasmid 
BR14 (Bracco) Direct tumour 
injection, 50µg 
plasmid 
1MHz; 2.0W/cm
2
; 50% 
DC; 10 min exp. 
Treatment reduced tumour 
growth by 70% at 6 weeks vs. 
no treatment 
No necrotic effects in 
tissue. Apoptosis 
seen in tumour cells. 
Wang X., 
2005, 
[157]
 
C57BL10, 
Mouse, 
TA muscle 
GFP plasmid Optison, 
SonoVue, 
Levovist 
IM injection, 
10µg plasmid 
1MHz; 3.0W/cm
2
; 
100Hz PRF; 20% DC; 
30s exp. 
Optison and SonoVue improve 
transfection ~3.7 and 3.3 fold 
vs. plasmid respectively 
No increase in muscle 
damage for all MBs 
except Levovist 
Chen S., 
2006, 
[87]
 
Sprague-Dawley, 
Rat, 
Pancreatic β-cells 
Luc, DsRed, 
β-gal, HKI 
and human 
insulin 
plasmids; 
RIP or CMV 
promoter 
Lipid MB 
containing 
plasmid 
Jugular vein 
infusion; 
~250µg plasmid 
1.3MHz; 1.2-1.4MI; 
ECG triggered 4 frame 
burst every 4 cardiac 
cycles; 20 min exp. 
67% transfection efficiency of 
β-cells; 4 fold increase in luc 
expression using RIP vs. CMV; 
30% and 20% reduction in 
serum glucose with HKI and 
human insulin 
No histological 
evidence of damage, 
no change in serum 
enzymes, no change 
in behaviour, weight 
gain or metabolic 
homeostasis 
Haag P., 
2006, 
[178]
 
BALB/c athymic 
nude, 
Mouse, 
SC prostate 
tumour 
Antisense 
ODN for 
human AR 
gene 
Cationic lipid 
MB containing 
antisense 
ODN 
Direct tumour 
or IV injection, 
100µg ODN 
1.5, 2.5, 7MHz; 1.9MI; 
9 min exp. 
All frequencies achieve delivery 
of ODN; minimal difference 
between ±MB samples 
Not reported 
Howard C.M., 
2006, 
[231]
 
Nude, outbred, 
Mouse, 
SC melanoma 
tumour 
GFP 
adenovirus 
(Ad-GFP) 
Imagent 
containing Ad-
GFP 
IV tail injection, 
100µL of MB 
containing Ad-
GFP 
4MHz; PNP: 304-
657kPa; 4 min exp. 
US + MB specifically targets 
complement inactivated Ad-
GFP to tumour 
Not reported 
Sonoda S., 
2006, 
[182]
 
New Zealand, 
Rabbit, 
Cornea 
GFP plasmid Optison Direct injection 
to cornea, 10µg 
plasmid 
1MHz; 1.0-2.0W/cm
2
; 
50% DC; 2 min exp. 
3 fold increase in GFP 
expression using MB + 
2.0W/cm
2
 vs. US only 
No corneal damage 
or defects. Cellular 
structures intact. 
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First author, 
Year, Citation 
Strain, Model, 
Target 
Delivered 
Material 
Microbubble 
(MB) 
Method Ultrasound settings Optimal or notable 
transfection characteristics 
Safety 
Duvshani-
Eshet M., 
2007, 
[175]
 
C57BL, 
Mouse, 
SC prostate 
tumour 
Luc or GFP 
plasmid 
Optison SC or IT 
injection, 100µg 
plasmid 
1MHz; 2.0W/cm
2
; 30% 
DC; 20 or 30 min exp. 
Peak luc expression with IT 
injection + MB + 20min US: 2.5 
fold increase vs. US only.  
No histological tissue 
damage 
Leong-Poi H., 
2007, 
[242]
 
Sprague-Dawley, 
Rat, 
Ischemic skeletal 
muscle 
GFP or GFP-
VEGF165 
plasmid 
Cationic lipid 
MB attached 
to plasmid 
IV infusion; 
500µg plasmid 
1.3MHz; power: 0.9W; 
pulse interval: 5s; 
20min exp. 
Significant increase in vessel 
density and blood volume and 
flow with US + MB at 28 days 
vs. GFP plasmid or control;  
Not reported 
Suzuki R., 
2007, 
[243]
 
ddY, 
Mouse, 
Femoral artery 
Luc plasmid Liposome MB IA injection; 
10µg plasmid 
1MHz; 1.0W/cm
2
; 50% 
DC; burst rate: 2Hz; 
1min exp. 
Significantly increased luc 
expression with MB + US vs. 
controls or lipofectamine 2000 
Not reported 
Chen Z., 
2008, 
[244]
 
BALB/c, 
Mouse, 
Myocardium 
GFP plasmid 
and PEI 
SonoVue IV tail injection, 
30µg plasmid 
3MHz; 1.0W/cm
2
; 20% 
DC; 2 min exp. 
2 fold GFP expression increase 
with US + MB +PEI vs. US+ MB, 
6 fold increase vs. plasmid only 
No inflammatory cell 
infiltration nor 
haemorrhage  
Suzuki R., 
2008, 
[233]
 
ddY, 
Mouse, 
IP and footpad 
ascites tumours 
Luc plasmid Liposomal MB IP or IV 
injection, 10µg 
plasmid 
IP tumour: 1MHz; 
1.0W/cm
2
; 50% DC, 
1min exp. 
Footpad: 0.7MHz; 
1.2W/cm
2
; 50% DC, 
2min exp. 
Luc expression of IP delivered 
MB + US comparable to 
Lipofectamine 2000; superior 
for IV 
No in vitro 
haemolysis under US 
settings used. 
Shen Z.P., 
2008, 
[183]
 
C57BL6, 
Mouse, 
Liver 
Luc plasmid Optison IV hepatic 
portal or direct 
liver injection, 
50µg plasmid 
1.17MHz; PNP: 0-
4.3MPa; 20-667 cycles; 
17-571µs pulse 
duration; PRF: 3-50Hz; 
30-150s exp. 
85 fold increase in expression 
using 3MPa vs. negative 
plasmid only. 2 fold vs. 4.3MPa 
Macroscopic damage, 
haemorrhage, 
ischemia at PNP 
4.3MPa 
Sheyn D., 
2008 
[245]
 
C3H/HeN, 
Mouse, 
Thigh muscle 
Luc or 
rhBMP-9 
plasmid 
Optison IM injection 
against femur, 
50µg plasmid 
1MHz; 5.0W/cm
2
; 50% 
DC; 10min exp. 
13 fold increase in gene 
expression vs. control 
Not reported 
Chai R., 
2009, 
[236]
 
Sprague-Dawley, 
Rat, 
Pancreatic β-cells 
DsRed 
plasmid; RIP-
type or CMV 
promoter 
Lipid MB 
containing 
plasmid 
Jugular vein 
infusion, 1mL 
bubbles with 
carried plasmid 
1.3MHz; 1.2-1.4MI; 
ECG triggered 4 frame 
burst every 4 cardiac 
cycles; 20 min exp. 
Extended RIP region gave 
significantly greater expression 
vs. truncated + normal RIP and 
CMV 
Not reported 
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First author, 
Year, Citation 
Strain, Model, 
Target 
Delivered 
Material 
Microbubble 
(MB) 
Method Ultrasound settings Optimal or notable 
transfection characteristics 
Safety 
Kobulnik J., 
2009, 
[94]
 
Sprague-Dawley, 
Rat, 
Hind limb 
ischemia 
GFP and 
VEGF 
plasmid 
Cationic lipid 
MB 
Infusion IV 
injection, 500µg 
plasmid 
1.3MHz; 0.9W; PNP: 
2.1MPa; pulse interval: 
5s 
Greater increase in 
microvascular blood flow and 
GFP positive areas vs. IM 
injection 
Not reported 
Alter J., 
2009, 
[98]
 
mdx, 
Mouse, 
Myocardium 
Dystrophin 
exon 23 
PMO or GFP-
luc plasmid 
Optison, 
SonoVue, 
Sonazoid 
IV tail injection, 
16mg/kg body 
weight PMO, 
200µg plasmid 
6.1MHz; 1.8MI; 2min 
exp. 
~3 fold increase in dystrophin 
expression using Sonazoid or 
Optison vs. SonoVue; ~2.5fold 
increase using 300µL Optison 
vs. 150µL; ~2fold increase using 
neat Sonazoid vs. 1:3 dilution 
No histological tissue 
damage detected 
Guo H., 
2009, 
[246]
 
Sprague-Dawley, 
Rat, 
Peritoneal 
adhesion 
Smad7 
plasmid 
SonoVue IP injection; 
100µg plasmid 
1MHz; 2.0W/cm
2
; 20% 
DC; 30s exp. 
~8.2 fold increase in Smad7 
expression vs. control; ~44% 
reduction in adhesion vs. no 
treatment 
Not reported. 
Improvement in 
adhesion injury vs. no 
treatment 
Mou Y., 
2009, 
[247]
 
ICR, 
Mouse, 
Myocardium after 
infarction 
β-gal or 
asPLB 
plasmid 
PESDA IV tail infusion; 
600µg plasmid 
1.3MHz; ECG triggered 
3 frame burst every 8
th
 
end diastole; 4min exp. 
~23% increase in LVEF and FS 
and 1.7 fold increase in Ser16-
PLB expression for MB + US + 
plasmid vs. saline only 
Transfection of β-gal 
expression limited to 
target site 
Sakai T., 
2009, 
[177]
 
Wistar, 
Rat, 
Parotid glands 
GAPDH 
siRNA 
Optison Reverse 
injection into 
parotid gland; 
32µg siRNA 
Transdermal or directly 
applied US: 1MHz; 0.5-
4.0W/cm
2
; 50% DC; 
2min exp. 
80% decrease in GAPDH mRNA 
after 48hrs using 2.0W/cm
2
 + 
20% Optison vs. no treatment  
4.0W/cm
2
 caused 
shrinkage of acinic 
cells, destruction of 
acini, apoptosis and 
inflammation 
Geis N.A., 
2009, 
[232]
 
Rat, 
Myocardium 
Luc plasmid Lipid MB 
containing 
plasmid 
Jugular vein 
infusion, 1mL 
bubbles with 
carried plasmid 
1.3MHz; 1.6MI; PNP: 
1.0-1.2MPa; ECG 
triggered 4 frame burst 
every 4 cardiac cycles; 
20 min exp.; static or 
moving US beam 
19-, 32- and 6-fold increase in 
expression in anterior ventricle, 
apex, and posterior wall of 
heart respectively using moving 
US vs. static 
No inflammation or 
cellular damage 
observed. 
Li Y.S., 
2009, 
[170]
 
C3H/HeN, 
Mouse, 
Syngeneic tumour 
or hind limb 
muscle 
Luc plasmid 
with 
episomal 
region 
Sonidel 
MB101 
IM or IT 
injection; 20µg 
plasmid 
1MHz; 1.9W/cm
2
; 25% 
DC; IM delivery: 6min 
exp.; IT delivery: 3 min 
exp.; ±40kHz pulse 
regime  
18% increase in expression in 
muscle on Day 5 using pulse 
regime vs. no regime; long term 
expression using episomal 
plasmid >85 days 
No adverse effects in 
limb mobility noted. 
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Year, Citation 
Strain, Model, 
Target 
Delivered 
Material 
Microbubble 
(MB) 
Method Ultrasound settings Optimal or notable 
transfection characteristics 
Safety 
Wang Z.-X., 
2009, 
[248]
 
Wistar, 
Rat, 
Liver fibrosis 
HGF plasmid Cationic lipid 
MB loaded 
with plasmid 
Femoral IV 
infusion; 1mL of 
loaded MB 
300kHz; 10s pulse 
interval; 10s pulse 
duration; 20min exp. 
22% increase in ADC, 18% 
reduction in EADC on MRI DWI 
using US + MB vs. plasmid only; 
29% reduction in collagen I 
density on histology  
Not reported 
Xing Y., 
2009, 
[82]
 
Wistar, 
Rat, 
Left Kidney 
Luc or 
human EPO 
plasmid 
Optison Renal vein 
hydrodynamic 
delivery into 
isolated kidney; 
50µg plasmid 
1.0, 2.0W/cm
2
; 10% 
DC; 3, 15, 30 min exp. 
4.5 fold increase in luc 
expression with 2.0W/cm
2
 + 
15min exp. – MB vs. 
hydrodynamic delivery only; 2.3 
fold increase in EPO expression 
with 1.0W/cm
2
 + 3min exp. + 
MB vs. hydro-dynamic delivery 
Serum creatinine and 
BUN levels elevated 
but within normal 
range. No apparent 
pathological changes 
in kidney. 
Yoon C.S., 
2009, 
[173]
 
C57BL6J with 
induced diabetes, 
Mouse, 
Skin wound 
VEGF
165
 
plasmid or 
minicircle 
SonoVue SC wound edge 
injection; 20µg 
plasmid or 
minicircle 
1MHz; 2.0W/cm
2
; 20% 
DC; 30s exp. 
1.5 fold increase in wound 
closure by day 6 using minicircle 
vs. control; 1.2 fold vs. plasmid; 
significant increase in angio-
genesis and blood flow 
Transfection using a 
null plasmid resulted 
in slower wound 
closing than control. 
Kodama T., 
2010, 
[249]
 
BALB/C, 
Mouse, 
TA muscle 
Luc or β-gal 
plasmid 
Optison,  
Lipid MB,  
Liposomal MB 
IM injection; 
10µg plasmid 
973.65kHz; 3.0W/cm
2
; 
PNP: 0.21MPa; 10-50% 
DC; number of cycles: 
2-10000; PRF: 9.7-
97365Hz; energy 
density: 18-180J/cm
2
; 
60-120s exp. 
Peak US settings: 20% DC; 200 
cycles; PRF: 973.65Hz; 60s exp.; 
4- fold increase in luc activity 
with liposomal bubbles vs. 
Optison or lipid MB; no 
significant differences in β-gal 
expression 
No increase in tissue 
damage beyond 
needle damage 
Phillips L.C., 
2010, 
[211]
 
Pig, 
Coronary artery 
after balloon 
angioplasty 
RFP plasmid Cationic lipid 
MB with 
attached 
plasmid 
Coronary artery 
infusion;  
Intravascular US 
transducer; 5MHz; 
PNP: 1MPa; 4min exp. 
6.5 fold increase in transfection 
efficiency of vessel perimeter 
cells using US + MB vs. plasmid 
only. 
Not reported 
Suzuki J.-i., 
2010, 
[250]
 
GFP [C57BL/6], 
Mouse, 
Femoral artery 
injury 
ICAM-1 or 
GFP siRNA 
Optison + 
DOTAP 
Direct injection 
to isolated 
femoral artery; 
20µg siRNA 
1MHz; 0.5 W/cm
2
; 50% 
DC; 20s exp. 
Significant increase in delivery 
of siRNA to artery cells with US 
+ MB vs. controls; significant 
decrease in GFP expression in 
GFP mice; significant reduction 
in intimal thickening after injury 
Not reported 
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(MB) 
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Suzuki R., 
2010, 
[251]
 
B6C3F1, 
Mouse, 
Ovarian tumour 
Luc or IL-12 
plasmid 
Liposomal MB IT injection; 
10µg plasmid 
1MHz; 0.7 W/cm
2
; 60s 
exp. 
Luc expression significantly 
increased with MB + US vs. 
controls; complete tumour 
regression in 80% of IL-16 + MB 
+ US treated mice 
No decrease in body 
weight. 
Un K., 
2010, 
[171]
 
ICR, 
Mice, 
Liver and spleen 
Luc or OVA 
plasmid 
Man. modified 
MB lipoplexes 
loaded with 
plasmid 
Tail IV injection; 
50µg plasmid 
1.045MHz; 1.0W/cm
2
; 
50% DC; burst rate: 
10Hz; 2min exp. 
~500-800 fold greater luc 
expression with Man. MB 
lipoplexes vs. Man. lipoplexes; 
increased survival rate after 
OVA tumour transplantation 
after OVA vaccination using 
Man. MB lipoplexes 
No liver toxicity 
following MB and US 
treatment 
Chen Y.-C., 
2011, 
[174]
 
C57BL10, 
Mouse, 
TA muscle 
GFP plasmid Optison with 
P85 (pluronic 
block 
copolymer) 
IM injection; 
10µg plasmid 
1MHz; 1.0W/cm
2
; 
100Hz PRF; 20% DC; 
2min exp. 
~10 fold increase in GFP 
expression using US + MB + P85 
vs. plasmid + US; 1.3 fold vs. 
P85 + US; 2.7 fold vs. MB + US 
Area of damage after 
injection significantly 
increased using MB + 
US. 
Chen Y.-Z., 
2011, 
[161]
 
BALB/c, 
Mouse, 
Myocardium 
Luc, DsRed, 
or GFP 
plasmid 
Liposome MB 
and PEI 
IV tail injection; 
15µg plasmid 
3MHz; 1.0, 2.0, 
3.0W/cm
2
; 20%, 50% 
DC; 100Hz PRF; 1, 2min 
exp. 
Optimal settings: 2.0W/cm
2
, 
20% DC, 2min exp.; >1000 fold 
increase in luc expression with 
US + MB + PEI vs. plasmid only; 
22 fold vs. MB + US; 16 fold vs. 
MB + PEI. Same trend for GFP + 
DsRed expression 
No notable 
cardiomyocyte 
injuries. No 
inflammation or 
haemorrhage. 
Wang X., 
2011, 
[158]
 
C57BL10, 
Mouse, 
TA muscle 
GFP plasmid Optison or its 
constituents 
IM injection, 
10µg plasmid 
1MHz; 2.0W/cm
2
; 
100Hz PRF; 20% DC; 
30s exp. 
Optison or heat treated Optison 
± US produced equivalent 
transfection as did albumin + 
US 
Increased area of 
damage with caprylic 
acid or N-
acetyltryptophan 
Negishi Y., 
2011, 
[252]
 
ICR, 
Mouse, 
Ischemic or 
normal TA muscle 
Luc, GFP or 
human bFGF 
plasmid 
Liposomal MB IM injection; 
10µg plasmid 
1MHz; 2.0W/cm
2
; 50% 
DC; 60s exp. 
200-fold increase in expression 
of luc with MB + US vs. plasmid; 
GFP and bFGF expression 
significantly increased; 
significant increase in capillary 
density and blood flow with 
bFGF + MB + US vs. controls 
Tissue damage 
detected at 4.0 
W/cm
2
, other 
damage associated 
with needle tract. 
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(MB) 
Method Ultrasound settings Optimal or notable 
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Safety 
Fujii H., 
2011, 
[253]
 
Sprague-Dawley, 
Rat, 
Myocardium after 
infarct 
Mouse SCF 
and human 
SDF-1α or 
control 
plasmid 
Definity IV tail injection; 
0.6mg/kg body 
weight of 
plasmid 
1.6MI; burst US: 1.8-
2.0Hz; 3min exp.; 
repeated every 2days 
Significant increase in SDF-1α 
and SCF mRNA and protein 
levels with US + MB vs. control 
plasmid; significantly increased 
myofibroblast recruitment, 
blood vessel density, cardiac 
systolic function, myocardial 
perfusion, heart wall thickness; 
significantly reduced infarct size 
No histological 
inflammation or left 
ventricle dysfunction. 
Significant increase in 
Troponin I levels in 
blood after treatment 
which returned to 
baseline after 7 days 
Nomikou N., 
2012, 
[172]
 
C3H/HeN, 
Mouse, 
Hind limb muscle 
Luc plasmid Lipid: neutral, 
cationic or 
biotinylated 
cationic MB 
IM injection; 
20µg plasmid 
1MHz; 1.3W/cm
2
; 50% 
DC; 1min exp. 
15% and 30% greater luc 
expression with biotinylated 
cationic MB vs. neutral and 
cationic MB respectively 
Not reported 
Luc = luciferase, MB = microbubble, GFP = green fluorescent protein, DC = duty cycle, exp. = exposure, US = Ultrasound, PESDA = 
perfluorocarbon exposed sonicated dextrose albumin, SC = subcutaneous, IT = intratumoral, IV = intravenous, IM = intramuscular, ODN = 
oligodeoxyribonucleotides, TA = tibialis anterior, HKI = hexokinase I, DsRed = Discosoma sp. red fluorescent protein, RIP = rat insulin promoter, 
CW = continuous wave, CMV = cytomegalovirus, asPLB = antisense phospholamban, GAPDH = glyceraldehydes-3-phosphate dehydrogenase, 
VEGF = vascular endothelial growth factor, siRNA = short interfering RNA, HGF = hepatocyte growth factor, ADC = apparent diffusion 
coefficient, EADC = exponential ADC, EPO = Erythropoietin, RFP = red fluorescent protein, OVA = ovalbumin, Man. = mannose, PEI = 
Polyethylenimine, DOTAP = 1,2 dioleoyl-3-trimethylammonium-propane, GM-CSF = granulocyte-macrophage colony-stimulating factor, bFGF = 
basic fibroblast growth factor, SCF = stem cell factor, SDF-1α = stromal cell-derived factor-1α, ICAM-1 = intercellular adhesion molecule-1.
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1.6. Aims 
So far, a number of people have used ultrasound and microbubble mediated gene 
transfection in vivo for the purposes of preclinical treatment of disease[98, 123, 170, 236, 248]. 
These studies have helped to demonstrate the feasibility and potential power of ultrasound 
mediated transfection for gene therapy, but transfection efficiencies have been poor in 
comparison to other techniques[70, 93, 94, 100, 123, 211, 248]. It is therefore desirable to pick out the 
key factors which affect the success of UMGT. Many research groups have gone on to try 
and improve transfection using new techniques or adjuncts which tend to show improved 
results[173, 244]. However, these studies use a variety of different ultrasound parameters, 
animal models and microbubbles, which makes it difficult to compare them and apply their 
improvements in other designs.  
It is important therefore, to attempt to find key factors which are responsible for 
UMGT success. Much of this work has been done for ultrasound parameters[85, 150, 160], 
however the key microbubble factors remain unknown. It is the hypothesis of this work that 
identifying and understanding the key microbubble factors will improve the subsequent 
optimisation of UMGT transfection. The hope is that these factors will be easy to integrate 
into any other research design and advance the field towards clinical relevance. 
 To explore this hypothesis, the following aims were performed: 
 To create a reproducible Model Protocol capable of exploring the link between in 
vivo transfection of the heart and microbubble characteristics 
 To explore how changes in the Model Protocol affect microbubble characteristics 
and subsequent transfection 
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1.7. Chapter Summaries 
Chapter 2 – Methods and Materials 
In this chapter, the techniques used throughout the investigation will be described. 
These will include; isolation of plasmid DNA, the types of microbubbles used and 
manufactured, microbubble characterisation using bulk acoustics, optical microscopy and 
fluorescence, and the in vivo procedure for transfection of the heart. Some justification for 
these methods will be given here and in Chapter 3 which describes the Model Protocol. 
Chapter 3 – The Model Protocol 
In this chapter, the creation of the Model Protocol is described. Justification of the 
methods used is further expanded upon. Population statistic techniques are compared and 
the chosen optical microscopy method described. The use of bulk acoustic characterisation 
of microbubble scattering, attenuation and stability is explained. Preliminary transfection 
experiments are detailed to explain the choice of certain time parameters in terms of peak 
bioluminescence after treatment. Potential sources of variability are then described in 
depth to explain high variability seen with UMGT therapy. An investigation into one 
potential source of variability is described.  
Chapter 4 – Influence of needle gauge on UMGT in vivo 
In this chapter, the effect of needle gauge on transfection is explored. In vitro 
experiments into the effect of needle gauge on SonoVue microbubbles demonstrates a 
reduction in concentration after passage through high gauge (narrow bore) needles. 
Transfection experiments show a significant reduction in transfection when using high 
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gauge needles. A link is established between high gauge needles, microbubble destruction 
and low transfection, with a recommendation that needles with a low gauge should be used 
for UMGT. 
Chapter 5 – Investigation into effect of albumin and dextrose concentration on UMGT in vivo 
In this chapter, the effect of changing the initial concentrations of an albumin 
microbubble formulation is explored. Albumin microbubbles were made from albumin and 
dextrose, sonicated with perfluoropropane gas. By changing the concentration of albumin 
(2% or 5% w/v) and dextrose (20% or 40% w/v) in the initial pre-sonication mixture, 
microbubbles of different properties were produced. Microbubbles were optically examined 
for stability, acoustically characterised and their transfection ability was investigated. The 
results demonstrated that an increase in dextrose concentration would increase the 
scattering and attenuation behaviour of a microbubble as well as its stability and 
transfection ability. Decreasing the albumin concentration resulted in an increase in both 
attenuation and transfection but only for 40% dextrose microbubbles. A strong link was 
noted between transfection success and bulk attenuation for a microbubble formulation, 
the first demonstration of how a microbubbles acoustic properties affect its transfection 
ability. 
Chapter 6 – Investigation into effect of DNA co-localisation on UMGT in vivo 
In this chapter, preliminary work is presented into the production of an albumin and 
glucosamine microbubble capable of loading DNA with the aim to investigate how co-
localisation of plasmid at the treatment site affects transfection. The first section describes 
the results of several trial experiments with different formulations of albumin, dextrose and 
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glucosamine to produce a useable microbubble. A reproducibility experiment for the final 
chosen microbubble formulation is presented. The second section describes the calibration 
of a potential fluorescence technique to investigate the DNA loading capacity of 
microbubbles. A preliminary experiment into the DNA loading capacity of a glucosamine 
microbubble is described. 
Chapter 7 – Discussion, Future work and Conclusion 
In this chapter, the key outcomes of the project are described and the project is 
discussed in relation to the field.  Future experiments are detailed and a final conclusion on 
this project is presented. 
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2. Methods and Materials 
In this chapter, the methods and materials used in the project are discussed. 
Experimentation involved three major parts; optical microscope examination of 
microbubbles, bulk acoustic characterisation, plasmid-loading and in vivo UMGT of CD1 
mice. Justification for these methods is primarily discussed here and in Chapter 3, where the 
use of these methods as a Model Protocol is discussed. For several of the methods, the 
information provided here is a broad overview of the procedures; individual methods were 
often adapted and refined during experimentation. Specific details of these changes are 
provided in the chapters in which they are used. Additionally, Chapter 6 includes a number of 
methodological changes particular to the experimentation undertaken. Unless otherwise 
stated, all chemicals were purchased from Sigma-Aldrich Company Ltd. (Dorset, UK).  
  
2.1. Plasmid 
In this work, bioluminescence imaging was used as the reporter mechanism for 
transfection. Bioluminescence imaging provides a simple, fast and quantifiable system for 
monitoring the level of transfection. It provides information on the localisation of 
transfection and can be performed in vivo on live animals with minimally invasive 
techniques. It has greater sensitivity than fluorescent imaging and is a commonly used 
modality in investigating the delivery efficiency of gene therapy techniques[34, 69, 254].  
The plasmid pGL4.13 (Promega UK Ltd., Southampton, UK) was used in all 
experiments (Fig. 2.1). It contains the Phontinus pyraelis luciferase gene, luc2, controlled by 
the Simian Virus 40 (SV40) promoter. It is 4.6 kb in size and encodes beta-lactamase for 
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ampicillin-resistant, bacterial selection. The pGL4.13 plasmid, part of the pGL4 family of 
luciferase plasmids produced by Promega, is engineered for efficient expression in 
mammalian cells, boasts improved luminescence in comparison to previous generations of 
pGL plasmids, and has a reduced number of potentially interfering consensus transcription 
binding sites (information taken from the Promega website).  
Plasmid DNA was amplified in MAX Efficiency DH5α Competent Cells (Invitrogen Ltd., 
Paisley, UK) in 2.4 L overnight cultures and purified using Qiagen’s EndoFree Giga Prep kit 
(Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions. Endotoxin 
free methods were used to avoid pyrogenic effects from bacterial cloning. Recovered 
plasmid was resuspended to a concentration of 4 mg/mL in injectable water for in vivo use 
(Norbrook, Newry, Northern Ireland), which is known to give strong, reproducible 
bioluminescence[123]. Quantification was performed using the standard technique of 
ultraviolet (UV) spectroscopy at 260 nm and purity was determined by the 260 nm vs. 230 
nm, 280 nm, and 320 nm ratios. Plasmid integrity was checked by restriction digests and gel 
electrophoresis.  
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Figure 2.1. pGL4.13 plasmid map (taken from www.promega.com). 
 
2.2. Restriction enzyme digest 
The integrity of pGL4.13 was checked by restriction enzyme digestion using SpeI and 
HpaI restriction enzymes, which yields three fragments of 612 bp, 1920 bp and 2109 bp. 
These were run in an electrophoresis chamber using 0.5X Tris/Borate/EDTA (TBE) buffer (5.4  
g/L Tris base, 2.75 g/L boric acid, 1 mM EDTA in distilled water) on a 1% (w/v) agarose gel 
made with 0.5X TBE buffer and 0.5 µg/mL ethidium bromide. Digested plasmid samples 
were run against undigested plasmid and 1 kb DNA markers. Imaging of bands was 
performed using a closed transilluminator (representative image given in Fig. 2.2). 
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Figure 2.2. UV image of digested (a, b, c) (n=6) and undigested, non-linearised (d) (n=6) 
pGL4.13, electrophoresed on a 1% (w/v) agarose gel containing 0.5 µg/mL ethidium bromide 
for 1 hour at 80 V. Lane; 1: 1 kb DNA markers; 2-7: SpeI and HpaI digested pGL4.13; 8-13: 
undigested pGL4.13. Gel band; a: 2109 bp; b: 1920 bp; c: 612 bp; d: 4641 bp. 
 
2.3. Microbubbles 
Two types of microbubbles were used during this project; the commercially 
available, lipid-shelled SonoVue® (Bracco Research SA, Geneva, Switzerland) and a custom-
made, perfluorocarbon exposed, sonicated, dextrose and albumin (PESDA) type. In addition, 
attempts were made to create a third type of bubble based on PESDA but substituting 
dextrose for the amino sugar glucosamine, the methods of which are provided in the 
Chapter 6.2. 
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2.3.1. SonoVue 
SonoVue is a lipid-shelled microbubble of sulphur hexafluoride gas supplied as a 
lyophilised powder with 5 mL of 0.9% saline for reconstitution. When prepared according to 
the manufacturer’s specification, the microbubble concentration ranges from 2 – 5 x 108 
microbubbles/mL, with a mean diameter of 2.5 µm[185, 202]. Unless specified, all experiments 
used SonoVue that was prepared at double the normal concentration by reconstituting the 
lyophilised powder with half of the supplied saline. Previous studies have shown increasing 
SonoVue concentration leads to increased transfection, however, increasing beyond double 
concentration leads to increased mortality in mice[98]. 
 
2.3.2. PESDA type 
Several formulations of PESDA bubbles were prepared, using a well-established 
method[213, 227]. They are typically referred to as albumin-based or albumin microbubbles in 
the text. Bubble formulations are labelled according to the initial % (w/v) concentrations of 
their starting materials for simplicity. The basic method of production is given below along 
with the different formulations produced and any specific changes in method (Table 2.1). 
The albumin solution and sugar solution were prepared separately in 0.9% saline 
(hameln Pharmaceuticals Ltd., Gloucester, UK) and sterile filtered using 0.2 µm pore, 
cellulose acetate syringe filters. These were mixed 1 part to 3 parts respectively and heated 
in a stirred, water bath for five minutes. 10 mL of octafluoropropane gas (F2 Chemicals Ltd, 
Lea Town, UK) was bubbled through the solution before sonication at 20 kHz at half 
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maximum power (Sonicator 3000, Misonix Inc., Farmingdale, NY, USA). The resulting 
suspension was immediately centrifuged at 500 rpm for 1 minute to form a liquid 
infranatant and solid “cake” on top of the solution. The liquid infranatant, which contains 
the microbubbles was aspirated by 19G needle and 5 mL syringe, whilst the “cake,” which 
contains larger bubbles, was discarded. A second centrifugation under the same settings 
was performed for some formulations due to poor initial separation between microbubbles 
and “cake”. 
 
Table 2.1. PESDA type bubble formulations produced with specific changes in manufacture 
methods. *Other glucosamine formulations are discussed in Chapter 6.2. 
Abbreviated  
Name 
Initial concentration (w/v) of… Sonication 
time (s) 
Centrifugation 
steps Albumin Dextrose Glucosamine 
2%, 20% 2% 20% N/a 60 1 
2%, 40% 2% 40% N/a 60 2 
5%, 20% 5% 20% N/a 60 1 
5%, 40% 5% 40% N/a 60 2 
2% 40% 15%* 2% 40% 15% 30 2 
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2.4. Microbubble population statistics 
Concentrations and size distributions were determined by optical microscopy using a 
haemocytometer as previously described[255]. A diluted sample of microbubbles was loaded 
onto a haemocytometer (Bright-Line, Hausser Scientific, UK) and allowed to rise to the cover 
slip over 5 minutes. Images were then captured using a light microscope (Fig. 2.3) with 
digital acquisition (40x magnification, Nikon Eclipse 50i, Nikon Digital Camera DXM1200C, 
Nikon, Tokyo, Japan) with each sample repeated once. Images were analysed in MATLAB 
(The Mathworks Inc., Natick, MA, USA) using a custom sizing and counting program to 
determine the concentration, mean diameter, median diameter and gas concentration[255]. 
Justification for using an optical sizing method is given in Chapter 3.2.2. 
 
Figure 2.3. Nikon Eclipse 50i Fluorescence and Light Microscope. 
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2.5. Experimental syringes 
Three types of syringes were used for intravenous (IV) injections into mice, each with 
an integrated needle of a different gauge (Table 2.2). IV syringes with integrated needles 
were used to minimise dead space, the area between syringe and needle where the solution 
can become trapped, which is considerable when using standard hub mounted needles. This 
was an important consideration during microbubble administration since microbubbles 
float. This buoyancy is dependent upon their gas volume, and therefore size, which can 
result in a heterogeneous size distribution in the syringe developing over time. A portion of 
the dose is left in the dead space after administration which leads to the loss of a size 
section of microbubble population. By using integrated needles, the dead space introduced 
by the needle-syringe connection is significantly reduced. 
 
 
Table 2.2. Properties of the three IV syringes. (ID = Internal diameter, OD = Outer diameter) 
Manufacturer/Brand 
Needle… Syringe… 
Gauge 
OD 
(mm) 
OD 
(mm) 
Length 
(mm) 
Volume 
(mL) 
ID 
(mm) 
OD 
(mm) 
Terumo Insulin syringe 29G 0.184 0.337 13.0 0.5 3.45 5.40 
BD Tuberculin syringe 27G 0.210 0.413 12.7 0.5 3.55 5.70 
Terumo SurSaver syringe 25G 0.31 0.514 16.0 1.0 4.7 6.6 
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2.6. Effect of needle passage on SonoVue 
200 µL of a freshly prepared SonoVue suspension were removed to a 1.5 mL 
microcentrifuge tube using a 19G needle and 1 mL syringe. 150 µL of the suspension was 
added to 50 µL of injectable water by pipette and mixed gently by stirring of the pipette tip. 
The 200 µL sample was drawn up into an IV syringe and held vertically for 20 seconds as air 
bubbles were removed. The IV syringe was held horizontally for a further 20 seconds to 
simulate the placing of the needle which would occur in vivo, and contents expelled into an 
empty microcentrifuge tube over 10 seconds. A “no needle” control sample was also 
prepared by pipette from the diluted microbubble suspension. Microbubble population 
statistics were then measured. Three sample repeats were prepared per syringe or control. 
Repeat samples were interleaved over time, to monitor the effect of bubble decay within 
the vial on suspension characteristics. The bubble decay was calculated from control values 
and used to adjust experimental results. 
 
2.7. Bulk suspension acoustic stability 
The stability of a bulk suspension of microbubbles was investigated using the 15L8 
linear array probe on a Siemen’s Acuson Sequoia 512 diagnostic ultrasound machine 
(Siemens plc., Surrey, UK). Setup is shown in Figure 2.4. 30 µL of a microbubble suspension 
was added to a 300 mL vessel with acoustically transparent, 6 µm thick, polyester film 
windows filled with gas saturated, 37oC distilled water. The probe was placed approximately 
5.0 mm from the chamber and focused at 7.5 mm, so the focus fell 2.5 mm within the 
chamber. The scanner was set to transmit at 6.1 MHz and receive at the second harmonic 
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over a power range of 0.52 to 1.6 MI according to the machine display. B-mode images of 
frames 1 to 5 (frame refresh of 70 Hz) were collected and exported from the machine. Each 
read was performed three times and the experiment repeated a further two times. Control 
images of the chamber without microbubbles were taken at each power as background. 
Images were processed in MATLAB (The Mathworks Inc.) to recover scatter 
intensities from a defined region of interest at the centre of the acoustic focus with control 
images used to remove background noise. Scatter intensity values were normalised against 
Frame 1 and plotted over the 5 frames. The area under curve (AUC) was measured to 
generate a stability value at the three acoustic powers. Justification for this method is given 
in Chapter 3.2.4.  
 
Figure 2.4. Experimental setup for measuring bulk suspension acoustic stability. Transducer 
is set back from chamber for clarity. Note: transducer displayed is the 7V3c probe of the 
Acuson Sequoia, not the 15L8.  
 
Heater
Transducer
Chamber
Windows
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2.8. Acoustic scattering and attenuation 
Acoustic scattering and attenuation measurements of bulk microbubble suspensions 
were performed by Dr Helen Mulvana as previously described[256]. A 300 mL vessel with 
acoustically transparent, 6 µm thick, polyester film windows filled with gas saturated, 
distilled water was placed at the mutual focus of a matched pair of single element 
transducers (Videoscan V380 Panametrics-NDT, Waltham, MA, USA). A sufficient volume of 
microbubbles was added to generate an approximate 50% attenuation of the total 
transmitted signal. One transducer was driven with a stepped pressure ramp made up of a 
series of pulse-inversion (PI) pairs where the pulse was a 2 cycle Gaussian windowed 
sinusoid with centre frequency 3.5 MHz over a pressure range from 22 - 217 kPa in 30 kPa 
increments. A pulse repetition frequency (PRF) of 2 Hz was used, while the intra PRF 
between the incremented pressure ramp pulses was 5 kHz. The acquisition was repeated 
every 30 seconds for 10 minutes.  
Signals were generated in MATLAB and uploaded to an arbitrary signal generator 
before power amplification. Scattered signals were received using a second, matched 
transducer and amplified (PR5800, Panametrics-NDT), while attenuated signals were 
acquired in the far field using a 1 mm diameter needle hydrophone (Precision Acoustics Ltd., 
Dorset, UK) connected to a pre-amp. All signals were acquired via a digitizer to a PC for post-
processing in MATLAB to recover the attenuation, total scatter and non-linear scatter 
component of the receive signals in each case. Measurements were normalised against the 
actual volume of contrast agent added to generate each measurement. Justification for this 
method is given in Chapter 3. 
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2.9. In vivo transfection of cardiac muscle 
All animal work was conducted under the authority of a UK Home office project 
licence as required by the Animals (Scientific Procedures) Act 1986. Mice were maintained 
in a Home Office approved, minimal disease facility with food and water provided ad 
libitum. Six to eight week old, female, CD1 mice were anaesthetised using 5% isoflurane gas 
and maintained at 2-3% isoflurane on a heat mat. Hair was removed from the chest of each 
mouse by shaving and depilatory cream, to ensure good coupling with warmed ultrasound 
gel. The Siemens Acuson Sequoia ultrasound scanner and 15L8 linear array transducer were 
used throughout. Organ location and imaging was conducted at low ultrasound intensity to 
avoid bioeffects (14 MHz, 0.06 MI, focal depth 0.75 mm). The transducer was positioned 
using a cranial-dorsal long axis orientation through the left side of the chest so that the 
acoustic focus was coincident with the heart and once aligned the scanner was frozen (i.e. 
acoustic emission was stopped) to prevent premature destruction of microbubbles. Set up is 
shown in Figure 2.5. 
Each set of animals was treated with freshly prepared microbubbles that were used 
within three hours of preparation. 150 µL of microbubbles was mixed with 50 µL of 4 mg/mL 
pGL4.13 plasmid and injected via the tail vein using an IV syringe. The suspension was 
administered by hand at an approximate flow rate of 0.02 to 0.04 mL/sec, i.e. each 200 µL 
injection took between 5 and 10 seconds. This was immediately followed by two minutes of 
high intensity ultrasound (6.1 MHz, 1.6MI, focal depth 0.75 mm) exposure, with the focus 
fixed on the heart section located by low intensity ultrasound. After treatment, the 
transducer was removed and the mouse was recovered in a heated box. Justification for this 
method is given in Chapter 3. 
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Figure 2.5. In vivo transfection set up. A mouse is placed in position with its head in the Bain 
coaxial anaesthetic cone. The mouse is shaved and depilated and the transducer focus 
adjusted to the cardiac position. Note: transducer displayed is the 7V3c probe of the Acuson 
Sequoia, not the 15L8. 
 
2.10. In vivo bioluminescence imaging 
Three days after transfection, the transfected mice were imaged live in an IVIS 100 
bioluminescence camera (Fig. 2.6) using Living Image V3.2 software (Caliper Life Sciences, 
Hopkinton, MA, USA). Mice were anaesthetised using 5% isoflurane and maintained during 
imaging at 1-2% isoflurane on the heated imaging platform of the IVIS 100 machine. An 
intraperitoneal (IP) injection of the substrate D-luciferin (Gold Biotechnology Inc., St. Louis, 
MO, USA) (300 mg per kg body weight in injectable water) was administered and the 
resulting bioluminescence in transfected tissues expressing luciferase was imaged. 
Heat pad
Transducer
Adjustable stand
Bain coaxial system
Mouse position
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Bioluminescence images were taken every two minutes for twenty minutes (1 minute 
exposure, Field of View: 10 cm, f-stop: 1, medium binning, automatic height focusing).  
Using the analysis tools of the Living Image V3.2 software, a region of interest was 
drawn around the area of bioluminescence from the cardiac region on each image and the 
photon flux (photon/s) measured. Signals were normalised for noise by removal of the 
background signal measured from an untreated site on each image. The background 
normalised photon flux values over the 20 minutes were examined to find the peak 
bioluminescence value within the linear phase of the bioluminescence. This was to ensure 
luciferin had saturated the system and that signal level was related to the level of luciferase. 
 
Figure 2.6. IVIS 100 bioluminescence camera with XGI-8 anaesthetic system. Animals are 
anaesthetised in the Anaesthetic chamber, before injection with luciferin and transfer to the 
Imaging chamber. Images are then taken by the Cooled CCD Camera. 
Anaesthetic chamber
Cooled CCD Camera
Anaesthetic system
Imaging chamber
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2.11. Ex vivo bioluminescence imaging 
After in vivo bioluminescence imaging, mice were culled and internal organs rapidly 
harvested and arranged on a Petri dish. Bioluminescence images of the organs were taken 
to determine the exact source of bioluminescence and to confirm transfection in the target 
organ (1 minute exposure, Field of View: 10 cm, f-stop: 1, medium binning, automatic height 
focusing).  
 
2.12. Tissue preparation for ex vivo bioluminescence 
quantification  
Tissues were prepared for ex vivo bioluminescence quantification following a well-
established method[257]. Harvested organs were placed in microcentrifuge tubes and snap 
frozen in an alcohol bath at -80oC. Organs were pulverised in a liquid nitrogen chilled pestle 
and mortar to a fine powder and weighed. Fine powder was mixed with 500 µL of Promega’s 
Luciferase Cell Culture Lysis buffer (Promega UK Ltd.) and frozen/thawed three times to fully 
lyse cells. Lysed organs were stored at -80oC until required. 
 
2.13. Ex vivo bioluminescence quantification 
A Centro LB 960 plate luminometer (Berthold Technologies GmbH, Bad Wildbad, 
Germany) running MikroWin 2000 V.4 (Mikrotek Laborsysteme GmbH, Overath, Germany) 
was used to quantify luminescence in the lysed organ samples. 10 µL of lysed organ samples 
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were rapidly loaded in triplicate on to a 96-well plate and placed in the luminometer. 
Luminescence was triggered by automated addition of 50 µL of luciferase assay reagent (0.2 
mM D-luciferin (Gold Biotechnology Inc.), 0.2 mM adenosine triphosphate, 7 mM 
magnesium sulphate, 0.25 mM coenzyme A). Luminescence was then read for 10 s after an 
initial 2 s delay. Luminescence values were normalised against organ weight. 
 
2.14. Visualisation of DNA loading on microbubbles 
The DNA binding fluorescent dye, 4',6-diamidino-2-phenylindole (DAPI) was used to 
label plasmid DNA bound to microbubbles. DAPI emits at a peak of ~461 nm when excited at 
~358 nm, with fluorescence increasing approximately 20 fold upon binding of the minor 
groove in AT regions of DNA. The dye is commonly used for cell staining of the nucleus and 
fluorescence spectrophotometry of DNA. 
A dispersion of microbubbles was incubated for 5 minutes at room temperature with 
4 mg/mL pGL4.13 or injectable water at a 3:1 ratio, as used for in vivo injections. This was 
then diluted 1:1 with 500 ng/mL DAPI in sterile distilled water. After a further 5 minutes, 
microbubbles were washed by centrifugation. Solutions were spun at 450 rpm for 5 minutes 
causing bubbles to float and form a “cake”. The clear liquid was tapped off and replaced 
with phosphate buffered saline (PBS). Microbubbles were resuspended with gentle 
pipetting. Solutions were washed twice. After the second wash, microbubbles were 
resuspended in in distilled water. 
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Microbubbles were loaded onto a haemocytometer and examined in a fluorescence 
microscope (40x magnification, Nikon Eclipse 50i, Nikon Digital Camera DXM1200C, Nikon) 
using a UV-2A filter cube (excitation filter: 330-380 nm, dichromatic mirror: 400 nm, 
emission barrier: 420 nm, Nikon). Corresponding bright field and fluorescence images were 
taken.  
 
2.15. Quantification of DNA loading on microbubbles 
Microbubbles were incubated for 5 minutes with pGL4.13 or injectable water, but 
not DAPI, and washed as above. After the second wash, microbubbles were resuspended in 
distilled water and transferred to a 5 mL syringe. The end of the syringe was sealed and the 
microbubbles destroyed by negative pressure applied by drawing out the plunger. 
Destroyed microbubbles were diluted 1:1 with 1.2 M NaCl (final concentration: 0.6 M NaCl) 
or distilled water for 5 minutes. The high salt concentration and microbubble destruction 
were used to release plasmid DNA from the albumin shell. Samples were diluted 1:1 with 5 
µg/mL DAPI and read in an F-2500 Fluorescence spectrophotometer (Hitachi High 
Technologies Corporation, Tokyo, Japan). Fluorescence values were compared to standard 
curves to return the DNA concentration. 
Protein quantification was also performed using the Qubit™ Protein Assay Kit 
according to the manufacturer’s instructions. This was used to normalise the DNA 
concentration to account for differences in microbubble concentration after washing. 
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Full details of the calibration experiments performed are given in Chapter 6, where 
the use of fluorescence spectrophotometry is discussed. 
 
2.16. Statistical tests 
The exact statistical tests used were dependent upon the individual data and are 
described in each chapter. All statistical tests were performed in MATLAB (The Mathworks 
Inc.) or Excel (Microsoft Corp., Redmond, Washington, USA). In general, data was tested for 
normality using the D’Agostino-Pearson K2 omnibus test for n≥8, or the Shapiro-Wilks test 
for n<8. Homoscedasticity was tested for using Bartlett’s test for parametric data, or the 
Brown-Forsythe test for non-parametric data. One-way ANOVAs (parametric) and Kruskal-
Wallis ANOVAs (non-parametric) were used to check for significance in single factor data 
groups. Two-way ANOVAs (parametric) and the Friedman or Mack-Skillings test (non-
parametric) were used to check for significant differences and interactions in multifactorial 
data groups. Pairwise comparison was performed using the Tukey-Kramer test (adjusted for 
non-confounded groups in multifactorial designs) or the non-parametric Dunn’s test. For 
comparison between two sample groups, a Student’s t-test or a Mann-Whitney U test was 
performed. In all cases, significance was assumed if p≤0.05. 
Both retrospective and a priori power analysis were performed post-hoc in the free 
statistical program G*Power v3.1.3 (Franz Faul, Universität Kiel, Germany)[258] on in vivo 
data to determine the statistical power of the one-way ANOVA test and the required sample 
size for a power of 0.95. Effect size, as the f measure, was calculated by the program using 
the means of groups and their average standard deviation[259]. For multifactorial data, the 
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effect size was first calculated as the ηp
2 (partial eta squared) measure in MATLAB, then 
converted to the f measure in G*Power. Unbalanced two-way data could not be effectively 
processed in G*Power due to balanced data assumptions. As such, retrospective power 
analysis of unbalanced two-way data is not presented. 
2.17. Summary 
This project aims to identify key factors that control the effectiveness of UMGT in 
vivo. To do so, a Model Protocol was developed, described in detail in Chapter 3. The 
experiments above form the basis of the Model Protocol, providing detailed 
characterisation of novel microbubble formulations, specifically their bulk acoustic 
response, visual appearance, population statistics, and stability under several different 
conditions, e.g. storage, acoustic excitation, needle passage. The effect of these 
characteristics on UMGT is then investigated in vivo using a bioluminescent reporter gene. 
Additionally, the plasmid loading capacity of a novel microbubble formulation is investigated 
using fluorescence spectrophotometry and imaging, discussed in detail in Chapter 6. 
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3. The Model Protocol 
In this chapter, the basic methodology used throughout the thesis is presented. There 
are many factors which can potentially affect UMGT success, however few studies have 
investigated them. To identify the key UMGT factors a fixed protocol was developed, termed 
the Model Protocol. It involves bulk acoustic methods to characterise microbubbles 
behaviour and optical microscopy to monitor stability and population statistics. In vivo 
transfection studies are then performed to determine how changes in these characteristics 
affect the transfection efficiency. Key factors can then be highlighted, providing new 
potential avenues for optimisation. This chapter discusses the techniques chosen for 
microbubble characterisation. Preliminary UMGT experiments are also presented to 
highlight development of the protocol and discuss potential issues with variation. 
 
3.1. Introduction 
Ultrasound and microbubble mediated gene transfection (UMGT) has undergone a 
great deal of research. The early demonstrations of proof of principle determined that 
transfection was possible and could present a safe, reliable form of gene therapy[147]. 
Although there were a few early publications attempting to optimise the procedure, the 
range of machines, protocols, model organisms and ultrasound parameters meant that only 
broad generalisations about settings could be made, for example, lower frequency cause 
greater transfection due to higher acoustic energy[85, 150].  
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As such, many groups have proceeded directly to preclinical treatment of a disease 
model[87, 88, 90, 236]. Whilst very useful in demonstrating the potential advantage of the 
technique and promoting interest in the field, the work also highlighted the disappointing 
transfection and treatment efficiencies in comparison to other techniques. Attention must 
be turned to discovering the important factors which influence the success of UMGT. 
To this end, a fixed Model Protocol was devised to investigate the different factors at 
work in UMGT. This protocol would use a mix of microbubble interrogation techniques and 
a repeatable in vivo transfection experiment. In this way, the effect on microbubble 
properties due to changes in formulation or methodological procedure can be described 
and their effect on transfection can be measured. In this chapter, the Model Protocol is 
broken down into two sections; the in vitro microbubble characterisation protocols and the 
transfection protocol.  
 
3.2. In vitro characterisation of microbubbles 
3.2.1. Introduction 
Microbubbles play a key role in the success of UMGT[147, 148, 155, 166, 226, 260]. They 
consist of 1 to 10 µm sized, shell-stabilised gas bubbles which are strongly resonant under 
the ultrasonic frequencies commonly used for imaging and therapy. Bubbles oscillating 
under the influence of ultrasound will cause a number of cavitation events resulting in 
severe mechanical perturbation, temperature rises and free radical generation. When used 
in vivo, these result in a number of bioeffects, including cellular sonoporation, endocytosis 
pathway activation and blood vessel extravasation. Microbubbles essentially focus the 
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acoustic energy of ultrasound into discrete, localised areas causing a significant increase in 
transfection compared to using ultrasound only. 
The characteristics of any microbubble will therefore strongly affect the resultant 
transfection and represents a key topic of investigation in this study. There is a requirement 
for techniques that provide detailed information about the behaviour of microbubble which 
can be linked to transfection efficiency. In this section, three characterisation techniques 
will be described; optical sizing and counting, bulk acoustic attenuation and scattering, and 
bulk stability under the influence of ultrasound. 
 
3.2.2. Optical sizing and counting 
The simplest characterisation that can be performed on microbubbles is 
determination of their concentration and size distribution. The importance of these data 
should not be underestimated though as many factors will be affected by them. The 
acoustic characteristics of microbubbles are strongly influenced by their size and 
concentration. The size of a microbubble will affect its resonant frequency which will affect 
its response under the influence of ultrasound of a particular frequency[186, 261, 262]. 
Microbubbles which are closer to resonance will undergo more extreme oscillation and 
potentially cause greater bioeffects than non-resonant bubbles. Microbubbles outside of 
resonance can also affect the acoustic response of a bulk suspension. Strong attenuation 
may also be the result of a high concentration of microbubbles which will strongly absorb 
ultrasound and can also cause significant damping of scattering[263]. Any measurements 
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made of the acoustic characteristics of a bulk suspension of microbubbles must have sizing 
and concentration data for the interpretation of measurements. 
The size distribution and concentration of a microbubble solution can also affect the 
success of transfection[97, 98]. As mentioned, bubbles at resonance will potentially cause 
greater bioeffects, and thus transfection, due to more extreme oscillatory behaviour. 
Knowledge of the size distribution of a bubble population could allow optimisation of the 
ultrasound properties used for insonation. A high concentration of microbubbles will result 
in a greater degree of transfection due to the increased likelihood of cavitation events[85], 
but there also safety implications. Bubbles must be sufficiently dilute in the vasculature to 
prevent blockages occurring within capillary beds. Safe passage through these small vessels 
also dictates a microbubble’s maximum diameter. 
Determination of size distribution and concentration of a microbubble solution is 
therefore a vital part of any project involving microbubbles, particularly custom, in house 
preparations. Manufacturers of commercial microbubbles will have already experimentally 
determined these values and tolerances of their products[202, 205] but any deviation from 
their recommended protocol, such as using half the provided saline to double concentration 
as done in this project for SonoVue, will require characterisation of the resultant bubble 
population. 
There are three common techniques available for determining the size distribution 
and concentration of microbubbles; electrical-zone sensing (Coulter Counter), optical 
microscopy and laser diffraction, the performance of which have been recently evaluated in 
tandem[264]. In this project, sizing and counting by optical microscopy is the chosen method. 
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It is a simple technique that requires a light microscope, a camera capable of digital image 
acquisition, and image processing MATLAB program[255]. Briefly, a dilute suspension of 
microbubbles is loaded onto a haemocytometer and a number of images are captured 
(example image Fig. 3.1). The microbubbles can then be examined directly from the 
captured images, which can reveal other visible features of the microbubbles suspension; 
for instance, unusual bubble shapes, clumping or debris from bubble manufacture. 
Capture images are then analysed in MATLAB using a custom program to determine 
the concentration, mean diameter, median diameter and gas concentration as well as 
presenting a graphical representation of the size distribution (example image Fig. 3.2). 
Briefly, the program works by segmenting the bubbles from the image background, which 
are then sized and counted. Clustered bubbles, identified through comparison to the ideal 
bubble shape, are excluded from the distribution estimation but included in the total bubble 
count. The program will also exclude bubbles less than 0.5 µm and greater than 10 µm in 
diameter due to the microscope’s optical resolution limit and the negligible contribution to 
acoustic response respectively. The program is described in detail in the literature[255].  
This method of microbubble sizing and counting has been extensively used in our lab 
and others for a number of years[98, 213, 265-267]. It has the advantage of being the least 
potentially damaging to the microbubbles under examination as both other methods 
available rely on some form of pressure gradient along fine apertures or tubes which is 
potentially damaging to bubbles[264, 265, 268]. 
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Figure 3.1. Typical image captured by optical microscopy. SonoVue microbubbles are diluted 
1:4 in distilled, gas saturated water. (40x magnification, red scale bar = 10 µm) 
 
Figure 3.2. Typical output from counting and sizing program. Histogram plot shows the 
percentage number distribution of SonoVue microbubbles against grouped microbubble 
diameter (group size: 0.25 µm). Associated population statistics (e.g. concentration, mean 
diameter, etc.) are found above. Bubbles less than 0.5 µm or greater than 10 µm are 
displayed as uncoloured bars and are excluded from the population statistics calculations.  
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3.2.3. Bulk microbubble acoustic scattering and attenuation 
The behaviour of a microbubble in an acoustic field is governed by two factors; its 
formulation, and thus its resultant properties; and the acoustic field conditions. These are 
incredibly broad factors which cover a multitude of different properties and parameters. 
Many of these properties are also directly linked, for instance; microbubble size affects its 
resonance and thus its response to different ultrasound frequencies, whose bandwidth is 
determined by the number of cycles in an ultrasound pulse which will in turn affect the 
amount of acoustic energy deposited into a microbubble and affect its behaviour, 
independent of the amplitude of the wave. As such, acoustic characterisation is a 
challenging procedure and difficult to interpret without a strictly defined and detailed 
protocol and description of the acoustic wave parameters.  
The protocol used in this project to acoustically characterise microbubbles was 
developed and performed by Dr Helen Mulvana and Dr Robert Eckersley. It attempts to 
measure the total and non-linear scattering and attenuation produced by a bulk suspension 
of microbubbles insonified in an acoustic field at physiological body temperature. These 
values help to define the core behaviour of a microbubble; essentially how much acoustic 
energy it will absorb, and how much it will reflect. Both of these have implications for 
transfection. 
These values also have strong implications for the use of microbubbles in contrast 
enhanced ultrasound (CEUS) imaging. Microbubbles are blood-pool agents, meaning they 
remain within the cardiovascular system after intravascular injection, and cause strong CEUS 
imaging of the vasculature, allowing diagnosis of certain disease states, e.g. cardiovascular 
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disease, vascularity of liver and breast lesions (information taken from SonoVue and Optison 
product inserts). Additionally, there is significant interest in the potential of quantitative 
imaging of contrast enhanced regions to become a diagnostic measure in other diseases, 
such as tumours or atherosclerotic vessels[129, 131, 132, 138, 269]. Knowing how a microbubble will 
behave under the influence of ultrasound in vitro allows development of image processing 
techniques for use in vivo[270-273]. 
The attenuation experiment set up in this project, uses a single element transmit 
transducer focused directly on the midpoint of a suspension of microbubbles, with a 
hydrophone placed in the far field. Any acoustic signals which are absorbed or reflected 
away from the hydrophone by the microbubbles are said to be attenuated. As such, 
attenuation is a product of both scattering and absorption. Attenuation can therefore be a 
useful property of a microbubble in imaging providing a strong backscattered signal, 
however, strongly attenuating microbubbles can result in significant loss of information 
beyond the bubbles, particularly in highly vascular or perfused tissue such as the heart, as 
the acoustic wave is completely disrupted by passage through microbubbles (Fig. 3.3). 
Additionally, a bubble with high absorption but low scatter will be of little use in imaging as 
it will only return acoustic energy reflecting off the impedance mismatch between the 
gaseous bubble and solid tissue/liquid blood. 
The scattering experiment uses a similar setup to the attenuation except that a 
matched receiver transducer is placed at 90o to the transmit transducer so that the foci are 
coincident and the bulk suspension of microbubbles is twisted 45o to allow signals to escape 
out the acoustically transparent window. A microbubble oscillating under the influence of 
ultrasound will scatter sound in all directions, so any signals picked up by the receiver 
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transducer will have been reflected from the bubbles. The greater the oscillatory behaviour 
of the bubble, the greater amount of reflected sound will reach the receiver.  
A strongly scattering bubble is of great use in CEUS imaging, however this is only 
considering the case of fundamental scatter. CEUS imaging also relies on the use of the non-
linear behaviour to separate out the tissue component of reflected signal to signal coming 
directly from microbubbles. As such, the non-linear behaviour of a microbubble is another 
important behaviour to be examined in terms of microbubble characterisation, as a strong 
fundamental scatter does not indicate a bubble will have a strong non-linear scatter as it is 
highly resonant dependent. Looking for non-linear scatter can help to identify the resonant 
characteristics of a microbubble population. As such, the pulse sequence used to 
interrogate the bulk suspension consisted of pairs of inverted pulses, so that linear scatter, 
which would be the same for either the original or inverted pulse, could be subtracted from 
total scatter to reveal the non-linear behaviour. To reduce the effects of frequency 
dependent behaviour, a 2 cycle broadband pulse at 3.5 MHz was used and mean scatter and 
attenuation measurements of bubble response over 1 to 4.5 MHz are used. Additionally, the 
non-linearity of microbubble behaviour increases with acoustic pressure[274] so an increasing 
stepped pressure gradient ramp was also used to monitor bubble response over a range of 
powers. To ensure bubble destruction was not occurring, a decreasing stepped pressure 
gradient was used to examine any changes in bubble response after the increasing ramp. To 
ensure an accurate result, the pulse sequence was repeated 50 times over a period of 30 
seconds using a pulse repetition frequency of 2 Hz, before stirring to replenish the acoustic 
focus with new microbubbles and 10 further repetitions to chart any bubble destruction 
over longer time periods. 
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This pulse sequence gives detailed information, covering both total and non-linear 
scatter behaviour, as well as an indicator of bubble stability under the influence of 
ultrasound and over time. For this project, primary interest was given to the factors most 
likely to be relevant in an in vivo transfection setting, so only the bubble total and non-linear 
scattering and attenuation response at the maximum pressure of 200 kPa was examined 
and presented. Additionally, to avoid any influence of microbubble destruction on 
measurements, only the first 50 pulse sequences were examined. From these, only the first 
10 pulses sequences were used to form a mean attenuation measurement. For scatter 
measurements, the full 50 pulses were used, as microbubble movement causes large 
fluctuations of scattered signal requiring a greater number of repeats for accuracy[185]. The 
stability data has not been presented in this project as microbubble stability was already 
under investigation using the in vivo frequency; however, the data was examined to ensure 
that microbubble destruction was not occurring during the pulse sequences used for scatter 
and attenuation measurements.  
There is however, a potential issue when a population of microbubbles with differing 
size distributions are compared. As mentioned, resonant behaviour of microbubbles will 
strongly affect both the attenuation and scattering. A bubble close to resonance size will still 
scatter and attenuate sound but will be primarily linear in its response. A resonant bubble 
will have similar scatter and attenuation profile but its scatter will show a far higher degree 
of non-linearity. Larger bubbles further outside of resonant will be highly attenuating due to 
their size but won’t oscillate strongly and thus have correspondingly low scatter. Comparing 
between bubbles of highly different size distributions when using a single pulse frequency 
can give rise to erroneous interpretations of the data and size distribution should be taken 
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into account whenever the scattering and attenuation data is examined. However, the 
choice of a broadband pulse does help to minimise this resonance effect and as there will be 
some overlap with the broadband frequency used for transfection, it is still an important 
characterisation to perform for bubble comparison. 
The scattering and attenuation values can therefore be highly useful for comparing 
bubble types, particularly novel bubble formulations. By keeping a fixed setup and pulse as 
described above, differences between the acoustic response of different microbubbles 
formulations can be examined and compared against transfection efficiency. There is very 
little literature concerning how a bubble acoustics affects its transfection ability and as such, 
the inclusion of acoustic microbubble characterisation in the Model Protocol will help fill 
this gap in knowledge and potentially highlight new avenues for research. 
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a)  
b)  
Figure 3.3. B-mode second harmonic ultrasound images of a single mouse heart a) before 
and b) ~2 s after administration of microbubbles. Note the loss of information beyond 
microbubbles due to attenuation, highlighted by the red arrow.  
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3.2.4. Bulk microbubble stability under ultrasound 
Microbubble stability is a key concern in their use for diagnostic imaging. 
Microbubbles that are able to persist in the circulation for extended periods of time allow 
the clinician sufficient time to provide a diagnosis, or alter the circumstances of the test to 
examine either other sites, or flow conditions in the target organ. This is equally important 
in transfection studies, as microbubbles must be stable enough to persist in circulation for 
the entire treatment time and oscillate under the influence of ultrasound. Stability has been 
demonstrated to be a key factor determining UMGT efficiency[98]. 
Microbubbles are subject to several forms of destruction whilst in circulation. The 
greatest of these is thought to be caused by the presence of other gases in the blood, 
principally oxygen, carbon dioxide and nitrogen. If the subject is under gas anaesthesia, this 
will also include the anaesthetic used, e.g. Isoflurane. These gases will enter the bubble due 
to the concentration gradient, whilst the original microbubble gas will dissolve out. Rapid 
influx and efflux can destabilise a bubble leading to rapid destruction. To counteract this, 
the current generation of microbubbles use a heavy gas, typically a perfluorocarbon or 
sulphur hexafluoride. These gases have low solubility, which greatly decreases the rate at 
which these bubbles dissolve in the circulation[189, 227]. Persistence of microbubbles can also 
be increased by inhalation of the heavy gas to “prime” the blood or lungs and thus reduce 
the pressure gradient[275]. Either way, gas influx will still occur, causing bubbles to bloat in 
the multigas blood environment[189]. This problem can be especially severe in the lungs, 
where there is constant gas exchange, mechanical pressures from breathing, and a large 
capillary bed directly exposed to the environment. Resistance to dissolution is a limiting 
factor in the time a microbubble can spend in circulation[276]. 
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Other forms of microbubble clearance are also occurring within the circulation. 
Areas of high pressure and shear stress, such as the spleen red pulp or kidney glomerulus, 
could lead to the destruction of pressure sensitive microbubbles[266, 268]. There are also 
immunological responses to the presence of microbubbles. Kupffer cells, a specialised 
macrophage present in the liver, are well known for their ability to phagocytose several 
different types of microbubble[133-135]. Immune recognition is a particularly serious problem 
for molecular imaging strategies using microbubbles, where targeted antibodies or receptor 
targeting peptides can inadvertently activate the complement system, not only hastening 
their demise, but also potentially causing fatal reactions in subjects[140, 277, 278]. 
Finally, any microbubble will also be under acoustic pressure from the ultrasound. In 
diagnostic imaging strategies, relatively low acoustic pressures are utilised to avoid causing 
potentially dangerous thermal or mechanical effects, however even these can cause destroy 
unstable microbubbles. Transfection techniques usually rely on higher pressures to ensure 
the greatest bioeffects and transfection[85, 150] and consequently can become the primary 
mode of microbubble clearance. Increasing the stability of a microbubble, primarily by 
changes in formulation[219] or adjuncts[279] can enable a microbubble to survive longer under 
ultrasound, increasing the treatment time and potential transfection efficiency[98]. 
In this project, stability during ultrasound exposure is tested by insonifying a bulk 
suspension of microbubbles and quantifying the change in backscatter intensity. By using 
gas-saturated, 37oC water and the ultrasound machine and settings used for in vivo 
transfection, it is possible to compare any changes in microbubble acoustic stability under 
physiological temperatures and treatment protocol. Harmonic B-mode images (Fig. 3.4a, b) 
are captured using the ultrasound machine for 5 frames at 70 Hz frame refresh (total time: 
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71 ms). Backscatter intensities are measured in MATLAB using a custom program by 
averaging pixel intensity at the ultrasound focus after conversion to a linear scale from the 
70 dB scale used by the machine. Intensities are then normalised by Frame 1 and plotted 
(Fig. 3.4c). The area under the curve provides a measure of stability, the larger the value, the 
more stable the bubble. Change in backscatter intensity is a simple way to measure 
microbubble destruction over short term insonation. 
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a)  
b)  
c)  
Figure 3.4. Harmonic B-mode images of 2% albumin, 20% dextrose microbubbles after a) 14 
ms (Frame 1) and b) 71 ms (Frame 5) of ultrasound (6.1 MHz, 1.6 MI) and c) their normalised 
back scatter intensities over 5 frames. Area under the curve (AUC) is a measure of stability.  
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3.3. Transfection Protocol 
3.3.1. Introduction 
Bioluminescence imaging was used as the reporter mechanism for transfection. 
Delivery of a reporter gene is a typical step for quantification or optimisation of a delivery 
technique and UMGT is no exception, with many of the common reporters having been 
used, e.g. chloramphenicol acetyltransferase (CAT)[280], Discosoma sp. red fluorescent 
protein (DsRed)[87], GFP[240], LacZ[89]. These promoters can give highly quantifiable results 
and information about the localisation of transfection but require culling of the animal and 
subsequent histological analysis of tissues. This increases the cost, time and workload. 
Bioluminescence imaging has the advantage of being rapid, simple to implement, relatively 
inexpensive and can be used for continuous monitoring of treatment or disease progression 
on live animals. It is able to provide a sensitive, semi-quantitative measure of transfection 
level and is well-suited for comparative studies, such as this project. Additionally, luciferase 
transfection can be quantified using mRNA analysis, histological labelling, or ex vivo 
luminescence, in a similar manner as the other reporter genes mentioned above.  
The transfection protocol is based on existing methods from previous work[123]. 
However, there are two important changes; the plasmid and the murine strain (Table 3.1).  
These changes were primarily done to improve the protocol. pEGFPLuc (Clontech, 
USA) produces a fusion protein of enhanced green fluorescent protein (EGFP) and luciferase 
which is larger than the recombinant luciferase protein produced by pGL4.13, ~88 kDa and 
~62 kDa respectively. The plasmid size is also larger at 6.4 kb compared to 4.6 kb. As 
fluorescent histological examination of tissues was not planned, the fusion protein was 
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unnecessary and the increased protein and plasmid size could hinder 
transcription/translation and transfection respectively. 
The change in murine strain was due to fur colour; the dark pigmentation of C57BL10 
mice potentially absorbs photons emitted from transfected areas. Bioluminescence from 
the albino CD1 strain should suffer from less photon absorption during imaging.  
The heart was chosen as the target organ. The previous work initially targeted the 
liver before moving transfection to the heart and switching to a custom heart-specific 
luciferase plasmid. The liver can strongly absorb photons reducing the chance for 
confirmation of expression, especially for deep tissue transfection[281]. As the heart was 
easier to confirm and also easier to identify and target during transfection, all 
experimentation was performed on the heart.  
It should also be noted that the previous work used luciferase transfection primarily 
for proof of principle. The work’s primary focus was treatment of the mdx muscular 
dystrophy murine strain by transfection of phosphorodiamidate morpholino oligomers 
(PMOs) into the heart.  
A proof of principle experiment was therefore necessary to demonstrate the validity 
of the changes. Additionally, the changes required investigation into the most suitable time 
points for imaging after transfection. Changes in the plasmid reporter gene, promoter and 
the murine strain can alter the peak maximum expression after transfection. It is important 
to hit this maximum expression peak so any between-group differences in expression will 
not be hidden by within-group variability. This should also help reduce the animal numbers 
required for significant results, an important consideration for any in vivo experiment. 
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Table 3.1. Changes from Alete, 2008[123]* (EGFP – enhanced green fluorescent protein, CMV 
– cytomegalovirus, [gene/promoter]) 
Change Current work Previous work* Reasons for change 
Plasmid 
pGL4.13 – 
[luc2/SV40] 
pEGFPLuc – 
[EGFPluc2/CMV] 
Improve luminescence and 
transfection, EGFP unrequired 
Murine strain 
CD1 strain – 
white fur, outbred 
C57BL10 strain – 
black fur, inbred 
Improve luminescence,  
reduce photon absorption 
 
3.3.2. Methodological Particulars 
UMGT was performed as described in the methods using pGL4.13 (4 mg/mL) and the 
commercial microbubble SonoVue (4 – 10 x 108 microbubbles/mL) administered IV with the 
Terumo Insulin syringe (29G). A steady, alternating motion of the transducer was performed 
to sweep the focus through the heart during the 2 minute ultrasound transfection period. In 
vivo bioluminescence protocols were dependent on the experiment and are outlined below. 
 
3.3.2.1. Proof of principle 
A single bioluminescence image was captured 48 hours after transfection and 8 
minutes after luciferin administration using a 5 minute exposure time (Field of View: 10 cm, 
f-stop: 1, medium binning, automatic height focusing). Ex vivo bioluminescence imaging was 
used on harvested organs to confirm cardiac transfection. The experiment was performed 
on three batches of mice using fresh SonoVue bubbles for each batch of mice and a single 
batch of plasmid for all mice. This was a preliminary experiment to investigate whether the 
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transfection could be achieved and imaged. As this work was purely exploratory and the 
methodology subsequently changed, the experiment was not repeated under this protocol. 
 
3.3.2.2. Peak luminescence after D-luciferin injection 
Bioluminescence images were captured 48 hours after transfection with images 
taken every 2 minutes after luciferin administration for 20 minutes using a 1 minute 
exposure. Ex vivo bioluminescence imaging was used to confirm cardiac transfection. The 
experiment was performed on four batches of mice using fresh SonoVue for each batch of 
mice and a single batch of plasmid for all mice. Although the experiment has not been 
reproduced under this method, as mentioned in the discussion, the use of a 20 minute long 
multiple read time was used for all subsequent transfection experiments to avoid missing 
peak expression. 
 
3.3.2.3. Peak luminescence after transfection 
A single bioluminescence image was captured every day for five days, 14 minutes 
after D-luciferin injection using a 1 minute exposure. After imaging, mice were recovered in 
a warm recovery box. On Day 5, mice were culled for confirmation of cardiac transfection. 
The experiment was performed on two batches of mice using fresh SonoVue for each batch 
of mice and a single batch of plasmid for all mice. The experiment was not been 
independently reproduced for reasons later discussed. 
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3.3.3. Results 
3.3.3.1. Proof of Principle  
Eight mice were successfully transfected and imaged. Bioluminescence images 
showed distinct areas of luminescence from the treated region (Fig. 3.5a). Transfection of 
targeted hearts was confirmed using ex vivo bioluminescence imaging (Fig. 3.5b). The 
individual photon flux measured from each mouse was plotted along with the average and 
+/- 1 standard deviation (SD) values (Fig. 3.6). The majority of photon flux values fall 
between 3.5 x 105 and 6.5 x 105 photon/s, besides two low values at 1.2 x 105 and 0.7 x 105 
photon/s which are responsible for the large standard deviation seen.  
 
 
Figure 3.5. Representative image of in vivo and ex vivo bioluminescence. A CD1 mouse 
transfected by pGL4.13 in the heart by ultrasound and SonoVue imaged a) in vivo and b) ex 
vivo using the bioluminescence camera two days after transfection. Scale is on the right is 
applicable to both images. Ex vivo organs clockwise from top; ribcage and sternum, right 
kidney, spleen, liver, lung segments (4 in total), left kidney, diaphragm. Heart is central. 
 
200 
150 
100 
50 
x1
0
3 p
h
o
to
n
s/sec/cm
2/ste
rad
ian
 
b) a) 
116 
 
 
Figure 3.6. Individual photon flux measurements taken 48 hours after transfection of 
pGL4.13 into CD1 mice hearts using SonoVue and ultrasound (n=8). The average value, 4.2 x 
105 photon/s is marked as a solid line, with +/- 1 SD values as dotted lines.  
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3.3.3.2. Peak luminescence after D-luciferin administration 
The photon flux values from nine transfected mice were plotted against time after 
substrate administration (Fig. 3.7). The peak values, marked in red, varied widely although 
the majority fell between 2.7 x 105 and 5.2 x 105 photon/s with three values above 
approximately 8.0 x 105 photon/s. The average and median time to reach peak 
luminescence was 14.2 and 16 minutes respectively, but the values were spread from 8 to 
20 minutes. Photon flux values tended to drop off after reaching a peak. 
 
 
Figure 3.7. In vivo photon flux 48 hours after transfection from in vivo bioluminescence 
images of pGL4.13 heart transfected CD1 mice using SonoVue and ultrasound against time 
after D-luciferin administration (n=9). Black markers indicate values at each time point. Red 
markers indicate peak expression per line. Each line represents a single mouse. 
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3.3.3.3. Peak luminescence after transfection 
Five mice were successfully transfected and imaged over the course of five days. The 
photon flux values vary significantly between the five mice, with peaks occurring on 
different days (Fig. 3.8). Day 2 has the highest average value (the black dotted line) over the 
five days but also the largest variation (+/- 1 SD shaded in grey). Day 1 has the least variation 
but a lower average than the following two days. After Day 2 average values tended to 
decrease, although in individual cases, photon flux values were still rising for Day 3. After 
Day 4, bioluminescence was dropping in all cases. 
 
 
Figure 3.8. Photon flux values over 5 days from individual CD1 mice hearts transfected with 
pGL4.13 using ultrasound and SonoVue, 14 minutes after D-luciferin administration (n=5). 
Black dotted line indicates the average value per day. Shaded grey area indicates +/- 1 SD 
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3.3.4. Discussion 
3.3.4.1. Proof of Principle 
The preliminary experiments have demonstrated that the combined use of 
ultrasound and the SonoVue can be used to transfect the cells of CD1 mouse hearts with the 
pGL4.13 plasmid. It has also been demonstrated that the pGL4.13 is functional in the CD1 
mouse heart and produces sufficient luminescence for in vivo and ex vivo bioluminescence 
analysis. 
The bioluminescence seen in IVIS camera images indicate regions of successful 
transfection, however, there is no depth information about the source of the luminescence. 
Photons from a point source are scattered through overlaying tissues to form a diffuse 
circular pattern seen on the skin, disguising the origin of luminescence (Fig. 3.5a). It is 
therefore challenging to deduce which tissues have been successfully transfected, as the 
photon emission is an amalgamation from all transfected tissues expressing luciferase. Use 
of ex vivo bioluminescence images is therefore essential to confirm successful transfection 
of target tissues (Fig. 3.5b). 
However, ex vivo bioluminescence images captured by the camera cannot be used as 
a measure of transfection. The positioning of the organ influences the magnitude of the 
signal received by the camera (Fig. 3.9). The tissue and remaining blood absorb emitted 
photons, causing attenuation of the signal. Whilst this effect is also present for in vivo 
bioluminescence (discussed further on) (Fig. 3.11), it is exacerbated ex vivo by the post 
mortem drop in temperature which causes the photon emission spectra of firefly luciferase 
to red-shift to wavelengths which suffer greater absorption[281]. The decrease in 
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temperature also reduces luciferase activity. Finally, preliminary studies on kidney 
transfection (results not shown) demonstrated that luminescence can fade rapidly after 
death (Fig. 3.10), likely as a result of depletion of the substrate, ATP and oxygen. 
 
Figure 3.9. Ex vivo bioluminescence images of photon absorption on an individual heart. The 
same heart which was flipped 180o from the a) first image to the b) second image. Scale is a 
measure of photon flux from the surface of an object and is applicable to both 
(photon/s/cm2/steradian). ROI is region of interest and values are measured in photon/s. 
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(min:sec) 
5:34 7:42 9:54 12:02 
Photon flux (photon/s) 41274 18508 13757 9456 
 Bioluminescence Image 
 
 
 
 
 
 
 
 
 
Figure 3.10. Ex vivo bioluminescent images of a single pGL4.13 transfected kidney from a 
SonoVue and ultrasound treated mouse 24 hours post-transfection. Kidney expression was 
followed for 12 minutes post mortem.  
a
) 
b
) 
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3.3.4.2. Peak luminescence after D-luciferin administration 
By measuring the photon flux over time after substrate administration, it was 
possible to make a qualitative interpretation of the influx/efflux kinetics of D-luciferin and 
luciferase, in terms of the optimum time for imaging (Fig. 3.7). After IP substrate 
administration, D-luciferin diffuses into the blood from the peritoneum. As it is absorbed, 
photon emission rises as it is catalysed by luciferase. As luciferin in the blood increases, 
saturation of the luciferase enzyme occurs and the photon emission will plateau. The signal 
plateau will continue until luciferin influx from the peritoneum is exceeded by efflux through 
kidney excretion and luciferase catalysis. The photon emission will then decrease.  
The peak or plateau of luminescence represents the peak enzyme activity and is a 
qualitative measure of total enzyme expression, which is directly related to transfection 
efficiency. The results show the majority of transfected reached peak luminescence at 16 
minutes after substrate administration; however peaks occurred before and after this value. 
Choosing an arbitrary imaging time point could lead to underestimation of transfection, as 
luminescence could be still rising or falling. As the peak luminescence is the desired value, 
repeat measurements of luminescence over the full 20 minutes would be a better approach. 
The reason for the differences in time to peak is likely due to the level of luciferase 
transfection and expression. A high level of luciferase expression will result in a rapid 
catalysis of the available D-luciferin. Rapid depletion of the substrate by catalysis and kidney 
excretion will outstrip the influx causing rapid substrate absorption and an earlier fall in 
photon emission. This could potentially be a problem as saturation may not occur, and the 
results are then not indicative of the level of transfection efficiency. By repeat monitoring of 
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luminescence over the full 20 minutes, this problem can be identified as a lack of an 
extended plateau.  
 
3.3.4.3. Peak luminescence after transfection 
Genetic material transfected into mammalian cells is active for a limited period of 
time unless it has been designed to either integrate into the genome or be replicated 
episomally. As the pGL4.13 plasmid has no episomal or integrating elements, luciferase 
expression will peak and then fall as the plasmid is eliminated over time through either cell 
death or silencing by methylation. It is therefore ideal to measure expression on the peak 
day to maximise any differences in transfection.  
By measuring the in vivo bioluminescence expression over five days, it was possible 
to decide upon an optimal day after transfection to image, however, the results from the 
time course were very variable and determining an appropriate peak day was not possible. 
This may be attributed to various factors. For example, tissue attenuation will vary over time 
due to variability in day to day body positioning. Additionally, repeat IP injections can be 
inconsistent and cause injury to the mouse leading to immune responses and scarring which 
would affect luciferin kinetics. Another potential issue was the transfection of non-target 
organs as seen in the preliminary experiments, (Fig. 3.5b). These tissues may have different 
expression profiles and peaks, which would affect the observed photon emission from the 
heart region over 5 days.  
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Peak expression appeared to fall on Day 2 but values were highly variable, seriously 
affecting the number of mice required to produce significant results. Day 1 suffered the 
least variation but also fell before the peak which could reduce observable differences and 
again increase the number of mice required. Day 4 and 5 had average values lower than Day 
1 although equivalent variation, and were potentially too far past the peak to provide 
observable differences. Day 3 had the second highest value and a similar variation as Day 1. 
Additionally, all values were decreasing from Day 3 to Day 4. As such, Day 3 was determined 
to be the optimum day to image on, albeit perhaps not the peak. While a greater number of 
mice may have helped to refine this estimate, it was considered unethical due to the injury 
and stress suffered by the mice over 5 days of repeat luciferin administration. 
 
3.3.5. Issues with Variability 
One of the main findings was that in vivo photon flux measurements are prone to 
large variation in averaged group results. Whilst some variability was expected due to 
imprecision inherent in the equipment and biological variation in the outbred mouse strain, 
the extent of the variation found could affect attempts to determine statistical differences 
between treatment groups. As such, attempts were made to determine the potential 
sources of variation.  
Broadly, there are six areas where variation could be introduced; the plasmid, the 
microbubble, the mouse, the bioluminescence imaging and the transfection protocol. This 
chapter will highlight several potential sources of variation in each area and what, if 
anything, was done to control for them. 
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3.3.5.1. The Plasmid 
Potential sources of plasmid variability typically result from poor handling or poor 
quality control, e.g. re-use of pipette tips, contaminated tubes, etc. The following list of 
potential sources are mostly methodological considerations that have been controlled for in 
the Model Protocol but always warrant consideration when using genetic material for 
transfection. 
The pGL4.13 plasmid used for all experiments was transformed into a typical DH5α 
strain of E. coli and prepared using the Qiagen EndoFree Plasmid GigaPrep Kit (Qiagen) 
following the manufacturer’s instructions. The kit is designed to purify approximately 10 mg 
of plasmid from a 2.5 to 3 L overnight culture of bacteria and remove any endotoxins 
released by the bacteria during lysis. Endotoxins, such as lipopolysaccharides, trigger the 
immune system of animals, causing sickness and occasionally leading to rapid endotoxic 
shock and death. Removal of endotoxins is vital for both in vivo and mammalian cell 
cultures. The amount of endotoxin required to trigger a response is also quite low in a 
mouse, a 50% lethal dose is approximately 20 mg/kg[282], which for a typical 20 g CD1 mouse 
is only 400 µg. A small amount of endotoxin could also trigger immune effects affecting 
aspects of the transfection or expression of the foreign luciferase gene.  
The level of endotoxin was not directly quantified in each batch of plasmid however, 
manufacturer literature on the Qiagen EndoFree products suggests a ng endotoxin to µg 
DNA ratio of approximately 0.056, e.g. that there will be 0.056 ng of endotoxin for every 1 
µg of purified DNA. In a 200 µg plasmid injection this equates to 11.2 ng of endotoxin, which 
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should be far below the levels capable of causing an immune response. Additionally, to 
ensure plasmid samples avoided contamination with further endotoxin, oven-baked 
glassware and new, pyrogen-free plastic ware was used for sample handling. 
After preparation, plasmid preparations were diluted to 4 mg/mL using a UV 
spectrophotometer for DNA quantification. Whilst a commonly used and accurate tool, UV 
spectrophotometry does have some drawbacks. The linear range of quantification for DNA 
at 260 nm lies between an optical density reading of 0.1 and 2, which for a typical path 
length of 10 mm and an average extinction coefficient of 0.020 (µg/mL)-1 cm-1 for double 
stranded DNA, means a minimum and maximum reading of 5 µg/mL and 100 µg/mL. 
Confirmation of a 4 mg/mL solution therefore requires a dilution factor of at least 40 and 
typically performed at 100. Errors in serial dilution pipetting could lead to inaccuracy in the 
dilution of plasmid, which in turn would strongly affect the resultant transfection using the 
plasmid solution. To account for this, readings were performed on three individually 
prepared samples to determine the imprecision in the pipetting and provide an accurate 
concentration. 
Contamination of the plasmid with protein, RNA and chemicals from the purification 
procedure can also affect the transfection in vivo by triggering immune responses and 
affecting the measured concentration of the plasmid. UV spectrophotometry ratios of the 
absorbance at 260 nm against 230 nm, 270 nm or 280 nm were used to reveal 
contamination with organic compounds, phenol or RNA respectively. A reading at 330 nm or 
above can reveal any particulate matter in the solution, e.g. dust, etc. All batches were 
found to be free of contaminants by these methods. 
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A previously reported issue could also lie in batch to batch variability. Manthorpe et 
al. (1993) reported issues with interbatch variation with luciferase expression after direct 
muscular injection ranging from 600 to 7000 pg luciferase per muscle. The same study also 
noted large intrabatch variability when injections were performed on separate days, but a 
much reduced variability when performed on the same day. This batch variability was also 
noted in other direct muscle injection papers[283]. However, this batch effect has not been 
commented on outside of direct muscle injection studies of transfection and may be more 
intrinsic to variability in the muscle transfection than plasmid batch. In this project, several 
batches of plasmid were used however comparable results typically came from the same 
batch of plasmid and no intrabatch variability or interbatch variability could be discerned 
from the variable results. 
A further potential source of variation lies in plasmid degradation over the course of 
storage. DNA is a relatively stable molecule when stored appropriately but there are always 
some considerations. DNA will eventually degrade when stored in water over long periods 
of time at -20oC (>6 months) and repeated freeze/thaw cycles of an aliquot can be seriously 
damaging to DNA, particularly if slow frozen. To control for this, single use aliquots of 
pGL4.13 were prepared to be used per batch of 4 to 6 animals and sufficient experiments 
took place to fully deplete the plasmid stocks within 6 months. Any plasmid that required 
longer storage was stored in an ethanol salt solution which is stable for >1 year. 
The most uncontrollable source of variation is that of the interaction between 
plasmid and microbubbles. Before injection, a solution of 50 µL plasmid and 150 µL 
microbubbles is prepared and drawn into the experimental IV syringe. There is then a period 
of time during which air bubbles are removed from the syringe, the needle is positioned into 
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a tail vein, and the solution injected. Whilst attempts were made to keep these as constant 
as possible, there were undoubtedly small variations in timings. During this variable time, 
binding of the plasmid to the microbubbles or disruption of microbubbles by the plasmid, 
perhaps due to electrostatic interactions, could occur which would potential cause changes 
in transfection. Plasmid binding to albumin microbubbles is already documented and occurs 
very rapidly[284]. Lipid microbubbles tend to need functionalization to bind plasmid due to a 
typically uncharged surface, however work has gone into examining how cationic and 
anionic microbubbles load plasmid and affect transfection [99, 280, 285, 286]. If the timings were 
constant these binding or disruption effects could be assumed to be constant, however the 
timings are very experiment specific, sometimes air bubbles are rapidly removed, 
sometimes tail vein placement takes longer than usual. As such, the interaction between 
plasmid and microbubbles is a potential source of variability for both the plasmid and the 
microbubble. 
 
3.3.5.2. The Microbubble 
Commercial and in-house microbubble preparations share potential sources of 
variability as well as a few type specific ones. For commercial microbubbles, the 
manufacturer will have already tested the reproducibility of microbubble populations and 
any required preparation steps. By following the manufacturer’s guidelines, microbubble 
introduced variability can be kept to a minimum. However, there is always a potential that 
the off-label use for transfection, and any changes to preparation, e.g. doubling the 
concentration of SonoVue by using half the saline, could introduce variability. For instance, 
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the expected use of SonoVue will be a single or two doses delivered soon after 
reconstitution of the lyophilised powder in the vial. In the experiments described above, up 
to 6 individual doses are withdrawn from the vial, which will alter the conditions each dose 
is subjected to and the conditions within the vial. Additionally, these 6 doses may be given 
over a time period of up to 3 hours. SonoVue microbubbles are not designed to be stable 
long term at room temperature and some degradation of microbubbles in both 
concentration and size occurs. As the time period of the experiment is not fixed, each 
delivered dose will have variability in the microbubble concentration, stability, and any 
history the microbubble has experienced whilst in the vial, i.e. perturbation by needles, 
decreasing pressure in sealed vial due to decreasing liquid volume, introduction of outside 
air by repeated needle introduction, etc. There will also be the change in solution salinity by 
mixing saline suspended microbubbles with water suspended plasmid, affecting the 
environment of the microbubble, although this would form a constant for all experiments 
and could therefore be considered negligible. Lastly, user variability in SonoVue preparation 
could alter microbubble concentration and size distribution. All these changes will 
potentially affect the resultant transfection and form a number of potential sources of 
variability for commercial microbubbles. 
In house microbubble preparations share some of these issues, e.g. variable time 
between production and use. Unlike commercial microbubbles, some batch to batch 
variability will be unavoidable due to the non-automated process and incremental human 
error over a multi-step production procedure. To counter this as far as possible, optical 
sizing and counting of each batch was performed to monitor reproducibility and allow 
normalisation against gas concentration to account for any slight differences in population. 
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One of the shared potential sources of variation will be exposure to environment of 
microbubbles. For instance, after removal of microbubbles from their vial or production 
tube, they will be exposed to air and mixed with plasmid liquid solution containing dissolved 
air. Microbubble gas diffusion and exchange can happen rapidly and affect a bubble stability 
and echogenicity[189, 227] and thus transfection[98]. Again, slight variations in time before 
administration will introduce a potential source of variability into the result. Additionally, 
changes in day to day environmental conditions, such as ambient temperature and air 
pressure, could affect microbubble populations. Temperature affects the behaviour of 
microbubbles primarily by affecting gas expansion and thus bubble diameter which at higher 
temperatures can result in increased microbubble degradation over time[256]. Ambient 
pressure would likely have a similar, albeit small effect[265]. 
 
3.3.5.3. The Mouse 
Biological variations are a fundamental part of any in vivo experiment and controlling 
for them can be difficult. As microbubbles and plasmid are injected into the blood pool, any 
variation in cardiac or respiration cycles between mice, e.g. blood pressure, heart rate, 
respiration rate, depth of breath, etc., could strongly affect microbubble persistence and 
stability, potentially introducing variation in transfection. It may also affect luciferin uptake 
from the peritoneum during bioluminescence imaging affecting photon flux kinetics. Even in 
anaesthetised mice, heart and respiration rate can vary wildly between mice and during a 
procedure. For non-pressure sensitive drugs or delivery techniques this may not be an issue, 
but microbubbles will be affected by heart rate, e.g. by increased destructive shear stresses 
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and clearance via biological passage through liver, lungs and spleen, and respiration rate, 
which can cause high pressure changes in the thoracic cavity and will affect the gas 
saturation of blood. Monitoring of heart rate, respiration rate, blood pressure and blood 
oxygen levels can be performed in mice but add to the complexity, cost and difficulty of 
experiments and was not performed in this work. Additionally, while they can be monitored, 
control of these parameters is practically impossible in small animals. This potential source 
of transfection variation has to be accepted as part of the cost of doing any animal work. 
In this project, the albino CD1 strain of mouse was used to improve bioluminescence 
imaging by reducing potential absorption of photon emission due to pigmentation. The CD1 
strain is also an outbred strain of mice, meaning that the animals are not genetically 
identical unlike an inbred strain. This leads to heterogeneity of the phenotype, besides the 
fundamental strain characteristics, e.g. albinism. The idea was that this would cause some 
biological differences between mice, e.g. size, weight, etc., that would more accurately 
reflect a clinical situation of treatment response from genetically different patients. This 
obviously introduces a source of variation in transfection, for instance changes in 
size/weight will influence the positioning of the transducer and effect of the ultrasound as 
well as causing smaller mice to have a greater proportion of their body insonified than 
larger mice. In this project, no relationship between body weight/size and luminescence was 
ever observed, however it does indicate how other anatomical or physiological variations, 
e.g. organ size, cardiac cycles, etc., may affect transfection.  
One of the other biological variations noted in the project was the differing response 
of a mouse to the anaesthetic gas isoflurane. Isoflurane is a commonly used small rodent 
anaesthetic favoured for its low toxicity, easy control, rapid onset and rapid recovery. Mice 
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were generally anaesthetised using 5% isoflurane and maintained from between 3 to 4%. In 
most cases, this would be unremarkable however in the case of microbubbles, this 
introduces yet another gas into the circulatory system which will further affect the gas influx 
dynamics already occurring in vivo. Additionally, isoflurane is highly lipid-soluble, a vital 
characteristic for its clinical function, meaning that for lipid-based microbubbles such as 
SonoVue, rapid influx of isoflurane into microbubbles would be expected, potentially 
disrupting them and reducing transfection efficiency. Isoflurane will also have a number of 
cardiovascular effects during its administration[287-290]. As the amount of gas required and 
length of time spent under anaesthesia varied between mice this is a potential source of 
transfection variation. 
 
3.3.5.4. The Imaging 
Whilst variation in bioluminescence imaging will not affect transfection efficiency, it 
is the measure by which transfection is measured and thus, any variation here will appear in 
the results. The primary source of variation in bioluminescence imaging of live animals is 
variable attenuation of the emitted photons. Like acoustic attenuation, photons emitted 
from a point source will be scattered and be absorbed by surrounding tissues and air, and 
like acoustic attenuation, certain tissues will be more attenuating than others. This gives rise 
to the characteristic diffuse circular pattern seen on the skin of an animal in a 
bioluminescence image. Biological variation and body positioning will affect the tissues and 
distance that the photons have to pass through to reach the camera which will affect the 
reading and photon flux recorded. In some cases, this attenuation can be extreme and 
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highly noticeable (Fig. 3.11), however even slight variation in body positioning and anatomy 
can alter photon flux measurements.  
As previously mentioned, this attenuation can also be worsened by drops in 
temperature. At 37oC, the firefly luciferase enzyme emits photons over a wavelength 
spectra ranging from approximately 500 nm to 700 nm with an emission peak at 612 nm. As 
the temperature drops to 25oC, the emission peak red shifts to 578 nm. Haemoglobin in 
blood strongly absorbs light below 600 nm, particularly when oxygenated. When any animal 
is under anaesthesia, homeostatic thermoregulation is disrupted. This causes a decrease in 
body temperature requiring maintenance using heat pads or other heating apparatus. Still, a 
small drop in body temperature would be expected and would again be subject to 
environmental factors, e.g. room temperature, humidity, etc., and biological factors, e.g. 
weight, size, response to isoflurane. This could potentially introduce variability in the results 
unrelated to transfection efficiency but emission efficiency. Whilst not related to the 
variability under discussion here, this drop in temperature is also a potential issue when 
confirming transfection site using ex vivo bioluminescence imaging on harvested organs, 
especially when time limitations related to substrate depletion limit the imaging window. 
A potential user introduced source of variation is positioning of the region of interest 
(ROI) on bioluminescence images for photon flux measurement. Ideally, point sources of 
transfection emit photons up through overlying tissues creating a diffuse circular pattern of 
scattered signal on the skin which is detected by the camera. However, there will likely be 
several point sources of transfection in a particularly area and tissue-dependent 
attenuation, e.g. vascularised tissue, bone, cartilage, etc., which can produce non-circular 
diffusion patterns upon the surface. This can complicate the positioning of ROIs over 
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bioluminescence, making it highly user dependent. To maintain consistency in any 
introduced variability, only one user was involved in the analysis of bioluminescence images. 
One of the major potential sources of variability in the bioluminescence imaging lays 
in the luciferin IP injection. Intraperitoneal injections are notoriously inconsistent even 
when performed by experienced researchers[291, 292]. This can lead to changes in the 
influx/efflux kinetics of the delivered luciferin as well as potentially the amount delivered, 
which will affect the luminescence. A common source of error is the presence of “fat pads” 
within the intraperitoneal space. Injection into these relatively avascular structures can 
cause a slow influx of luciferin, affecting luminescence. Nicking of blood vessels either 
within the peritoneum or, more commonly, in the overlying peritoneal muscle wall, can 
cause rapid influx of luciferin, as can accidental injection into liver. Injection directly into the 
intestines which occupy the majority of the peritoneal space, besides being highly 
dangerous for the mouse, will result in almost complete loss of luciferin influx. As long as 
luciferin influx sufficiently saturates the enzyme, these issues should not introduce a high 
degree of variability, however, for high levels of transfection or slow influx, full saturation 
might not occur leading to potential variability between similarly transfected mice. In this 
project, no single time point of luminescence was used, instead a 20 minute read was 
employed so as to monitor the luminescence kinetics to ensure that appropriate kinetics 
were occurring and that a peak maximum luminescence value was used. Additionally, 
dissection of the mouse after imaging was used to confirm that luciferin was administered 
appropriately. Even with these precautions, there will still be some variability in luciferin 
injection between mice, which will contribute to variability in the measured 
bioluminescence. 
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The substrate luciferin itself can introduce variability. Solid D-luciferin powder can 
become highly electrostatic during solution preparation potentially causing some loss due to 
sudden attractive or repulsive behaviour, a problem compounded by the small amounts 
typically prepared. A simple solution to this would be to prepare a set of aliquots for the 
experiments as was done for the plasmid, however storage of luciferin solutions is 
problematic. The compound is sensitive to water, oxygen and light, and is not stable for 
more than a few hours as a liquid at room temperature and only two years as a powder. 
Storage is further complicated by the luciferase inhibitory products produced during 
degradation. There is some disagreement in the field about the most appropriate storage 
conditions, some sources suggest that storage in nitrogen-purged liquid at -80oC is effective 
for up to a year (information from Regis Technologies Inc. website and Promega Luciferase 
Assay Reagent product information), however some recommend only preparing a solution 
when required (information from GEN website and Sigma D-Luciferin product information). 
In this project, the latter approach was used and solutions were made as required at 
concentrations that should be highly saturating to combat any degradation. However, as a 1 
g vial of luciferin could last for several months of experiments, some degradation was 
possible and could introduce further variability into the bioluminescence imaging. It should 
be noted though that this effect was not seen during this project, but could have been 
hidden by other factors. 
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Figure 3.11. Demonstration of severe attenuation by mouse forelimb. Scale bar is in 
photons per second per centimetre squared per steradian. 
 
3.3.5.5. The Transfection Protocol 
The transfection aspect of the experiment has a number of variables to consider 
which have the potential to introduce variability into the experiment. One of the potentially 
largest sources of variation that could be introduced is inadvertent transfection of other 
tissues besides the heart. Ultrasound propagation through microbubble perfused tissues 
above and below the focal depth will potentially cause transfection in those tissues outside 
the focal region. Additionally, the mouse heart is closely surrounded on all sides by the 
lungs. Ex vivo bioluminescence imaging on dissected tissues from the preliminary 
experiments using the IVIS camera did occasionally show luminescence in other thoracic 
tissues (Fig. 3.5b). This variable transfection will be compounded by variation in the size, 
body shape, heart size and weight of a mouse by altering the transducer position required 
to target the heart and the tissues the ultrasound beam has to pass through. Any 
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transfected tissue will give off bioluminescence, contributing towards the photon flux 
measurements. As this potential source of transfection variability could contribute heavily 
towards the variation seen in the results, it was investigated in more detail as described in 
the final section of this chapter. 
As an aside, although the transfection of other thoracic tissues is undesirable in 
terms of targeted heart transfection, it does indicate that ultrasound mediated transfection 
can be extended to targeting other organs. There are several diseases potentially treatable 
by gene therapy in the diaphragm and lungs, for example Duchenne muscular dystrophy and 
cystic fibrosis[3, 293]. 
There are a number of other potential sources of variability, particularly in the time 
taken to inject a dose. As already mentioned, changes in experimental timing could have a 
number of effects on the variability of transfection, particularly exposure of microbubbles to 
air, plasmid, etc. Microbubbles also come with another potential issue strongly affected by 
time; buoyancy. During the time required to remove air bubbles and find a vein with the 
experimental syringe and inject the dose, the microbubbles will be undergoing floatation, 
rising up and resting against the wall of the syringe. Not only does this affect the shear 
stress that a microbubble will experience during administration[265] (personal 
correspondence, Dr E. Stride) but also affects the homogeneity of the delivered dose as 
buoyancy is size dependent. The effect this might have on transfection is unknown, 
although presumably increased shear stress from the wall will destroy the larger bubbles 
which have floated up, leading to a reduction in microbubble concentration and a potential 
shift in size population. The heterogeneity of the injected dose could also result in the loss 
of subsection of bubble population due to syringe dead space trapping some of the dose, 
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however in this project this issue is reduced by the use of integrated needle syringes which 
have very low dead space. Whilst, this ensures that essentially the whole bubble population 
is delivered; the dose will still be heterogeneous, the effect of which is unknown. Work 
presented in Chapter 4 and published in the journal of Ultrasound in Medicine & Biology on 
the use of needles of different gauges, which will affect the shear stresses experienced by 
the microbubbles, suggest that this will reduce the transfection efficiency [294]. With 
variation in time taken to prepare a dose, remove air, find a vein and inject the dose, this is 
a potential source of variability in transfection. 
Variation in injection speed will also vary the pressure gradients and shear stresses 
experienced by the microbubbles[268] as well as the biological route of blood flow within the 
mouse[295, 296]. It can also have implications on the commencement of ultrasound treatment. 
The rapid heart rate of a mouse heart, ensures that blood, and any delivered substance, is 
rapidly circulated around the body. As mentioned previously, there are a number of 
biological clearance systems in place which eliminate microbubbles, particularly the lungs, 
liver, and spleen. In this project, ultrasound treatment was started after the full dose was 
delivered to ensure that microbubbles were not destroyed during injection by the 
ultrasound before saturating the target organ. However, a slow bolus delivery, to avoid 
pressure/shear stress microbubble damage, or late ultrasound treatment start, to avoid 
premature microbubble destruction, could unintentionally lower the microbubble load the 
ultrasound hits due to clearance. To avoid these issues, an injection speed of approximately 
0.02 mL/s was used, however as the injections were performed by hand, some variation 
would be expected, which could lead to variability in transfection. 
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Further variation will be introduced by the choice of IV injection site on the tail vein. 
The tail vein decreases in diameter along its length towards the end of the tail which 
potentially affects the pressure environment the microbubble population and plasmid 
experience upon administration. This effect will again be exacerbated by mouse biological 
variation, such as the size of the mouse, length of tail, etc. as well as the temperature of the 
mouse and tail, which affects the vasodilation. This variation will again introduce variability 
into the transfection by affecting the microbubble load in the mouse, as well as the plasmid 
load, as pressure at the injection site will cause hydrodynamic delivery of plasmid to the 
surrounding tissue. 
 
3.3.5.6. Discussion 
Controlling as many aspects that might affect the results is one of the most 
important parts of any experimentation; however complete control over all elements can be 
impossible, impractical or not even desirable. Many of the potential issues described above 
are inherent in any animal experiment, particularly biological variation in subjects, and are a 
consequence of performing any in vivo experimentation. However, some of the above issues 
are specific to using pressure-responsive and buoyant microbubbles. Each problem may only 
contribute a small amount of variability to the transfection results, but in combination, they 
could result in the large variability seen. 
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3.4. Ex vivo bioluminescence quantification 
3.4.1. Introduction 
As seen in the Transfection Protocol experiments, there were some significant issues 
with variability, which were explored in detail in the previous section. One of the potential 
sources is transfection of non-target tissues as seen in some of the ex vivo bioluminescence 
images (Fig. 3.5b). As the ultrasound beam passes through several different tissues before 
and after reaching the heart, there is the potential for transfection in thoracic region. The 
resulting bioluminescence from non-target tissues can affect the in vivo bioluminescence 
measurement for the heart. Ex vivo bioluminescence imaging of harvested organs using the 
IVIS 100 camera is not accurate enough due to luciferin and oxygen depletion during the 
dissection as well as cooling of the exposed organs which affects the performance of 
luciferase[281]. The positioning of the organ can also affect the luminescence seen by the 
camera. As such, the use of a luminometer could give a more accurate transfection reading 
in comparison to the camera. 
 
3.4.2. Methodological Particulars 
UMGT was performed as described in the methods using pGL4.13 (4 mg/mL) and the 
commercial microbubble SonoVue (4 – 10 x 108 microbubbles/mL) administered IV with the 
experimental IV needles. A steady, alternating motion of the transducer was performed to 
sweep the focus through the heart during the 2 minute ultrasound transfection period. 
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Bioluminescence images were captured 72 hours after transfection with images 
taken every 2 minutes after luciferin administration for 20 minutes using a 1 minute 
exposure. Ex vivo bioluminescence imaging was used to confirm cardiac transfection. Hearts 
of successfully transfected and imaged mice were prepared and the luminescence 
quantified as described in the methods. 
The experiment was performed on transfected mice from the investigation into the 
effect of needle gauge on transfection, as described in Chapter 4. In that work, several 
batches of mice were transfected using a single experimental needle gauge and fresh 
SonoVue for each batch of mice and an aliquot of plasmid from a single batch for all animal 
work. Eleven mice were selected from this experiment to give a range of in vivo 
bioluminescence values and their hearts were processed for ex vivo quantification. 
Luminometer readings were performed over several days using separate batches of 
luciferase assay reagent from a single stock. 
 
3.4.3. Results 
Eleven mice with a range of in vivo bioluminescence photon flux values as measured 
by the IVIS system, had their hearts extracted and homogenised for luminescence 
quantification in the luminometer. Luminometer values were normalised by tissue weight to 
account for differences in heart sizes and plotted against in vivo bioluminescence values 
from the same mouse (Fig. 3.12).  
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There was a strong, positive correlation between luminometer and IVIS values, with 
a significant Pearson product-moment correlation coefficient of 0.93 (p < 0.0001). 
 
Figure 3.12. Ex vivo bioluminescence from luminometer readings of individual mice hearts 
plotted against corresponding peak in vivo bioluminescence from the IVIS 100 (n=11) for 
CD1 mice transfected with pGL4.13 using SonoVue and ultrasound. The strong positive 
trend observed between the values gives a significant Pearson coefficient of 0.93 
(p<0.0001). 
 
3.4.4. Discussion 
An important part of this work is to identify factors that influence the effectiveness 
of UMGT. This requires sensitive techniques with little variation to discover any statistical 
differences between sample groups. In vivo bioluminescence is a sensitive technique but 
preliminary results using UMGT showed variation. If this variation is due to inappropriate 
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targeting or any inherent variation in using the IVIS system, then using a second, ex vivo 
technique directly on the organ of interest should remove this issue. Luminometers are a 
commonly used tool in measuring luminescence from tissue samples[99, 257, 281] and had the 
potential of reducing the variation seen in sample groups.  
However, values of in vivo bioluminescence taken from the IVIS images of individual 
mice correlated very strongly with ex vivo luminescence values from heart samples of the 
same mouse. As such, this technique does not reduce variation in this methodological setup, 
as any variation in one system will appear in the other. Considering the additional time, cost 
and difficulty of processing organs for no additional benefit, the technique was not included 
in the Model Protocol. Additionally, due to the strength of the statistically significant 
correlation, the experiment was not repeated. 
The technique has also suggested that the non-target organ transfection occasionally 
seen in ex vivo bioluminescence camera images is not fully responsible for the variation 
found in the in vivo bioluminescence values. 
 
3.5. Conclusion 
The Model Protocol given above consists of two stages; microbubble 
characterisation and transfection investigation. By detailed investigation in these two areas 
it should be possible to identify potential factors that could affect UMGT in vivo. Whilst 
there are other potential areas that could have been included, for instance, ultrasound 
characterisation, environmental conditions, etc., these have been kept constant for the 
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purposes of the project, as far as possible. In the following chapters, three factors will be 
investigated for their effect on UMGT; the effect of needle gauge, the effect of albumin 
concentration in a PESDA-type microbubble, and the effect of dextrose concentration in a 
PESDA-type microbubble. All three will affect the microbubble and the transfection which 
exploits the suitability of the Model Protocol. 
The Model Protocol is not without its limitations. Intragroup variability in 
transfection, as discussed in detail here, affects the strength of any conclusion that can be 
drawn from the data as well as affecting the sample numbers required to reach significance, 
which is of concern in any animal experiment. The microbubble characterisation is also still 
small in scope and ignores a number of other microbubble factors which could be 
potentially changed or fundamental in UMGT success. However, the Model Protocol is 
essentially just a framework of good experimental design and as such, is flexible to 
adaptions and additions. As the range of experimental apparatus available increases, a 
greater number of experiments can be included in the Model Protocol, which helps to limit 
its limitations. 
Overall, the Model Protocol provides accurate and useable data and will 
demonstrate links between changes in microbubble characteristics and UMGT. This will be 
of great use to the field by providing new potential paths of optimisation and improvement 
of UMGT which will encourage interest in the field and development to clinical significance.  
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4. Influence of needle gauge on UMGT in vivo 
In this chapter, the effect of the needle gauge used to deliver the systemic plasmid 
and microbubble injection on transfection was investigated. Many preclinical studies report 
low transfection efficiencies and use high gauge needles. Microbubbles are known to be 
affected by shear stress and changes in pressure during passage through needles and 
catheters, an effect exacerbated by high gauge needles. It was hypothesised that low 
transfection efficiencies were related to changes in microbubble concentration during high 
gauge needle passage. Three needle gauges were examined for their effect on population 
statistics of SonoVue and UMGT in vivo. It was found that 25G needles, the largest bore 
needle safe to be use on a 6 to 8 week old mouse tail vein, caused significantly less 
destruction of microbubbles than 29G needles, resulting in significantly higher transfection. 
27G needles caused a small decrease in microbubble concentration and reduced transfection 
compared to 25G but greater transfection than 29G needles. The use of lower gauge needles 
can improve transfection by reducing microbubble destruction during administration. 
 
4.1. Introduction 
A key aim of this project is to determine factors that influence the effectiveness of 
UMGT. To achieve clinical relevance requires extensive preclinical testing but currently the 
in vivo transfection by UMGT in animal models is poor in comparison to other techniques[70, 
94, 100, 123, 211]. However, there are several reasons why the choice of certain preclinical animal 
models might affect the UMGT outcome. For instance, the depth of a targeted organ, and its 
overlying tissues, strongly affect the strength, or amplitude, of the ultrasound wave 
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reaching it, due to attenuation. For a 20 g mouse, the maximum depth for any organ will be 
less than 2 cm, whereas a similar depth in a 60 kg human will reach muscle and little else. In 
such circumstances, the expectation is that deep organs in clinical patients, e.g. the heart, 
liver, etc. will be hit by comparatively little acoustic energy leading to poor transfection 
compared with mice, although it does not preclude the effectiveness of transfection of 
muscle or other shallow tissues. Several groups are therefore engaged in research on larger 
preclinical animal models, such as dogs[280, 297] and pigs[88, 211, 298], however the expense and 
ethical considerations of these models tend to limit sample sizes. 
The choice of preclinical model may also work in reverse by hindering the 
effectiveness of UMGT. The administration of microbubbles for in vivo UMGT treatment is 
typically performed by injection into the blood supply either as a bolus or infusion. It has 
been shown in vitro that lipid-shelled microbubbles are susceptible to changes in pressure 
and shear stresses that occur during passage through syringes and needles[265]. The 
concentration and size distribution of microbubble suspensions can be significantly 
decreased and altered, particularly when using large gauge (small bore) needles around 27G 
to 30G[268]. 
Few preclinical papers state the needle size used, however as the preclinical model is 
typically a rodent, the needle size will usually be around 27G to 29G[90, 231, 299]. Considering 
the influence of microbubble size and concentration on UMGT[97, 98], there could be 
significant implications using such needles. Importantly, this may also contribute to the low 
transfection efficiencies often reported in vivo[123, 211, 248]. This work investigates the 
influence of needle gauge on transfection in vivo and was published in the journal of 
Ultrasound in Medicine & Biology in 2011[294].  
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4.2. Methodological Particulars 
Three experimental syringes with 25G, 27G and 29G needles were trialled for their 
effect on SonoVue in vitro and for UMGT using SonoVue and pGL4.13 (Table 4.1, reprinted 
from Methods and Materials for convenience). The needles were integrated with the 
syringe to reduce dead-space, the area between the syringe and needle where the dose can 
become trapped, particularly in hub mounted needles. SonoVue was prepared at double the 
concentration, as described and justified in Chapter 2, and the effect on microbubble 
populations statistics of passage through the three experimental IV syringes was 
investigated using optical microscopy[255]. Values were adjusted against a no needle control 
to account for natural bubble decay over time. As SonoVue is a commercial product with 
company assurance of reproducibility between vials, the experiment was performed on a 
single vial of SonoVue only. Experimental error is revealed by the repeat measures. 
Freshly reconstituted, double concentrated SonoVue was mixed with pGL4.13 and 
administered to six to eight week old, CD1, female mice using the experimental IV syringes. 
Transfection of the heart was performed using the 15L8 transducer of the Acuson Sequoia 
diagnostic ultrasound machine. After 72 hours, mice were administered luciferin and 
imaged in the IVIS 100 bioluminescence camera over 20 minutes to determine peak photon 
flux. The experiment was performed with three batches of animals per needle group using a 
fresh vial of SonoVue for each batch. The experiment was not independently reproduced. 
A one way ANOVA was performed on the parametric in vivo transfection data and 
parametric in vitro population statistics: microbubble concentration, mean diameter and 
median diameter. Pairwise comparison was performed using Tukey’s test. Non-parametric 
gas concentration was investigated using the Kruskal-Wallis ANOVA and Dunn’s pairwise 
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comparison test. Significance was assumed at p≤0.05. A retrospective and a priori power 
analysis was performed on in vivo data to determine the power of the ANOVA test and the 
sample size required for a power of 0.95.  
 
Table 4.1. Properties of the three IV syringes. (ID = Internal diameter, OD = Outer diameter) 
Manufacturer/Brand 
Needle… Syringe… 
Gauge 
ID 
(mm) 
OD 
(mm) 
Length 
(mm) 
Volume 
(mL) 
ID 
(mm) 
OD 
(mm) 
Terumo Insulin syringe 29G 0.184 0.337 13.0 0.5 3.45 5.40 
BD Tuberculin syringe 27G 0.210 0.413 12.7 0.5 3.55 5.70 
Terumo SurSaver syringe 25G 0.31 0.514 16.0 1.0 4.7 6.6 
 
4.3. Results 
4.3.1. Effect of needle gauge on microbubbles 
Microbubbles were examined by optical microscopy after passage through the 
experimental syringe (Fig. 4.1). Optical examination and comparative statistics against the 
control revealed that: a 25G needle caused no change in any population statistic; a 27G 
needle caused a ~6% drop in concentration and gas concentration but no change in size; a 
29G needle caused a significant 30% decrease in microbubble concentration, an insignificant 
45% decrease in gas concentration, and a slight decrease in mean (9.8%) and median 
diameter (5.9%).  Additionally, 25G and 27G needles did not affect size distribution whereas 
29G needles saw a 5.8% decrease in microbubbles of diameters 2 to 5 µm and a 6.9% 
increase in microbubbles of diameters 0.75 to 1.75 µm (Fig. 4.2). 
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Figure 4.1. Population statistics of microbubbles after passage through a 25G (blue), 27G 
(green) or 29G (purple) normalised against No Needle control (blue) as determined by 
analysis of microscope images. Values from three interleaved reads (two repeats each read) 
were adjusted for bubble decay. Error bars show ± 1 SD per experimental syringe. (*p<0.05 
vs. no needle, 25G or 27G needle, †p<0.05 vs. 25G needle only) 
 
Figure 4.2. Size distribution histogram for SonoVue after needle passage. The plot shows the 
percentage of microbubbles per total microbubble count for each diameter, bin size 0.25 
µm, for each of the conditions: No needle control (blue line), 25G (red line), 27G (green line) 
and 29G (purple line) needles (n=3/condition). Error bars are ± 1 standard deviation. 
Microbubbles greater than 10 µm and less than 0.5 µm were excluded from analysis.  
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4.3.2. Effect of needle gauge on transfection in vivo 
The in vivo peak bioluminescence measured three days after transfection was 
averaged over 9 mice per needle group (example images: Fig. 4.3). A trend of increasing 
transfection with decreasing needle gauge is apparent (Fig. 4.4); using 27G needles (7.21 x 
105 photon/s) causes double the transfection compared to using 29G needles (3.57 x 105 
photon/s) whilst using 25G needles (1.05 x 106 photon/s) significantly increases transfection 
by almost threefold (p<0.01).   
Additionally, as the needle gauge increases, so too does the standard deviation 
increasing between 29G needles and 25G needles; from 2.95 x 105 photon/s to 5.23 x 105 
photon/s respectively. However, the coefficient of variation (CV), e.g. the standard deviation 
divided by the mean, is actually highest for 29G needles (0.83) compared with 27G (0.47) 
and 25G needles (0.50). This suggests that the variability for 27G and 25G is equivalent and 
actually 29G needles show the greatest variability, although 29G has the lowest mean value 
and the CV value is more susceptible to changes in a low mean. 
A retrospective power analysis was performed to determine the power of the 
ANOVA test. Effect size was determined using the means and average standard deviation of 
the three different needle groups[259] to give a value of 0.711, which indicates a large 
difference between the different groups. Power, as defined by “1 – β error” where “β error” 
is the probability of falsely accepting the null hypothesis, was determined to be 0.883. This 
suggests that the sample size was not quite sufficient to detect the statistical difference. 
According to an a priori power analysis, using the 0.711 effect size, 36 animals, e.g. 12 
animals per group, would have been required for an ideal power of 0.95. 
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Figure 4.3. In vivo bioluminescence images of pGL4.13 transfected mice. Mice were treated 
with heart-targeted ultrasound after administration of pGL4.13 and SonoVue using a) a 25G 
needle, b) a 27G needle, or c) a 29G needle. (Scale in photons per second per cm2 per 
steradian) 
 
 
Figure 4.4. In vivo peak bioluminescence levels from mouse cardiac regions three days after 
UMGT treatment with SonoVue and pGL4.13 administered I.V. using needles of three 
different gauges. (n=9 mice per sample group). (Error lines are standard deviation, *p<0.01 
vs. mice treated with 29G needles)  
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4.4. Discussion 
The in vivo results demonstrate that using smaller needle sizes reduces the 
maximum transfection efficiency possible for a particular dose, a finding which has not been 
reported in the literature before. The in vitro work highlighted a potential mechanism; as 
needle size is reduced there is a decrease in concentration, suggesting that a change in the 
microbubble dose is responsible for decreased transfection. The difference in concentration 
after needle passage between 29G and 25G supports the finding of a significant difference 
in transfection efficiency. However, the drop in concentration through a 27G needle is more 
modest compared to the change in transfection. It is possible that additional factors during 
in vivo IV administration may also contribute to the transfection difference, such as back 
pressure from the blood or changes in blood flow caused by needle intrusion destroying 
microbubbles. Additionally, it may be that needle passage affects the long term stability of a 
microbubble, a factor which was not investigated as part of this work.  
Microbubble characteristics, such as size and concentration, play an important role 
in transfection. The size of a microbubble determines its resonant frequency and thus, how 
it will respond to the acoustic driving frequency employed during ultrasound exposure[180, 
261], which in turn affects the transfection efficiency[85]. Several studies have demonstrated 
the link between microbubble suspension concentration and transfection[97, 98]. As the 
bioeffects of cavitating microbubbles are thought to cause transfection, an increased 
number of microbubbles will cause increased bioeffects. This may also be related to a 
greater number of microbubbles being in contact with the cell, potentially leading to 
increased transfection. Additionally, microbubbles in vitro tend to be more stable at higher 
concentrations[187, 300] which may allow greater in vivo persistence and may increase the 
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likelihood of sonoporation. A drop in microbubble concentration would therefore lead to a 
drop in transfection. 
The in vitro investigation sought to identify potential reasons for the differences in 
transfection efficiency observed in vivo. The Talu et al. (2008) paper suggested that at flow 
rates around 0.03 mL/s and concentrations of approximately 5 x 108 microbubbles/mL, 
microbubble destruction was minimal through needles up to 30G (<10%)[268]. Although there 
were some differences between the current work and the previous literature, it was not 
expected that the flow rates (0.02 to 0.04 mL/s) and initial concentrations (4 to 10 x 108 
microbubbles/mL) used would significantly influence the microbubble populations before or 
after needle passage. It is hypothesised that the syringe position and time taken to 
eliminate air bubbles (needle vertical for 20 seconds) and position the needle for IV 
administration (needle horizontal for 20 seconds) alters the homogeneity of the suspension 
before delivery, and that this may influence both the number of bubbles affected by the 
shear stresses exerted at the syringe or needle wall and the concentration of the suspension 
delivered. However, as the change in bubble population only occurs for the higher gauge 
needles, the needle must be the primary agent in bubble destruction. It is possible that the 
shear stresses imposed on the bubbles as the plunger is depressed cause bubble instability. 
This instability leads to destruction during needle passage, but only if the needle is of 
sufficiently small diameter. It is likely that needle diameter is important due to the increase 
in pressure gradient from syringe barrel to needle or the greater shear stress occurring 
within the needle. A downward shift in microbubble size distribution may also be expected 
as larger bubbles would float faster, coming to rest against the syringe or needle wall sooner 
than smaller bubbles and being subjected to greater shear stress over the injection time [189, 
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203]. An insignificant reduction in both mean and median diameter was observed for 29G 
needles and the proportion of larger microbubbles (2 to 5 µm in diameter) was decreased, 
but no difference was noticed for the other needles, again suggesting that any microbubble 
effect is linked to needle gauge.  
Like the preliminary experiments, there is noticeable variability, the causes for which 
are discussed in depth in the previous chapter. It is worth noting that although the standard 
deviation is increasing with transfection, the actual proportion of the standard deviation to 
the mean, the CV, is less for both 25G and 27G compared with 29G. Interestingly, this 
increased CV for 29G is also seen with three of the four population statistics: concentration, 
mean diameter and median diameter. For gas concentration, the CV’s are approximately 
equal. This could suggest that the 29G needle somehow introduces a higher degree of 
variability than the other needles although some caution should be employed in this 
interpretation. CV is more strongly affected by small changes in low means and as 29G has 
the lowest mean values across all experiments the CV might be exaggerated. 
If the increased variability is a real phenomenon, there are some interesting 
potential explanations. One explanation may be the range of injection time durations, from 
5 to 10 seconds. As discussed in the variability section in the previous chapter, this could 
have influenced the microbubble suspension delivered due to bubble buoyancy and the 
shear stresses from the syringe and needle walls. If there is variability in the duration of 
injection this could lead to variability in the transfection, however the assumption is that 
this would be constant across the needle groups, causing intragroup rather than intergroup 
variability. The difference, however, could lie in the different diameters of the syringes and 
needles, which would cause differences in fluid velocity even if volumetric flow rates are 
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equal, as demonstrated by the volumetric flow rate equation in a tube for uniform flow 
parallel to the tube wall: 
       
Equation 4.1 
Where Q is the volumetric flow rate in mL/s, A is the area across the tube in cm2, and 
C is the linear fluid velocity in cm/s. The linear fluid velocity is related to the shear rate,  ̇, in 
a tube in s-1 by the following equation: 
 ̇   
  
 
 
Equation 4.2 
Where   is the diameter of the tube in cm. As the velocity of the liquid increases, so 
does the shear rate. The wall shear stress (WSS),  , in Pa, can be found by the final equation: 
    ̇    
Equation 4.3 
Where   is viscosity in Pa.s, which for water at 20oC is approximately 0.001 Pa.s. 
Under this assumption  ̇ =   in mPa. The results of the calculations of C and   for the syringe 
and needle at the maximum flow rate (0.04 mL/s) and the minimum flow rate (0.02 mL/s) 
are given in Table 4.2. The solution is assumed to be at 20oC, Newtonian and have uniform 
flow.  
 
Table 4.2. Fluid velocity and wall shear stress for the syringe and needle at maximum and 
minimum volumetric flow rates. 
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Needle 
Gauge 
Syringe Needle 
Fluid velocity  
(cm/s) 
Wall shear stress 
(mPa) 
Fluid velocity 
(cm/s) 
Wall shear stress 
(mPa) 
Maximum Flow Rate 0.04 mL/s 
29G 0.428 9.92 150 65,400 
27G 0.404 9.11 115 44,000 
25G 0.231 3.92 53.0 13,700 
Minimum Flow Rate 0.02 mL/s 
29G 0.214 4.96 75.2 32,700 
27G 0.202 4.55 57.7 22,000 
25G 0.115 1.96 26.5 6,840 
 
The bores for the 29G and 27G syringes are similar in diameter; giving similar fluid 
velocity and WSS values. The main differences lie in the needle, where the difference in 
bore is much greater and yields significantly different fluid velocity and WSS values. As 
expected, the smaller the needle gauge, the larger the needle bore and the lower the 
velocity and WSS. Interestingly, the WSS of 25G needles is approximately a third of 27G 
needles, yet differences in the population statistics for the in vitro experiment were 
minimal. For 29G needles the WSS is 470% higher than 25G, yet only 60% higher for 27G 
needles, despite a significantly different microbubble concentration against these needles in 
the in vitro experiment (Fig. 4.1). This does suggest that there may be a point where 
increasing WSS value begins destroying microbubbles. This may also help explain the higher 
variability seen in 29G. WSS values for 29G needles range from 32.7 Pa to 65.0 Pa over the 
minimum and maximum volumetric flow rates. If the WSS value for microbubble destruction 
lies somewhere in this range, possibly around 40.0 Pa as population statistics of 
microbubbles after 27G needle passage were slightly altered, then variation in injection 
speed for 29G needles will cause strong variation in microbubble bubble destruction. This in 
turn will cause greater variability in the population statistics and potentially UMGT.  
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However, this is a simplistic model of the administration and there will also be other 
effects occurring, such as floatation. As mentioned, the syringe may not have much effect as 
both 29G and 27G syringes have similar internal diameters, yet give strongly differing 
population statistics and transfection. In the needle though, the reduced diameter of the 
29G needle would allow bubbles to reach the wall faster where the shear stresses could 
cause increased destruction which may be responsible for the lowered transfection. But, 
this must be considered in line with the increased velocity within the needle, which 
although increasing the shear stress, would decrease the time a microbubble would spend 
within the needle and be exposed to the destructive forces. At maximum flow rate of 0.04 
mL/s, the microbubbles spend only 8.6 ms in the 29G needle in comparison to 11 ms for the 
27G needle, and 30 ms for the 25G needle. This though, should be considered against the 
floatation time spent in the syringe, which causes microbubbles to be resting against the 
syringe wall, which would then presumably enter the needle up against the wall where 
destruction may occur. Microbubbles at the end of the dose would suffer more destruction 
than those at the beginning of the dose due to floatation in the syringe. There are a number 
of mechanisms and influencing factors affecting microbubble destruction potentially 
occurring within a syringe and needle during IV administration. 
Considering the similarities to the in vitro experimentation carried out by Barrack 
and Stride (2009)[265] and Talu et al. (2008)[268] the following differences are highlighted to 
justify performing a similar in vitro experiment. In the Barrack and Stride (2009) study, the 
needles used were detachable 18G or 25G attached to a 5 mL or 10 mL syringe depending 
upon the experiment. The Talu et al. (2008) study instead used catheters of 6-inch 
polyethylene tubing attached to needle gauges of 23G, 27G and 30G. The diameter of the 
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tubing matched the needle gauge in use and the syringe size was unspecified. It was 
therefore important to perform in vitro experiments to effectively examine the effect the 
experimental IV syringes with integrated needles had on microbubble suspensions. 
Retrospective and a priori power analysis of the in vivo data suggested that 
insufficient mice were used to provide an appropriate level of power for the tests used. 
Statistical power is defined as the probability of a statistical test to correctly reject a false 
null hypothesis. Ideally, this would be as high as possible, to prevent rejection of real 
differences. In the in vivo data, it was determined there was a single significant difference 
between 25G and 29G needles. However, as the statistical power of the ANOVA test was 
0.883, this indicates there was an over 10% chance that other statistically significant 
differences may have been rejected. In an ideal scenario, the power of the ANOVA test 
would be 0.95. By performing an a priori power analysis using the effect size determined 
from the observed data, it was possible to calculate a required sample size of 36 animals, 
e.g. 12 animals per group, to achieve a power of 0.95. However, it is important to note that 
this does not necessarily mean there would have been a difference between other needle 
groups; it would only have reduced the possibility that a true difference was being 
inappropriately rejected due to the low power of the test, a type II error. 
The results, whilst novel, were not considered controversial. As mentioned, other 
groups have either shown that needle gauge affects microbubble concentration, or that 
concentration can affect transfection. This study has married these two aspects in a logical 
manner with both in vitro and in vivo experimentation. As such, it was not felt necessary to 
independently reproduce this work. 
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Most importantly the findings indicate that the largest needle size permitted by the 
pre-clinical model should be used when administering ultrasound contrast agent via an IV 
injection. This will cause the least change to the microbubble population and their acoustic 
response and subsequent bioeffects. However, it must be noted that the vein diameter itself 
will limit the size of needle that can be used. In mice of 6 to 8 weeks of age, a 25G needle 
was the largest needle size that could be safely used for IV injections. For larger animal 
models and clinical use, this limit should be less significant. 
 
4.5. Conclusion 
A current limitation of UMGT is the poor transfection efficiencies observed in 
preclinical models. This work here demonstrates that the limitations imposed by a 
preclinical model, such as high needle gauge, should be considered as a potential cause for 
the low transfection, not necessarily the weakness of the technique. This work shows that 
plasmid transfection using ultrasound and the contrast agent SonoVue can be improved 
when using needles of a larger bore. This simple change to the methodological procedures 
is, in theory, easy to implement in any UMGT work involving rodents and improves the 
treatment outcome. This work also demonstrates the usefulness and strength of the Model 
Protocol; a change in procedure was introduced, the effect on microbubble characteristics 
and UMGT in vivo was observed, and a link between the two identified. 
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5. Investigation into effect of albumin and dextrose 
concentration on UMGT in vivo 
In this chapter, the effect of microbubble shell components on transfection was 
investigated. Novel microbubble formulations with unique acoustic properties were created 
by variation of the concentration of the starting materials: albumin and dextrose. Optical 
examination of microbubbles to determine population statistics and stability was performed. 
Microbubbles were also acoustically characterised using bulk acoustics and their effect on 
UMGT in vivo was examined. A trend was observed between acoustic behaviour, particularly 
attenuation, and transfection efficiency. Stable microbubbles with strong attenuation and 
scattering behaviour could be produced by increasing the concentration of dextrose and 
reducing the concentration of albumin. These changes resulted in the highest levels of 
transfection compared to the other formulations. The acoustic behaviour and stability of 
microbubbles were found to be key factors controlling the effectiveness of UMGT and are 
potential characteristics for microbubble optimisation. 
 
5.1. Introduction 
As demonstrated in the previous chapter, the characteristics of a microbubble 
population can influence UMGT. When concentration was decreased by needle passage, the 
resultant transfection was strongly affected. It is also known that the shell material of 
microbubble used, i.e. albumin, lipid, etc., significantly influences transfection efficiency[98, 
152, 260, 286]. An interesting finding commonly reported is that albumin shelled microbubbles, 
such as Optison (GE Healthcare Ltd.) perform better than lipid shelled agents such as 
SonoVue (Bracco Research S.A., Geneva, Switzerland), causing greater in vivo transfection at 
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equivalent doses[98, 148, 157]. Indeed, some studies have shown that ultrasound is not 
necessary for effective in vivo transfection when using Optison reducing potential tissue 
damage from ultrasound[157, 240], but this is not always supported[148]. The reasons for this 
are not entirely clear as there are a number of differences in the properties of these 
microbubbles due to the difference in formulation, however differences in stability have 
been suggested[98]. It is worth noting though that Optison and SonoVue are commercial 
agents specifically designed for contrast imaging and are not optimised for transfection. 
Indeed, the literature is bereft of studies concerning optimisation of albumin microbubble 
shell components for the purposes of gene transfection. 
Previously, Porter et al. (1995) investigated the influence of albumin and dextrose 
concentration on the acoustic response of microbubbles for imaging[213]. In this study, 
different dilution ratios of 5% (w/v) albumin with 5% or 50% (w/v) dextrose, sonicated to 
form microbubbles, were trialled in the left ventricles of dogs for the purpose of 
determining the acoustic scatter compared to straight sonicated albumin. Detailed in vitro 
bulk acoustics were not performed and neither was the transfection potential investigated. 
Du et al. (2001) further investigated the influence of the dextrose concentration on bubble 
stability[219]. They found that increasing the dextrose concentration in the initial 
composition, produced microbubbles of increasing stability, able to persist for extended 
periods of time and more resistant to heat degradation.  
These studies indicate that control of the acoustic response and stability of a 
microbubble can be achieved by altering albumin and dextrose concentrations. In vivo 
transfection by ultrasound and microbubbles can be strongly dependent upon ultrasound 
characteristics, with maximal transfection occurring at high intensities[85]. At these high 
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intensities, microbubbles show more extreme oscillatory behaviours[301], characterised by 
high total and nonlinear scattering. The hypothesis was that by changing the composition of 
a microbubble, its material properties would also change, increasing its acoustic behaviour 
and thus resulting in increased transfection efficiency.  It was the aim of this study to 
investigate this. Parts of this work were published in Ultrasound in Medicine and Biology 
journal in 2012[302]. 
 
5.2. Methodological Particulars 
Four distinct formulations of albumin based microbubbles were manufactured in 
house using 2% or 5% (w/v) human serum albumin diluted 1:3 with 20% or 40% (w/v) 
dextrose. Their population statistics and stability over time were determined by optical 
microscopy and were interrogated using ultrasound to determine their bulk acoustic 
scattering, attenuation and stability under ultrasound. Bulk acoustic scattering and 
attenuation experiments were carried out by Dr Helen Mulvana. Acoustics experiments for 
each formulation were performed on one batch of bubbles and were not independently 
reproduced. Population statistics for each formulation were measured over several batches 
of bubbles produced from several sets of independent solutions. Stability over time was 
performed on one batch of bubbles for each formulation. 
To investigate how bubble changes over time affect transfection, 5% 20% 
microbubble suspensions were used less than and more than four hours after manufacture 
to transfect pGL4.13 into the hearts of CD1, female mice using the 15L8 transducer of the 
Acuson Sequoia diagnostic ultrasound machine. After 72 hours, mice were administered 
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luciferin and imaged in the IVIS 100 bioluminescence camera over 20 minutes to determine 
the peak photon flux. On the basis of these results, microbubble suspensions were used 
within four hours of manufacture to avoid any microbubble degradation effects. The 
experiment was performed on four batches of animals using a fresh batch of 5% 20% 
bubbles per two batches of animals to allow for degradation over time. The experiment was 
not reproduced as it led to a change in procedure to exclude the possibility of degradation 
over time affecting transfection and it was not necessary to investigate it further. 
Fresh microbubble suspensions of the four formulations were used, within four 
hours of manufacture, for in vivo transfection and mice were imaged after 72 hours to 
measure bioluminescence levels. As there were differences in the microbubble 
concentration and size distributions between and within the formulation groups, the fixed 
injection volume causes variation in dose. Thus, peak photon flux values were normalised 
against gas concentration to account for these differences. Gas concentration is a 
population statistic which measures the gas volume of microbubbles in a given volume of 
solution, and provides an appropriate adjustment factor for differences in both microbubble 
concentration and size distribution. The experiment was performed on multiple batches of 
animals using a new, freshly-made microbubble dispersion per batch to avoid degradation 
issues. Time constraints meant the experiment could not be independently reproduced. 
Statistical tests are described where they are used. For log transformed, gas 
concentration normalised in vivo data, effect sizes were calculated retrospectively in 
MATLAB and used for an a priori power analysis to determine the required sample size for a 
power of 0.95 for all factors and interactions in a two-way ANOVA.   
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5.3. Results 
5.3.1. Bubble population statistics 
Bubble manufacture produced suspensions with differing characteristics as 
presented in Table 5.1. Bubbles made with 20% dextrose had a lower mean diameter and 
gas concentration compared to 40% dextrose bubbles. 2% albumin bubbles had lower gas 
concentrations compared to the 5% albumin equivalent dextrose bubbles. 
Percentage coefficients of variation (CV = standard deviation (SD)/mean x 100%) are 
given as a measure of intra-, inter- and sample group variability for concentration, mean 
diameter, median diameter and gas concentration (Table 5.2). Intra-sample group variability 
is a measure of precision, i.e. the repeatability of a measurement on a single sample. The 
optical microscopy technique demonstrates good precision (≤5%) for concentration, mean 
and median diameter. Gas concentration is less precise at 13.4%. This measure is expected 
to be less precise as it is derived from two other measures: the microbubble diameter and 
number count. Additionally, the volume calculation is sensitive to slight variation due to the 
cube term in the volume equation, which will amplify any error.  
For example, consider two equally sized microbubbles measured to be 2 µm and 3 
µm in diameter. The mean diameter ± 1 SD is 2.5 ± 0.7 µm, which gives a CV of 28%. 
Meanwhile, the mean volume ± 1 SD is 73 ± 56 µm3, which gives a CV of 77%. The precision 
of the gas concentration measurement will always be worse than the other direct measures.  
Inter-sample variability gives a measure of the average variability expected for each 
of the population statistics. This can be useful to demonstrate reproducibility in 
manufacture between different formulations however, more detail can be gained by 
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examining the individual group samples. These CVs highlight the batch-to-batch variability 
for the different formulations. Mean and median diameters appear to have the least 
variability with CVs less than 15%. For microbubble concentration, a noticeable difference 
exists between albumin concentrations; with 2% albumin microbubbles having 
approximately twice the CV values compared to 5% albumin microbubbles. 
The gas concentration shows the highest variability with CVs around 30%. As 
mentioned, the CV will be the least precise measurement which may affect the perceived 
batch-to-batch variability; however it is also susceptible to small variation in size 
distribution. As mentioned, small variations in microbubble diameter can give large variation 
in gas concentration. This also applies to slight variations in size distribution. As gas 
concentration is a mean measurement across all microbubbles, even small numbers of large 
microbubbles can drastically shift the gas concentration. For instance, it would take 125 
microbubbles of 1 µm diameter (volume: 0.52 µm3) just to match the same volume as a 
single 5 µm microbubble (volume: 65 µm3). As such, a trivial increase in the proportion of 
larger microbubbles can have huge impact on its value. This leads to high batch-to-batch 
variability in the gas concentration. 
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Table 5.1. Microbubble suspension size and concentration analysis. (Average value ± 1 
standard deviation) (MB = Microbubble, Conc. = Concentration) 
Abbreviated 
name 
Albumin 
Conc.  
(w/v) 
Dextrose 
Conc.  
(w/v) 
Number of 
batches  
(n) 
Mean 
Diameter  
(μm) 
MB Conc.  
(x108 
MBs/mL) 
MB Gas Conc.  
(μL/mL) 
2% 20% 2% 20% 5 1.3 ± 0.1 6.63 ± 1.23 2.21 ± 0.79 
5% 20% 5% 20% 5 1.7 ± 0.2 9.41 ± 1.03 7.51 ± 2.36 
2% 40% 2% 40% 8 1.9 ± 0.2 9.10 ± 1.89 8.38 ± 2.39 
5% 40% 5% 40% 6 2.0 ± 0.2 12.2 ± 1.08 13.25 ± 3.64 
 
Table 5.2. Coefficients of variation for intra-, inter- and sample group variability for 
concentration, mean diameter, median diameter and gas concentration. Note that CV 
values are dimensionless. (MB = Microbubble, Conc. = Concentration) 
Population Statistic 
Percentage coefficient of variation for sample group variability 
2% 20% 5% 20% 2% 40% 5% 40% Intra- Inter- 
MB Concentration 18.5% 10.9% 20.7% 8.9% 5.0% 15.3% 
Mean diameter 6.0% 11.2% 10.1% 10.0% 2.4% 9.4% 
Median diameter 3.2% 12.4% 13.4% 11.9% 2.1% 10.7% 
Gas concentration 35.8% 31.4% 28.5% 27.5% 13.4% 30.4% 
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5.3.2. Stability over time 
A single batch of microbubbles for each formulation was examined over 4 hours 
using optical microscopy. Changes in concentration, mean diameter, median diameter and 
gas concentration were examined (Fig. 5.1). For all formulations, there is a slight decrease in 
mean and median diameter over time. Microbubble concentration remains generally 
constant, although 5% 20% microbubbles show a drop at two and a half hours, but become 
stable again afterwards. 5% 40% also show an unusual increase in concentration after 
manufacture which might indicate that the time 0 bubble reading might be anomalous. Gas 
concentration also tends to decrease over the four hours, due presumably to the decrease 
in microbubble diameter. As only a single batch of microbubbles for each formulation was 
examined, there are no error bars. 
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Figure 5.1. Population statistics for a single batch of the four bubble formulations over time, 
measured from optical light microscopy images. 
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5.3.3. Acoustic characterisation 
The rate at which microbubbles were destroyed by 6 MHz ultrasound varied 
depending upon bubble formulation (Fig. 5.2). Increasing the level of either dextrose or 
albumin significantly increased resistance to ultrasound at all acoustic powers (Mack-
Skillings test, p<0.0001). 
Bulk investigation of the formulations at 200 kPa by Dr Helen Mulvana showed a 
similar trend for both total scatter (n=50 per group) and mean attenuation (n=10 per group) 
normalised to gas concentration. Using 40% dextrose caused an increase in both scatter 
(Fig. 5.3a) and attenuation (Fig. 5.3b) for both albumin formulations. Interestingly, 2% 20% 
bubbles displayed the least attenuation, whilst 2% 40% bubbles showed the greatest, 
suggesting an interaction effect between the albumin and dextrose. An increase in dextrose 
caused a decrease in the proportion of the nonlinear component of total scatter for 5% 
albumin (~18%) but a slight increase for 2% albumin (~3%). Scatter data was very noisy with 
large error bars, giving a coefficient of variation (CV) of approximately 61%. Increased 
attenuation with 40% dextrose was perhaps due to microbubble size (Table 5.1), however as 
both 2% and 5% albumin microbubbles have similar diameters, there may be material 
effects as well. 
Statistical differences for bulk acoustics were attempted. For attenuation, the data 
was normal but heteroscedastic due to differences in variances between sample groups. As 
the data was balanced but non-parametric, a Friedman test for replicates was performed in 
MATLAB. There was a strongly significant difference between dextrose concentrations 
(p<0.00001), however due to the strong interaction effect between albumin and dextrose – 
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40% dextrose improves 2% albumin greater than 5% – a significant difference could not be 
found between albumin concentrations (p=1) despite the apparent data trend. 
Homoscedasticity could not be recovered by data transformation so parametric tests could 
not be performed. A tentative two-way ANOVA suggested that the two factors and their 
interaction were strongly significant (p<0.00001), but the assumption of homoscedasticity 
has been violated. 
For both total and non-linear scatter, the data was not normally distributed and 
heteroscedastic. No transformation could recover both normality and homoscedasticity. 
Again, a Friedman test for replicates was used. For total scattering, increasing dextrose gave 
a significant increase in scatter (p<0.001) but no difference between albumin 
concentrations. For non-linear scatter, increasing the dextrose (p<0.001) or albumin 
(p<0.05) resulted in a significant change in scatter. The data suggests an interaction exists as 
increasing dextrose for 2% albumin increases non-linear scatter but reduces it for 5% 
albumin, and increasing albumin for 20% dextrose increases non-linear scatter but reduces 
it for 40% dextrose. A tentative two-way ANOVA was performed giving strongly significant 
dextrose factor and interaction (p<0.0001) and a weaker significance for the albumin factor 
(p<0.05). Again, the homoscedasticity assumption has been violated reducing the power of 
the test.  
In summary, increasing dextrose caused a significant increase in a microbubble’s 
acoustic stability, attenuation and both total and nonlinear scattering behaviour. Increasing 
albumin caused a significant increase in acoustic stability but no change in total scattering 
behaviour. The interaction between albumin and dextrose affects the attenuation of a 
microbubble, and potentially its nonlinear scatter, causing 2% 40% microbubbles to have 
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the greatest attenuation and non-linear scatter behaviour compared to 2% 20% which has 
the weakest. 
Statistical measures on Figures 5.2 and 5.3 show only the Friedman test results. 
 
 
Figure 5.2. AUC measurements from normalised scatter intensities for each bubble 
formulation at three ultrasound powers for 6 MHz. The higher the bar, the more resistant 
the bubble. At all powers, differences between all non-confounded groups are significant in 
the Mack-Skillings test (p<0.0001). (Error bars are ± 1 SD, n numbers for each group is given 
in the associated bar) 
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a)  
b)  
Figure 5.4. Mean bulk microbubble suspension a) scattering (n=50/formulation), and b) 
attenuation (n=10/formulation) at 200 kPa over 0.9 MHz to 4.5 MHz normalised for gas 
volume against bubble formulation. (Error bars are ± 1 SD, *p≤0.05 vs 20% dextrose, † 
p≤0.05 vs 2% albumin. Friedman test only, differences are factorial not individual)  
0.000
0.005
0.010
0.015
0.020
0.025
0.030
2% 20% 5% 20% 2% 40% 5% 40%
M
e
an
 S
ca
tt
e
r 
(V
2
/µ
L 
o
f 
ga
s)
Microbubble Formulation
Linear
Non-linear
0
50
100
150
200
250
300
2% 20% 5% 20% 2% 40% 5% 40%
Microbubble Formulation
M
e
an
 A
tt
e
n
u
at
io
n
 (
%
 s
ig
n
al
 a
tt
e
n
tu
at
io
n
/µ
L 
o
f 
ga
s)
* * 
* 
*† 
† 
* 
* 
172 
 
5.3.4. In vivo transfection 
For the transfection experiments, peak bioluminescence values normalised against 
background, were further normalised against gas concentration to account for differences in 
microbubble concentration and size distribution. It was found that increasing dextrose 
concentration caused a significant increase in transfection for both albumin concentrations 
(Fig. 5.5). Interestingly, 2% albumin went from being the least to most effective, mirroring 
the trend seen for bulk attenuation, implying an interaction between albumin and dextrose.  
There were differences in the variability of the groups, causing the data to be 
heteroscedastic. The data was also unbalanced, with different numbers of sample per 
group, which further complicated statistical analysis. A Mack-Skillings test was initially used 
to compare the main factors of dextrose and albumin. This type of test is essentially an 
unbalanced, non-parametric two-way ANOVA, similar to the Friedman test, however it does 
not test for a significant interaction between the two factors. A significant difference was 
found due to dextrose (p<0.0001) suggesting that 40% dextrose bubbles cause significantly 
more transfection than 20% dextrose, however there was no significant difference between 
albumin concentrations (p>0.05).  
As there was a potential interaction, visually identified in the data, the data was log 
transformed to recover homoscedasticity, and an unbalanced, two-way ANOVA was 
performed. Like the Mack-Skillings test, significance was found for dextrose (p<0.0001) but 
not albumin (p>0.05). Due to the significant result in the interaction term (p<0.05), post-hoc 
analysis was performed. A Tukey-Kramer test was used to determine significant differences 
between groups, with the comparison term (k) adjusted for non-confounded group 
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comparisons only (k - 1). This revealed that 1) 2% 40% bubbles caused significantly more 
transfection than 5% 40% bubbles and 2% 20% bubbles; and 2) 5% 40% bubbles caused 
significantly more transfection than 5% 20% bubbles. There was no significant difference 
between 5% 20% bubbles and 2% 20% bubbles (p>0.05). As such, it can be said that 
increasing dextrose significantly improves transfection for 2% and 5% albumin bubbles, and 
that the improvement is more significant for 2% albumin bubbles. (See Table 5.3 for p-
values).  
Effect sizes for the two main factors and interaction factor for the two-way ANOVA 
were calculated using the log transformed, gas concentration normalised in vivo data. These 
were used for an a priori power analysis to determine the appropriate total sample size to 
achieve a power of 0.95 in a two-way ANOVA (Table 5.4.). It was determined that a total 
maximum sample size of 692 animals, 173 animals per formulation, would have been 
required to reach a power of 0.95 for all factors and interactions in the two-way ANOVA. 
This was due to the small effect size for the albumin factor as the difference between the 
albumin concentrations was not significant.  
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Figure 5.5. In vivo, microbubble gas concentration normalised, peak bioluminescence levels 
from CD1 mouse cardiac regions three days after UMGT treatment using the labelled bubble 
formulation and pGL4.13 averaged over n mice per sample group. (n=8, 8, 11 and 16 
respective to axis label, error bars are ± one standard deviation, *p≤0.05) 
 
 
Table 5.3. Probability values for statistical tests performed. Two-way ANOVA and Tukey-
Kramer tests performed on log transformed data. (NS = no significant difference: p>0.05, S = 
significant difference: p≤0.05) 
Factor Mack-Skillings Two-way ANOVA  
Tukey-Kramer test results for non-confounded 
formulations 
Albumin 0.439 0.396  Formulation 5% 20% 2% 40% 
Dextrose 7.85 x 10-14 8.94 x 10-08  2% 20% NS S 
Interaction N/a 0.0222  5% 40% S S 
  
* *
*
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Table 5.4. Power analysis measures for all three factors. Effect sizes were calculated in both 
the ηp
2 and f measures values from log transformed in vivo data and used to perform an a 
priori power analysis to determine the total sample size required for a power of 0.95 for a 
two-way ANOVA.  
Factor Effect size – ηp
2 Effect size – f 
Total sample size 
(Power = 0.95) 
Albumin 0.0185 0.137 692 
Dextrose 0.524 1.049 16 
Interaction 0.127 0.381 92 
 
 
5.3.5. Microbubble transfection against time of manufacture 
Single batches of 5% 20% microbubbles were used throughout a day, firstly within 
four hours of manufacture, and secondly four hours after manufacture to determine how 
transfection might be affected by short term storage. Peak bioluminescence values 
normalised against background, but not gas concentration. The non-parametric Wilcoxon 
rank sum test (equivalent to the Mann-Whitney U test) was used to compare values. It was 
found that using microbubbles more than four hours old resulted in significantly decreased 
transfection (p<0.01) (Fig. 5.6). Optical examination of 5% 20% microbubbles over 7 hours 
revealed a decrease in gas concentration, concentration and mean diameter (Fig. 5.7). 
Bubble disruption was noted in the optical images taken towards the end of the experiment 
(representative images from 0 minutes and 375 minutes after manufacture are displayed in 
Fig. 5.8). 
176 
 
 
Figure 5.6. In vivo peak bioluminescence levels from CD1 mouse cardiac regions three days 
after UMGT treatment with 5% 20% microbubbles and pGL4.13. (n=5 mice per sample 
group) (Error bars are ± 1 standard deviation) 
 
Figure 5.7. Change in a) Concentration, b) Gas Concentration, c) Mean Diameter and d) 
Median diameter of a single batch of 5% 20% microbubbles over time (n=1). (2 reads per 
time point, error bars are ± 1 standard deviation) 
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a)  
b)  
Figure 5.8. Representative images from optical sizing measurements for the 5% 20% 
microbubbles at a) 0 minutes and b) 375 minutes. Arrows indicate disrupted bubbles which 
have lost gas and spherical shape. Scale bar is 16 µm, the black centre mark is 8 µm.  
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5.4. Discussion 
The work here, demonstrates that microbubble acoustic attenuation, scatter and 
stability are vital parameters for in vivo UMGT using protein based microbubbles and that 
these properties can be selected for by altering the concentrations of the starting material. 
Reducing the initial protein content whilst increasing the sugar content, produced stable 
and strongly attenuating microbubbles capable of causing the greatest amount of 
myocardial transfection in vivo. 
The material components of a microbubble play an important role in determining 
both the acoustic and physical properties. As shown, small changes in starting material can 
cause significant differences in the average diameter and concentrations of produced 
microbubbles which will affect the acoustic response of the bubble population[180, 261]. Since 
bubbles are strongly resonant scatterers, changes in the size distribution and concentration 
of the suspension will interact with any change in material properties to affect acoustic 
behaviour. In this work, when 40% dextrose was used, both albumin concentrations 
produced bubbles with an approximate mean diameter of 2 µm; however those with 2% 
albumin showed far greater acoustic attenuation. This suggests that there is a physical 
effect on the ability of the 2% and 5% albumin bubbles to absorb and scatter acoustic 
energy. It is theorised that 2% albumin bubbles have a thinner shell wall, capable of more 
extreme oscillatory behaviour and increased attenuation.  
Support for this theory comes from concurrent acoustic research by Dr Helen 
Mulvana on 2% 20% and 5% 20% as well as a 10% albumin, 20% dextrose microbubble[303]. 
Direct imaging of bubble oscillation under the influence of ultrasound was performed using 
the Cordin 550 high speed camera (for setup, see Fig. 5.9). The Cordin 550 is capable of a 
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frame rate of 2.5 Mfps meaning a 0.5 MHz transducer must be used to cause slow enough 
bubble oscillation to be captured appropriately. This in turn means microbubbles of >10 µm 
must be examined to ensure resonant behaviour. The wave pressure was 100 kPa. The 
captured images of bubble oscillation were then analysed in MATLAB using a custom 
program to measure bubble excursion over the ultrasound pulse. The maximum bubble 
excursion was plotted against initial diameter radius (Fig. 5.10). This shows that 2% 20% 
microbubbles have more extreme oscillatory behaviour. This behaviour is likely due to a 
thinner shell wall and may also be responsible for the greater nonlinear scatter seen for 2% 
40% microbubbles.  
 
Figure 5.9. Schematic of the high speed imaging set up. With the camera at full speed, a 
trigger is sent to both the AWG and Flash light, causing transmission of ultrasound pulses, a 
burst of bright light, and image capture by the camera. AWG = arbitrary wave generator, PC 
= personal computer (Reproduced with permission from Mulvana et al. (2011)[303]) 
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Figure 5.10. Maximum radial excursion against initial microbubble diameter for 2, 5 and 
10% albumin, 20% dextrose microbubbles, using a 12 cycle, 0.5 MHz pulse at c.100 kPa. 
(Reproduced with permission from Mulvana et al. (2011)[303]) 
 
However, at 20% dextrose, 2% albumin bubbles showed lower bulk acoustic 
behaviour than 5% albumin. One possible explanation is that 2% 20% bubbles, being the 
least stable, were destroyed during the ultrasound pulses, artificially dropping the mean 
scatter results, however the response over time do not support this (not shown). Instead, it 
is likely that the difference in size distribution between the two bubble formulations is 
responsible (Table 5.1). Evidence for this comes from the high speed camera work. In Figure 
5.10, microbubble diameter for maximum resonance is approximately equal for both 2% 
20% and 5% 20% microbubbles. Assuming this holds true at 3.5 MHz frequency, the 2% 20% 
microbubbles show the least acoustic response due to being further off resonance than 5% 
 2% 20% 
 5% 20% 
 10% 20% 
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20% microbubbles. Simple modelling was performed using the encapsulated bubble 
adaptation of the Minnaert resonance equation[220]: 
   
 
   
 (
   
  
)
 
 ⁄
 
Equation 5.1 
Where   is resonance frequency (MHz),   is radius (µm),   is bulk modulus (Pa), and 
   is the density of the surrounding liquid, assumed here to be 1000 kg/m
3. Solving this 
equation for   for 2% 20% and 5% 20% microbubbles, with resonance diameters of 12.25 
and 12.5 µm respectively under the influence of 0.5 MHz ultrasound, gives bulk modulus 
values of 0.49 MPa and 0.51 MPa respectively, which can be put back into Equation 5.1 to 
generate resonance curves (Fig. 5.11). These suggest that at 3.5 MHz, resonance diameters 
are approximately 3.5 µm for both microbubble formulations. Neither bubble has a mean 
diameter at this range however, 5% 20% microbubbles are closer, 1.7 ± 0.2 µm compared to 
1.3 ± 0.1 µm for 2% 20% microbubbles, which may result in greater bubble response despite 
a thicker shell. However, it should be noted that this is very simplistic modelling and the 
numbers are unlikely to be exact. Additionally, albumin shelled microbubbles can have bulk 
modulus values which are dependent upon diameter[186]. Finally, different pressures were 
used in the high speed camera work (100 kPa) compared to the bulk acoustics (200 kPa) 
which may affect the resonance response.  
Interestingly, the fact that both bubble formulations have maximum response at 
approximately the same bubble diameter and similar bulk modulus values suggests that 
bubble formulation does not strongly affect size dependent resonance response. However, 
this may not hold true for 40% dextrose microbubbles which remain untested in this set up. 
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Figure 5.11. Theoretical resonance curves of 5% 20% and 2% 20% microbubbles. A free air 
bubble resonance curve is included for comparison. 
 
Differences in non-linear scattering were also noted. Nonlinear scattering is a 
product of bubbles altering the frequency of the scattered sound typically due to resonant 
or below resonant behaviour[304, 305]. When at resonance, bubble oscillation can become 
more complex leading to emission of harmonics of the original frequency. The more 
extreme its oscillation, the greater the nonlinearity of the bubble response, which is 
hypothesised to aid transfection in vivo by increasing the bioeffects on surrounding cells. 
Here, non-linearity of the bubble has been detected using pulse inversion, described in 
Chapter 3. Nonlinear signals are low in comparison to the total scattering (10% to 30%) 
which is possibly due to the 0.9 MHz to 4.5 MHz window missing out on the higher 
nonlinear harmonics. Nonlinear scattering follows a similar trend to the attenuation 
response, but not the total scattering. Nonlinear signals are also very noisy so making 
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interpretation difficult especially considering the interactions that appear to be present. 2% 
40% shows the greatest amount of non-linear signal, but 5% 20% has the greatest 
component of nonlinear scattering compared to total scattering at almost 30%. The 5% 40% 
shows a low nonlinear signal and the lowest component. 2% 20% microbubbles have a 
similar component to 2% 40% but half the signal. Tentatively, this suggests that increasing 
dextrose for 2% albumin microbubbles does not affect their non-linear behaviour in 
comparison to total scattering, implying that the thin shell wall is still present allowing more 
extreme oscillation. Increasing the dextrose for 5% albumin microbubbles does appear to 
stiffen the shell, damping the more extreme oscillation.  
However, nonlinear scattering will depend strongly on resonant diameter and 
material properties of the microbubble[186, 207]. As previously mentioned, the 40% dextrose 
microbubbles have similar diameters, indicating that 2% 40% microbubbles are undergoing 
more extreme, non-linear oscillation. The trend for nonlinear scattering somewhat mirrors 
the trend of in vivo transfection success. This supports the theory that thinner shell walls 
make for more extreme microbubble behaviour and transfection.  
Unfortunately, due to the bulk nature of the acoustic work, it is difficult to compare 
between those formulations with different size distributions. The 20% dextrose 
microbubbles have different distributions – 2% 20% microbubbles has the lowest mean 
diameter – which complicates comparisons. Normalisation by gas volume of microbubbles 
helps to reduce the linear response effects, e.g. microbubble concentration, but the 
nonlinear responses due to the resonance remain. To complicate things further, the change 
in material properties between bubbles formulation, although not necessarily seen for 20% 
dextrose, may also have an effect on resonant diameter[220]. As described in Chapter 3.2.3., 
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the broadband pulse and use of mean scatter and attenuation measurements do help to 
reduce resonance only effects. However, comparisons between bubble formulations should 
be done with consideration to the limitations of the experiments. Ideally, size distributions 
would be matched, however it should be noted that this work was an investigation into the 
effect of composition on microbubble properties, including population statistics. A more 
thorough approach may have been to perform single bubble acoustics, to investigate the 
effect of bubble formulation on acoustic behaviour, however single bubble acoustic 
experiments tend to have low signal-to-noise, requiring a great number of repeats for 
significance. 
Differences in size distribution are likely a result of changes in the viscosity of the 
pre-sonication solution. Increasing albumin or dextrose concentration increases the viscosity 
of the solution which would cause changes in the response to sonication. It is hypothesised 
that during sonication, initially large bubbles are created which are broken down into 
smaller bubbles during the sonication time until either the bubbles are destroyed or 
denatured and become “set”. With low viscosity solutions, such as that used to make 2% 
20% microbubbles, microbubbles are rapidly formed and broken down leading to the 
generation of smaller bubbles and maybe lower concentrations. Solutions with higher 
viscosities, such as that used to make 5% 40% microbubbles, the resistance to motion the 
viscosity imparts on the solution reduces the speed of bubble formation leading to larger 
bubbles. It is also possible that higher viscosities result in greater energy deposition into the 
solution giving higher sonication temperatures. This could lead to both earlier denaturation 
of microbubbles during the larger bubble phase of sonication, and greater gas expansion, 
forming larger bubbles and “setting” them. 40% dextrose microbubbles were significantly 
185 
 
larger than 20% dextrose microbubbles according to the Mack-Skillings test (p<0.0001), 
however no significant difference for albumin microbubbles was achieved (p=0.097). 
A strong link between the increase in microbubble behaviour and transfection has 
been demonstrated. Increases in microbubble behaviour, such as attenuation, can be 
achieved by changes in the acoustic driving amplitude or driving frequency which has been 
shown to affect transfection[306]. However, in this instance, the acoustic parameters used 
remain unchanged whilst the bubble’s inherent acoustic behaviour has been changed via 
the formulation for an increase in transfection. Increasing the bubble response by 
manipulation of its components could be of use in lowering acoustic intensities required for 
transfection, improving safety and increasing potential treatment times. It may also be of 
use in creating mixed microbubble formulations responsive to different intensities for a 
multi-step delivery system, as already demonstrated using polymeric microbubbles[190].  
Another important property controlled by the shell material, is stability. This has 
implications for both imaging and therapeutic use. A limitation of contrast agents in clinical 
imaging is the rapid clearance of microbubbles from the circulation, which reduces the 
amount of time a sonographer has to make useful observations and limits the different 
types of imaging strategies available. As such, much research has gone into creating more 
stable bubble formulations[188, 219, 307, 308]. It is also known that stability of microbubbles plays 
a role in transfection[98]. Our results here support such work, in that 20% dextrose bubbles, 
the least stable according to the ultrasound destruction experiment, were the least 
effective, to the point that there was no significant difference in transfection ability 
between albumin concentrations when differences in size distribution and concentration 
were removed. Increasing the dextrose concentration of the starting materials to 40% 
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produced acoustically stable bubbles, allowing investigation into the differences in 
transfection caused by albumin concentration, i.e. changes in scattering and attenuation 
behaviour.  
As discussed in Chapter 3.2.4., microbubbles are subject to number of destructive 
process in vivo, particularly gas dissolution. The speed of dissolution across a bubble shell 
will depend on its porosity and thickness. Microbubbles with thin shells, as suspected with 
the 2% 20% microbubble, will rapidly exchange gas, decreasing their stability and leading to 
rapid destruction. Increasing the albumin concentration increases the shell thickness and 
prolongs the lifespan of a bubble. A similar effect may be occurring for dextrose, in that 
increasing dextrose may increase the shell thickness; however dextrose is a small molecule 
compared to albumin so the effect would be minimal. Instead, on the assumption that 
dextrose is reacting with albumin, i.e. glycosylation of amino acid residues during the 
sonication and pre-warm step[216, 309-311], it may instead be reducing the porosity of the 
albumin shell and stiffening it. This would also reduce dissolution time, increasing stability 
and yet, for 2% albumin microbubbles, retaining a thin shell wall able to undergo a high 
degree of oscillation. The increased resistance to ultrasound may allow multiple passes of 
the targeted organ, however microbubble destruction under 1.6 MI ultrasound was very 
rapid. Instead, an increase in shell thickness or stiffness may help resist biological forms of 
destruction. Overall, this increase in stability will allow microbubbles to persist longer in the 
circulation and increase the number available for transfection. 
Stability over time after manufacture is another factor affecting transfection. Bubble 
dissolution in the vial leads to a lowered response to ultrasound. Over four hours, this is a 
gradual process leading to a slight decrease in diameter and gas concentration, although 
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microbubble concentration remains relatively stable (Fig. 5.1). To demonstrate the usability 
of the bubbles during these four hours and after, transfection experiments using 5% 20% 
microbubbles were performed using single batches of microbubbles. As before, bubble 
number concentration, gas concentration, median and mean diameter decreased over time, 
particularly after 4 hours (Fig. 5.7). Bubble disruption could also be seen directly on the 
optical images (Fig. 5.8). Transfection using the microbubbles was significantly worse four 
hours after manufacture compared to before. It was therefore essential that all microbubble 
experiments take place within the shortest possible timeframe after manufacture. 
This situation was only tested at room temperature though and it is possible that 
bubbles which are stored at 4oC may last longer. The recommended storage of Optison, a 
commercial albumin microbubble which is supplied as a liquid, is in a fridge (2-8oC) 
(information taken from Optison product information). Additionally, although the stability 
over time data does provide some useful information, the optical experiments were 
performed only on a single batch of bubbles. Without repeats, the accuracy of the results is 
questionable, especially with the high batch variation (Table 5.2). 
Inter-batch variation, particularly microbubble concentration and gas concentration, 
was high for the different formulations. This was likely due to the manufacture procedure 
when microbubbles are aspirated after centrifugation to separate foam and larger bubbles 
from the microbubbles. Some degree of user judgement is required to discern where the 
separation between the layers is; aspirating too much will increase the concentration and 
proportion of larger microbubbles, whilst too little will decrease them. Importantly, the 
mean and median sizes, show an acceptable amount of variation, with a CV of less than 14% 
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across all formulations. This helps to demonstrate that although the concentrations may be 
different, size distribution is relatively stable.  
As there were differences in the concentration and size distributions between the 
different microbubble formulations, and concentration differences between batches, some 
type of normalisation was required to account for this confounding factor. Photon flux 
measurements from mice were normalised against the gas concentration of the 
microbubble batch used for their transfection. Although gas concentration showed the 
greatest batch variation, it is a measure of both microbubble number count and diameter. 
By using gas concentration, the differences and variation in both concentration and size 
difference can be accounted for. However, whilst post experimental normalisation for 
concentration and size distribution may account for linear increases in transfection, it may 
not normalise correctly for non-linear effects, e.g. resonance. Differences in microbubble 
concentration and size distribution should always be taken into consideration when 
comparing different microbubbles, whether bought commercially or produced in house, and 
ideally should be matched before use, especially if other factors are under consideration.  
This increase in transfection ability of bubbles made with 40% dextrose compared to 
20% dextrose was strongly significant in original data and log transformed data. There was 
also a significant interaction term for the log transformed data, which meant that 2% 
albumin bubbles showed a greater increase in transfection efficiency compared to 5% 
albumin bubbles when dextrose concentration was increased. Differences in non-
confounded populations were confirmed by an adjusted Tukey-Kramer test, and 
demonstrated a significant difference between the two albumin concentrations when 
comparing 40% dextrose bubbles. Although significance was achieved between sample 
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groups, it should be noted that there is, once again, a large amount of variability in the data, 
the potential causes for which are discussed in depth in Chapter 3.3.5.  
Effect sizes for the three factors investigated by a two-way ANOVA (the two main 
effects and the interaction effect) were calculated from the log transformed, gas 
concentration normalised in vivo data. Whilst it was not possible to calculate the power of 
the two-way ANOVA, the effect sizes themselves also reveal that the change in dextrose 
creates a large difference in the transfection. The effect size for the albumin factor was 
much smaller, whilst the interaction effect lay in between the two. These results, as would 
be expected, are reflected in the probability data; a change in dextrose concentration 
causes a strong difference, albumin does not, but there is a significant interaction effect 
between the two. In turn, when using these effect sizes to determine the required sample 
size for a sufficiently powered study to ensure the null hypothesis is not being incorrectly 
rejected, the smaller the difference, the greater the number of animals required. As there is 
only a small difference caused by albumin, an unrealistic number of animals would be 
required to for a sufficiently powered two-way ANOVA. A compromise would be to instead 
use the sample size required for a sufficiently powered interaction observation (n=92 or 
n=23/group), although this would still be quite a high number of animals; over double the 
number already used. A certainly simpler approach would have been to instead investigate 
the two factors separately, however this would lose the interesting interaction effect noted 
in the experiment. Overall, it appears that this study did not have a sufficiently large sample 
size to ensure the absence of Type II errors from the statistical approach chosen. A greater 
number of animals or a simpler experimental aim would have helped avoid the possibility of 
failing to reject a false null hypothesis. Additionally, as this experiment revealed a novel link 
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between microbubble behaviour and transfection, it would have been of use to 
independently reproduce the in vivo work to further demonstrate the validity of the 
findings; however there was insufficient time for a full repeat. This also could extend to the 
in vitro acoustic work, however as they followed a fixed method with few sources of 
variability, and the microbubble variation was removed by gas concentration normalisation, 
this may not have been necessary. 
A fundamental reasoning behind performing this work is that albumin based 
microbubbles, such as Optison, have been shown to be more effective than lipid based 
ones, such as SonoVue, potentially due to increased stability[98], but that optimisation for 
albumin microbubbles has not been performed. It is therefore tempting to contrast our 
microbubbles against the commercial ones mentioned however there are a number of 
important differences. Optison has a mean diameter of approximately 4 µm according to 
the manufacturer (information taken from Optison product information); making it larger 
than our formulations and SonoVue at 2.5 µm[202]. Undoubtedly this affects acoustic 
response and potential transfection, although this is further complicated by material 
differences and their effect on resonance. SonoVue, as a lipid encapsulated microbubble of 
sulphur hexafluoride, will have a different resonance size profile compared to our 
formulations, but this will also apply for Optison despite being an albumin encapsulated 
microbubble of octafluoropropane. According to the manufacturer’s literature, there is no 
dextrose component. Additionally, the human albumin used will be different to the 
recombinant, rice-derived type used here. There are also other components in the Optison 
solution – N-acetyltryptophan and caprylic acid – which may have a role in maintaining 
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sterility. Finally, Optison contains 1% (w/v) albumin, which will result in significantly 
different shell properties.  
Therefore, extrapolation of these findings to commercial microbubbles requires 
caution. Optison has not been tested in the current set-up, however the previous Chapter 
investigated the effect of needle gauge on UMGT transfection using SonoVue microbubbles. 
Mean bioluminescence after SonoVue transfection using 27G needles normalised to mean 
SonoVue gas concentration was 1.33 x 105 photon/s/(µL gas/mL). This puts it as more 
effective at transfection than 20% dextrose bubbles but less than both 40% dextrose 
bubbles although significance has not been examined. Direct comparison is not valid though 
as there are slight changes in methodological procedure; for instance, the ultrasound focus 
was swept through the heart in the previous work, whereas here it is static. It is interesting 
that 20% dextrose microbubbles perform worse than SonoVue, and presumably Optison. It 
is likely related to their low stability, although other reasons cannot be ruled out. 
The two strategies used in this study to control bubble properties, albumin and 
dextrose concentration, have been examined by other groups[213, 219]. In the Porter et al. 
(1995) paper, a range of different albumin-to-dextrose dilution ratios were tested to 
optimise ultrasound contrast imaging. Interestingly, they found no significant difference 
between using 5% or 50% dextrose, whereas we found a higher dextrose concentration 
causes significant improvement in bulk acoustic scatter. However, there are many technical 
differences between the two studies making them distinctly incomparable, but importantly 
the bubbles were not used for transfection, nor were they acoustically examined in vitro. 
The Du et al. (2001) paper investigated the effect of increasing dextrose concentration on 
the long term stability of albumin based microbubbles. They found that as the dextrose was 
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increased, bubbles became stable for longer periods of time and were increasingly resistant 
to heat based destruction. This work is the first demonstration of altering dextrose and 
albumin concentrations to control microbubble properties for the purpose of improving 
transfection.  
 
5.5. Conclusion 
This study uses the Model Protocol described in Chapter 3 to investigate the bulk 
acoustic characteristics of scattering, attenuation and stability of differing formulations of 
albumin and dextrose microbubbles. By identifying interesting acoustic characteristics of the 
different formulations and utilising a repeatable in vivo transfection experiment, specific 
microbubble factors were identified which are important in the success of transfection; 
stability and attenuation behaviour. As mentioned, progression of UMGT to clinical 
relevance has stalled in the face of poor transfection efficiencies and a lack of information 
about the important factors affecting transfection success.  The Model Protocol attempts to 
solve both issues by using simple and repeatable techniques to characterise a microbubble’s 
acoustic behaviour and their transfection efficiency to determine which factors are vital in 
improving transfection. In this study two factors which improve transfection efficiency have 
been identified, proving its usefulness and highlighting potential paths for further 
optimisation of UMGT. 
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6. Investigation into effect of glucosamine in bubble 
shell on UMGT in vivo 
In this chapter, preliminary investigations into the effect of plasmid and microbubble 
co-localisation during ultrasound treatment were performed. A number of novel microbubble 
formulations were prepared using the positively charged glucosamine monosaccharide so as 
to bind negatively charged plasmid DNA to the albumin microbubble shell. These were 
optically observed for their stability and size distribution. Fluorescence imaging was used to 
determine localisation of the plasmid on the microbubble. Fluorescence spectrophotometry 
was investigated as a potential tool to quantify the degree of plasmid loading. The outcome 
was a novel albumin-dextrose-glucosamine microbubble capable of loading a quantifiable 
amount of plasmid DNA. Acoustic and transfection work will be the subject of future studies. 
 
6.1. Introduction 
As shown in the previous two chapters, having sufficient concentration and a 
strongly acoustic microbubble is important for transfection. Other groups have focused on 
improving transfection via the acoustic settings[85, 306], combination therapies[198, 244], 
magnets[266], viruses[231, 237], targeted microbubbles[140] and genetic material employed[173]. 
All approaches have shown improvements, although direct comparison is complicated by 
the many different treatment methods used, and undoubtedly the final ideal clinical set up 
will make use of many if not all of them. 
It has been demonstrated that for transfection or drug delivery to occur, the 
therapeutic agent must be delivered either with, during or soon after the ultrasound 
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treatment[92, 144]. Bioeffects on cells and blood vessels by ultrasound and microbubble 
treatment are transient[83, 84], which helps to improve their safety. However, for genetic 
material or a drug to enter the permeabilised cells or “leak” from the blood vessel, it must 
be within the target area during treatment. For techniques relying on direct injection this is 
not a problem[89, 157, 312], however for systemic injections this means a higher dose of 
therapeutic agents must be employed to reach a therapeutically relevant dose at the 
treatment site. As such, for the majority of the treatment time, much of the therapeutic 
agent will be in other areas of the body. This lowers the efficiency of the procedure, 
increases the costs and can increase the risk of side effects. 
As a result, research has been performed to co-localise the agent and microbubble, 
typically with the agent either attached directly to the microbubble[178, 285, 313], carried in the 
shell[88, 190, 314, 315] or carried within the gas core cavity[194]. All these approaches work on the 
principle that destruction of the microbubble in the target area will release the therapeutic 
agents directly to the permeabilised cells and blood vessels increasing passive uptake and 
extravasation. The force generated by oscillating microbubbles may also help to actively 
deliver the agents, effectively “injecting” the agent into the surrounding cells and interstitial 
space. 
Typically, these approaches to load microbubbles use lipid-based formulations. 
These have the advantage that specialised lipids can be used to attach the agent either 
directly[56, 178] or via a carrier[277, 316]. Microbubbles can then be created by simple agitation 
with lipids naturally assembling into a monolayer microbubble[206]. Such a “self-assembly” 
approach is already used for the commercial lipid based microbubbles SonoVue (Bracco) 
and Definity (Lantheus Medical Imaging, N. Billerica, MA, USA). Additionally, many drugs are 
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lipophilic allowing them to be loaded directly into the microbubble, or into an oil layer 
constructed within the microbubble. Loaded polymeric microbubbles are also used in this 
way[190, 194]. 
Albumin microbubbles have also been investigated for their ability to load 
therapeutic agents. Initially, this involved a simple approach of adding plasmid to the pre-
sonication mixture used to create albumin based microbubbles[314]. This demonstrated a 
significant increase in in vitro transfection compared with unloaded bubbles at optimal DNA 
concentrations, however in vivo experiments were never pursued. This approach was 
trialled by other groups as well, again without in vivo experimentation[88]. A different 
approach was to coat the albumin microbubbles with a cationic polymer, poly-(allylamine 
hydrochloride), which could bind DNA and was shown to protect the bound DNA from 
nucleases[267]. This improved the loading capacity and stability of the microbubble without 
affecting acoustic behaviour and protected the plasmid against nuclease attack, but no 
transfection experiments were trialled due to the potential safety concerns with the nature 
of the polymer. Despite these early promising results, in vivo experimentation with loaded 
albumin microbubbles never materialised as attention switched the more easily 
manipulated lipid and polymer based formulations. 
As discussed in the previous chapter, albumin based microbubbles are commonly 
found to be more effective at transfection than their lipid counterparts at equivalent doses. 
Comparison between both 2% 40% and 5% 40% revealed them to be more effective than 
SonoVue, as discussed in Chapter 5. It was therefore desirable to re-examine the potential 
of plasmid loading on to microbubbles as a factor affecting transfection. As DNA has a 
strong negative charge, adding a positive charge to the microbubble is the most effective 
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way to ensure loading. Lentacker et al. (2006) achieved this using a cationic polymer, 
however some of these can come with potential safety issues[317]. 
Glucosamine (GlcN) is an amino sugar which forms a major component of chitosan 
and chitin, the polysaccharide compound found in the exoskeletons and cell walls of 
arthropods and fungi respectively. It is a monosaccharide resembling glucose with an amine 
group at C2 (Fig. 6.1). This amine group gives glucosamine a positive charge in neutral pH 
solutions. It is also a reactive sugar and, like glucose (dextrose), reacts with proteins such as 
albumin, a process known as glycation[311]. It is less soluble than glucose, with a maximum 
concentration of approximately 15% (w/v). 
It is hypothesised that adding glucosamine to the albumin bubble will create a more 
positively charged microbubble which will be able to more effectively bind the negatively 
charged DNA. This should decrease its degradation by nucleases in vivo and potentially 
increase transfection by co-localising DNA to the target area during treatment. As 
glucosamine is a dietary sugar, it should also be well tolerated and metabolised after 
treatment.  
This chapter of the thesis covers the final research topic of the project. 
Unfortunately, due to time constraints, animal and acoustic experiments were not 
performed. Instead, the first section details experiments to produce an albumin based 
microbubble containing glucosamine. The second section details calibration set ups for 
proposed fluorescence spectrophotometry experiments to determine the binding efficiency 
of microbubbles. 
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a)  b)  
Figure 6.1. Chemical structure of a) α-D-glucosamine, b) β-D-glucose (pyranose form). 
Images from Wikimedia Commons.  
 
6.2. Production of an albumin based microbubble containing 
glucosamine 
6.2.1. Introduction 
No previous attempts to create an albumin/glucosamine microbubble have been 
detailed in the literature, and as such, this work represents entirely novel research. It was 
necessary to determine whether albumin/glucosamine microbubbles production was 
possible and whether it would produce a sufficient concentration for in vitro and in vivo 
studies. Ideally, it would share similar size distributions across any range of glucosamine 
concentrations to simplify analysis of results. 
In these initial experiments, 2% (w/v) albumin solution was chosen as the albumin 
component of the microbubble as it has the potential to give the highest effective 
transfection, as seen in the previous Chapter. The highest concentration of glucosamine 
possible was also used, 15% (w/v), to ensure any difference with the control would be 
maximised. Subsequent experimentation would use differing concentrations of glucosamine 
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to identify the optimal concentration and DNA loading required for transfection. Preliminary 
production experiments were based on the manufacture method used for typical 
albumin/dextrose microbubble production[213, 227]. This was adapted as experimentation 
proceeded, giving rise to an individual production method for albumin/glucosamine 
microbubbles. Unfortunately, due to time constraints and production complications, 
microbubble characterisation methods besides optical examination by microscope were not 
employed. 
6.2.2. Methodological Particulars 
Unlike previous chapters, specific method details will be described in the following 
experiments. In general, sonication followed the basic set up described in Chapter 2. Briefly, 
1 part of an albumin solution, typically 2% (w/v), was diluted with 3 parts of a sugar 
solution. This was then warmed in a water bath. 10 mL of octafluoropropane was always 
bubbled through the solution, followed by sonication using the Misonix Sonicator 3000 (20 
kHz, 39-42 W). The resultant bubble solution would then undergo centrifugation. A 
secondary centrifugation would be performed if necessary. Microbubbles were then 
optically examined and imaged for counting and sizing if necessary. 
For preliminary experiments, only 1 sample was created per experimental condition. 
For the final formulation, four separate samples were produced to test batch variability.  
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6.2.3. Experiments 
6.2.3.1. Extended incubation time to create albumin and glucosamine based 
microbubbles 
Preliminary experiments attempted to create microbubbles with 2% albumin and 
15% glucosamine following the standard procedure used to create albumin and dextrose 
based microbubbles (Methods & Materials, section 2.3). However the resultant microbubble 
solution would rapidly separate into an upper cake of bubbles/foam and a clear lower 
solution, or infranatant. Microscopic examination of the infranatant, revealed very few 
microbubbles; too low for optical counting and sizing to be performed. It was thought that 
glucosamine, being at a lower concentration than dextrose, results in low glycation of the 
albumin particle, as glycation rate is related to concentration[310]. Additionally, glucosamine 
may have a lower reactivity with exposed amino acid groups on the albumin compared to 
dextrose. Finally, as shown in the previous chapter, 2% 20% were the least stable and it is 
possible that the 15% glucosamine equivalent is not sufficiently stable to form 
microbubbles. 
Glycation is a time dependent process[310, 311]. To encourage greater glycation and 
produce a usable concentration of stable microbubbles, a solution of 1 part 2% albumin and 
3 parts 15% glucosamine was mixed and incubated at 55oC for 60 minutes in a water bath. 
During this incubation it was noted that the solution went cloudy after approximately 5 
minutes at 55oC. Octafluoropropane gas was then added and the solution sonicated for 1 
minute. Centrifugation of the solution at 500 rpm for 1 minute resulted in complete 
separation of the bubbles into a clear infranatant and upper “cake” of bubbles. As such, the 
solution was remixed by inversion and left to separate by buoyancy into a cloudy liquid 
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infranatant and upper cake of large bubbles. The infranatant was extracted and examined 
optically by microscope. 
Microbubbles were dilute in comparison to typical albumin/dextrose microbubbles 
at 2.94 x 108 microbubbles per mL, with a mean and median diameter of 2.01 µm and 1.42 
µm respectively, and a gas concentration of 4.54 µL/mL. A typical size distribution graph is 
given in Figure 6.2. Optically, microbubbles appeared clumped with unusual shapes and 
some debris (Fig. 6.3). Although the longer incubation appears to produce microbubbles, 
the presence of debris, clumping and the cloudiness in the pre-sonication mix during 
incubation suggests that albumin is becoming denatured before sonication. 
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Figure 6.2. Size distribution histogram of microbubbles prepared from a 1:3 mix of 2% 
albumin and 15% glucosamine solutions incubated at 55oC for 60 minutes.  Bin size = 0.32 
µm. Colourless bars indicate microbubble excluded from population statistics analysis (0.5 
µm < diameter < 10 µm). 
 
Figure 6.3. Representative 40x microscope image of microbubbles prepared from a 1:3 mix 
of 2% albumin and 15% glucosamine solutions incubated at 55oC for 60 minutes. Arrows 
indicate: M = Misshapen microbubble, C = Clumped microbubbles, R = Broken microbubble, 
D = Denatured albumin on microbubble. Scale bar is 16 µm, with a mark at 8 µm.  
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6.2.3.2. Effect of temperature on albumin mixed with glucosamine 
In preliminary experiments and during the extended incubation time experiment, it 
was noted that the solution would become cloudy and opaque when warmed to over 55oC. 
It was suspected that the temperature was prematurely denaturing the albumin leading to 
low bubble production and clumped microbubbles (Fig. 6.3).  
To investigate the effect of temperature on albumin, 2% and 5% albumin were 
diluted 1 part to 3 with 15% (w/v) glucosamine. The two solutions were then placed in a 
25oC water bath which was gradually increased in temperature to 60oC. At each 2.5oC 
increase in temperature, the transparency of the solution was judged by eye, as 
transparent, cloudy or opaque to determine if denaturation of the albumin had occurred. 
The two solutions were incubated at 60oC for 5 minutes and then judged again. The 
solutions were then placed in 25oC water for a further 5 minutes and the opacity judged 
again. As denaturation in some proteins is reversible over time, the solutions were re-
examined after three days to determine if the albumin was irreversibly denatured. The 
results are displayed in Table 6.1. 
For 2% albumin, the solution went opaque at approximately 55oC to 57.5oC, and 5% 
albumin started at 57.5oC and was fully opaque after 5 minutes at 60oC. Neither solution 
returned to transparency after returning to 25oC. After 3 days, the solution had separated 
into a solid sediment and a clear supernatant. It is thought that the albumin has been 
irreversibly denatured by heat and that a lower incubation temperature is required. A fresh 
solution of 2% albumin and 15% glucosamine was incubated at 50oC for 5 minutes without 
obvious cloudiness so 50oC was chosen as the new pre-sonication incubation temperature.  
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It may have been expected that the greater amount of albumin in the 5% albumin 
solution, would have resulted in it denaturing before the 2% albumin solution. However, the 
temperature readings were taken within the water baths not the solutions themselves. As 
such, there is likely a lag between the temperature of the solutions and the water bath. As 
5% albumin is a more viscous solution, this would have affected the heat transfer and may 
have had caused a longer lag period than 2% albumin, resulting in its slower denaturation. It 
is likely that both solutions would denature at the same temperature, somewhere around 
51oC to 55oC. 
 
Table 6.1. Transparency of 2% and 5% albumin solutions mixed 1:3 with 15% glucosamine at 
a range of temperatures. (T = Transparent, C = Cloudy, O = Opaque, S = Separation into 
sediment and clear supernatant, RT = Room Temperature) 
Condition 2% albumin 5% albumin 
25.0oC to 50.0oC T T 
52.5oC T T 
55.0oC C T 
57.5oC O C 
60oC O C 
60oC + 5 minutes O O 
25oC + 5 minutes O O 
RT + 3 days S S 
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6.2.3.3. Production of albumin and glucosamine microbubbles after 50oC incubation 
In the previous section, 50oC was determined to be an appropriate pre-sonication 
incubation temperature. To determine the effect on the production of albumin/glucosamine 
microbubbles, 2% albumin and 15% glucosamine solutions were mixed 1:3 and incubated at 
50oC for 5 minutes before addition of octafluoropropane gas and sonication for 1 minute. 
The resultant solution was not centrifuged due to rapid separation into a clear infranatant 
and upper “cake” of large bubbles and foam due to buoyancy.  
The clear infranatant was examined optically revealing a dilute solution of 5.71 x 106 
microbubbles per mL, with mean and median diameter of 2.87 µm and 2.39 µm 
respectively, and a gas concentration of 0.19 µL/mL. The size distribution was very different 
from previous results using albumin microbubbles (Fig. 6.4). Images of the microbubbles 
revealed a number of large microbubbles with a great deal of debris in the solution and 
attached to microbubbles, giving a “halo” like effect (Fig. 6.5).  
Despite the lowered temperature during incubation and no sign of denaturation, 
microbubble production is very dilute, producing a high number of large microbubbles (10% 
were >10 µm in diameter). The lowered temperature, sugar concentration and perhaps 
lowered reactivity of the glucosamine with albumin appeared to severely affect 
microbubble manufacture. 
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Figure 6.4. Size distribution histogram of microbubbles prepared from a 1:3 mix of 2% 
albumin and 15% glucosamine solutions incubated at 50oC for 5 minutes.  Bin size = 0.32 
µm. Colourless bars indicate microbubble excluded from population statistics analysis (0.5 
µm < diameter < 10 µm). 
 
Figure 6.5. Representative 40x microscope image of microbubbles prepared from a 1:3 mix 
of 2% albumin and 15% glucosamine solutions incubated at 50oC for 5 minutes. Arrows 
indicate “halo” like feature of denatured albumin attached to microbubbles. Scale bar is 16 
µm, with a mark at 8 µm.  
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6.2.3.4. Addition of 40% dextrose to albumin and glucosamine microbubbles 
In the preceding experiments, sonication of a solution of albumin and glucosamine 
has produced a low concentration of abnormal microbubbles. It was suspected that this was 
due to albumin’s increased sensitivity to heat and low glycation in the presence of 
glucosamine. As albumin/dextrose microbubbles are relatively simple to produce, an 
attempt was made to produce microbubbles using a mix of albumin, dextrose and 
glucosamine. It was hypothesised that this would produce stable microbubbles in which 
glucosamine would be incorporated. 
2% albumin was mixed with 40% dextrose and 15% glucosamine in a 2:3:3 ratio, and 
incubated at 50oC for 5 minutes. Octafluoropropane gas was added and the solution 
sonicated for 1 minute. Bubble solutions were then centrifuged at 500 rpm for 1 minute to 
separate the microbubbles from larger bubbles. The infranatant, containing microbubbles, 
appeared slightly cloudy and was extracted by syringe and needle. A second centrifugation 
was performed on the original samples and further infranatant was pooled with the first.  
Population statistics were determined by optical examination of the infranatant. The 
2:3:3 ratio used makes this bubble formulation equivalent to 2% 20% (albumin/dextrose) 
microbubbles with 7.5% glucosamine, effectively: 2% 20% 7.5% microbubbles. As such, they 
were compared with the albumin/dextrose microbubble to see if the glucosamine was 
affecting the population statistics (Table 6.2). The added glucosamine resulted in a lowered 
concentration but larger mean and median sizes and gas concentration.  
Whilst the microbubble concentration was still lower than anticipated, produced 
microbubbles were visually normal (Fig. 6.7) and had a reasonable size distribution from 0 to 
207 
 
10 µm (Fig. 6.6). The combination of dextrose with glucosamine as the sugar component of 
microbubbles has improved microbubble production. 
 
Table 6.2. Population statistics of albumin/dextrose and albumin/dextrose/glucosamine. MB 
= microbubble. 
Population Statistic 2% 20% microbubble 2% 20% 7.5% microbubble 
Concentration (x 108 MBs/mL) 6.40 2.32 
Mean Diameter (µm) 1.3 2.07 
Medium Diameter (µm) 1.14 1.49 
Gas Concentration (µL/mL) 2.11 3.71 
 
 
Figure 6.6. Size distribution histogram of microbubbles prepared from a 2:3:3 mix of 2% 
albumin, 40% dextrose and 15% glucosamine solutions incubated at 50oC for 5 minutes.  Bin 
size = 0.32 µm. Colourless bars indicate microbubble excluded from population statistics 
analysis (0.5 µm < diameter < 10 µm). 
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Figure 6.7. Representative 40x microscope image of microbubbles prepared from a 2:3:3 
mix of 2% albumin, 40% dextrose and 15% glucosamine solutions incubated at 50oC for 5 
minutes. Scale bar is 16 µm, with a mark at 8 µm. 
 
6.2.3.5. Production of albumin, dextrose, glucosamine microbubbles 
The previous section produced a 2% 20% 7.5% microbubble with a visually normal 
appearance and reasonable size distribution. However, the concentration was lower than 
anticipated and the glucosamine concentration was effectively halved. It is preferable in 
these preliminary experiments to use the highest glucosamine concentration possible to 
maximise any differences between control microbubbles. 
To remove the dilution effect on the glucosamine concentration and potentially 
improve microbubble concentration, a single solution of 40% dextrose and 15% glucosamine 
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was prepared. This was mixed 3:1 with a 2% albumin solution and warmed to 50oC for 5 
minutes. Octafluoropropane gas was added and the solution sonicated for 1 minute at half 
maximum power. It was noted, that despite using the usual settings on the sonicator, the 
output power started at 51 W, whereas typical sonication of albumin dextrose solutions 
starts at 39 W to 42 W. The output power of a sonicator is affected by the viscosity of the 
solution and is not directly controllable by the Misonix Sonicator 3000. The resultant 
solution was centrifuged at 500 rpm for 1 minute and the liquid infranatant recovered.  
Microscope examination revealed a dilute suspension of microbubbles with 
abnormal shapes and “halo” like effects from denatured albumin (Fig. 6.9). Microbubble 
concentration was 1.76 x 107 microbubbles per mL, with a mean and median diameter of 
2.57 µm and 2.07 µm, and a gas concentration of 0.42 µL/mL. 
The low microbubble concentration and abnormal microbubbles may be a result of 
the high power output of the sonicator compared to previous sonications. The high sugar 
content of the solution increases the viscosity of the solution. In Chapter 5.4, this was 
suggested as the reason why the higher dextrose microbubbles were significantly larger 
than the 20% dextrose microbubbles. The speed of bubble formation is reduced due to the 
increased resistance to motion, due to higher viscosity, generating microbubbles of a larger 
size distribution, (Fig. 6.8). Sonication also heats the solution which is necessary for 
denaturation and glycation of the albumin to form stable microbubbles. The higher power 
output will cause significant heating and energy deposition into the solution, potentially 
denaturing albumin before it is incorporated into a microbubble shell and destroying 
formed microbubbles by excessive, thermal gas expansion or shell wall destabilisation. 
Microbubbles may also become physically stuck together and coated in denatured albumin. 
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Figure 6.8. Size distribution histogram of microbubbles prepared from a 1:3 mix of 2% 
albumin and 40% dextrose, 15% glucosamine solutions incubated at 50oC for 5 minutes.  Bin 
size = 0.32 µm. Colourless bars indicate microbubble excluded from population statistics 
analysis (0.5 µm < diameter < 10 µm). 
 
Figure 6.9. Representative 40x microscope image of microbubbles prepared from a 1:3 mix 
of 2% albumin and 40% dextrose, 15% glucosamine solutions incubated at 50oC for 5 
minutes. Scale bar is 16 µm, with a mark at 8 µm. Arrows indicate abnormal microbubbles.  
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6.2.3.6. Reduced sonication time to produce 2% 40% 15% microbubbles 
Due to the viscous nature of the pre-sonication 2% 40% 15% microbubble solution, 
the power output from the sonicator was potentially too high. To resolve this, a shorter time 
of 30 s sonication was used. Otherwise the method was the same as the previous section. 
Centrifugation of the resultant bubble dispersion caused separation into a cloudy 
infranatant of the microbubbles and a supernatant of larger bubbles. Unlike previous 
centrifugations, there was no clear demarcation line between the two solutions. To avoid 
collection of excessive numbers of larger bubbles, only the lower portion of the cloudy 
infranatant was removed, and a second centrifugation was performed. The infranatant was 
again collected and pooled with the first. 
Optical examination revealed visually normal microbubbles (Fig. 6.11) at a 
concentration of 8.97 x 108 microbubbles per mL, a mean and median diameter of 1.75 µm 
and 1.70 µm respectively, and a gas concentration of 4.05 µL/mL. The size distribution 
revealed a wide peak and short-tailed distribution around 2 µm with very few microbubbles 
over 5 µm (Fig. 6.10). The size distribution bears some similarities to the 60 s sonication, 
with a peak microbubble count at approximately 2 µm and few under 0.5 µm in diameter. 
The longer sonication time appears to result in a greater number of large microbubbles, 
possibly due to excessive heating preferentially destroying smaller microbubbles. 
Importantly, visually normal microbubbles have been produced from an albumin, 
dextrose and glucosamine solution with a useable concentration and a sensible size 
distribution. There is some clumping visible in the microbubble images, which may be due to 
the high concentration. However, it is unknown if glucosamine is incorporated in the shell.  
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Figure 6.10. Size distribution histogram of microbubbles prepared from a 1:3 mix of 2% 
albumin and 40% dextrose, 15% glucosamine solutions incubated at 50oC for 5 minutes and 
sonicated for 30 s.  Bin size = 0.32 µm. Colourless bars indicate microbubble excluded from 
population statistics analysis (0.5 µm < diameter < 10 µm). 
 
Figure 6.11. Representative 40x microscope image of microbubbles prepared from a 1:3 mix 
of 2% albumin and 40% dextrose, 15% glucosamine solutions incubated at 50oC for 5 
minutes and sonicated for 30 s. Scale bar is 16 µm, with a mark at 8 µm. Arrows indicate 
clumps.  
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6.2.3.7. Reproducibility of 2% 40% 15% microbubbles 
To test the reproducibility of 2% 40% 15% microbubble production, several batches 
were made according to the method detailed in the previous section and compared. The 
results are displayed in Table 6.3. Batches 1 and 2 show good agreement in all population 
statistics with a slight difference in mean diameter and gas concentration. Batch 4 is also 
similar with a slightly lower concentration but higher mean diameter and gas concentration. 
Batch 3 shows the greatest difference with a high microbubble concentration, and low 
mean and median diameters, yet a similar gas concentration. All four batches show 
differences in their size distribution histograms (Fig. 6.12). 
Overall, the 2% 40% 15% microbubble batches show reasonable reproducibility but 
not ideal. A potential reason lies in the glucosamine sugar. Glucosamine, as an amino sugar, 
can undergo an auto-condensation reaction[318] involving its aldehyde and amine group, 
essentially reacting with other molecules of itself. This reaction is, in essence, similar to the 
glycation reaction expected between the sugar and albumin. Auto-condensation reactions 
will happen over time and are increased by basic environments and temperature. At 37oC, 
significant changes to the solution would be expected within 24 hours[311, 318-320]. As the 
solution is stored in the fridge, the reaction will be slower but glucosamine will still be 
forming auto-condensation products during storage with itself and with the dextrose, which 
is also capable of reducing the amine group on glucosamine. This will generate a range of 
differing products over time. Microbubbles made with these sugars are likely to have 
differing properties. 
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Batch 1 and 2 were made within 48 hours of each other using the same sugar 
solution which had been prepared two days prior. Batch 3 was made 10 days later with the 
same sugar solution, which could explain its significantly different population statistics. 
Batch 4 was made a further 8 days later with a fresh sugar solution prepared one day prior. 
It is quite likely that the differences in the products within the sugar solutions are 
responsible for the significant changes in microbubble populations produced. It is also 
probable that difficulties in finding an effective manufacture were also a consequence of 
these auto-condensation products. 
 
Table 6.3. Population statistics from four batches of 2% 40% 15% microbubbles. (Value ± 
standard deviation, Conc. = concentration, MB = microbubble) 
Batch 
Microbubble Conc.  
(x 108 MBs/mL) 
Mean Diameter  
(µm) 
Median Diameter  
(µm) 
Gas Conc.  
(µL/mL) 
1 8.97 ± 1.12 1.75 ± 0.01 1.70 ± 0.01 4.05 ± 0.29 
2 8.65 ± 1.60 1.83 ± 0.03 1.74 ± 0.06 4.90 ± 1.00 
3 13.4 ± 0.78 1.52 ± 0.01 1.47 ± 0.01 3.98 ± 0.15 
4 7.37 ± 0.67 1.99 ± 0.01 1.75 ± 0.04 6.65 ± 0.45 
     
Averages 9.59 ± 2.55 1.77 ± 0.18 1.66 ± 0.13 4.89 ± 1.23 
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Figure 6.12. Size distribution histograms of the 4 batches of microbubbles discussed in Table 
6.3.  Bin size = 0.32 µm. Colourless bars indicate microbubble excluded from population 
statistics analysis (0.5 µm < diameter < 10 µm). 
 
6.2.4. Discussion 
It was demonstrated that an albumin microbubble could be created which 
potentially incorporates the amino sugar glucosamine. Although neither acoustic 
microbubble characterisation nor in vivo transfection was performed, the microbubble 
presents a potential path for investigating whether co-localisation of plasmid to the 
sonoporation site is an important characteristic for UMGT. Additionally, the work above 
presents several issues when working with glucosamine. 
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As mentioned, glucosamine is poorly soluble. Preliminary attempts to create 
glucosamine only microbubbles failed most likely due to the low concentration of dissolved 
sugar. Chapter 5 demonstrated that low sugar concentrations resulted in a low 
concentration of unstable microbubbles which were poor at transfection. The reasoning is 
that there is not sufficient sugar binding to the albumin to stiffen and thicken the 
microbubble shell to resist ultrasound forces and reduce gas dissolution rates. To improve 
this glycation, a longer incubation time was trialled to encourage greater binding between 
glucosamine and albumin. 
This helped reveal a second issue with glucosamine. In albumin and glucosamine 
solutions, temperatures over 55oC would cause premature, irreversible denaturation of the 
albumin. This was unexpected as neither of the previously used dextrose concentrations 
showed this effect. However, dextrose is known to exhibit a thermal protective effect on 
albumin at high concentration, preventing its temperature denaturation[321-323]. 
Glucosamine, on the other hand, is not only at a lower concentration, but has also been 
shown to be the least effective in comparison to other sugars at inhibiting thermal 
denaturation of whey proteins, including bovine serum albumin[324]. 
The simple solution to this was to lower the pre-sonication, incubation temperature. 
The incubation step is used to primarily ensure that all solutions start sonication at the same 
approximate temperature. Additionally, it helps to ensure that the denaturation 
temperature of albumin is reached during heating of the solution during sonication. As such, 
changing the temperature should not affect the denaturation of albumin, but it does 
potentially have consequences for the reaction of glucosamine with albumin. Glycation 
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reactions are temperature dependent and the lowered temperature of the incubation step 
may reduce the amount of glucosamine bound to albumin. 
Changing the temperature did prevent albumin from denaturing during the 
incubation, however microbubble production was still poor, with low concentrations and a 
number of abnormalities seen on the microscope images. Although albumin may not be 
denatured during incubation, rapid denaturation during sonication may cause early creation 
of microbubbles followed by their destruction by continuing mechanical and thermal 
perturbation. This could explain the observations and potentially be fixed with a shorter 
sonication time, as was found for the final 2% 40% 15% microbubbles. 
However, instead 40% dextrose was added to the pre-sonication mix, with the 
hypothesis that the increased sugar concentration may protect the albumin from early 
thermal denaturation, producing functional microbubbles containing glucosamine. 
Microbubbles produced in this way were visually normal and in a potentially useful size 
distribution for acoustic imaging and UMGT, but were still more dilute than anticipated. As 
discussed transfection efficiency is linked to microbubble concentration[97, 98] and the aim 
was to compare against the dextrose only results from the previous Chapter as a control. As 
such, an ideal microbubble concentration would be around 9-10 x 108 microbubbles per mL 
or higher. Additionally, the 2:3:3 ratio used for mixing albumin, glucosamine and dextrose, 
results in “half strength” for both sugars, e.g. 20% dextrose and 7.5% glucosamine. 
As such, a single sugar solution was created containing 40% dextrose and 15% 
glucosamine. This would a) potentially increase the concentration of microbubbles 
produced, and b) maximise any differences these 2% 40% 15% microbubbles might have 
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with 2% 40% microbubbles. The production procedure had to undergo a further change as 
the increased viscosity of the solution caused excessive power output and energy deposition 
from the sonicator, effectively disrupting the microbubbles. Using a shorter sonication time 
resulted in visually normal microbubbles with a wide peak, short tailed size distribution and 
a desired concentration. 
The wide peak, short tailed size distribution in comparison to 2% 40% microbubbles 
was an interesting discovery. Typically, albumin microbubbles produced in this project have 
had a larger spread up to 7 µm, typically with a thin peak around 1 µm and a wide tail (Fig. 
6.13). As microbubbles under 0.5 µm are not analysed for population statistics due to the 
microscope’s optical resolution limitation, long tails can potentially skew the mean and 
median diameter data points towards larger values. The short tailed size distributions suffer 
less from this problem but the wide peak adds microbubble size as a confounding factor into 
the analysis of acoustic response, transfection effectiveness, etc. The ideal microbubble 
distribution would be a thin peak with short tails as this would avoid skewing errors and 
allow microbubble size to be controlled for. Attempts to produce monodisperse 
microbubbles make up a great deal of the current research, especially polymeric 
microbubbles[193, 263, 325]. 
A reproducibility study highlighted a final issue. Glucosamine does not remain as a 
monosaccharide over time. Auto-condensation reactions between the aldehyde carbonyl 
group (-CHO) and the amine group (-NH2) occur yielding a Schiff base derivative (RCH=NR’) 
shown below (intermediates not shown). A similar reaction occurs with the exposed amine 
groups on albumin’s amino acid side chains, particularly lysine residues.  
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Equation 6.1 
 
Although reversible, reactions do not stop at the first Schiff base. Instead, the sugars 
may undergo further Amadori rearrangements which can give rise to a range of irreversible 
complex products. This complexity will be compounded by the glucose in the solution, 
which can also react with the amine group on glucosamine. As such, any microbubbles made 
using such a solution which has had time to undergo these reactions will contain an 
unknown variety of sugar moieties. As the batch experiment suggests, differences in the age 
of the sugar solution could lead to significant differences among the batches. Additionally, 
this reaction removes the positively charged nature of the amine group of interest, which 
could reduce the hypothesised cationic charge on an albumin/glucosamine microbubble. 
This issue however is relatively trivial to control. As long as the solution is kept cold, 
reactions proceed very slowly. As such, a fresh solution could be created at low temperature 
when required. Although a fresh solution would be the ideal regime, the large amounts of 
dextrose and glucosamine required are slow to dissolve, especially at cold temperatures, 
which results in a long preparation time. Additionally, multiple small volume solutions for 
individual use, requires weighing of smaller amounts of constituents. The imprecision of a 
scale balance will have a greater effect on smaller amounts, potentially affecting the 
accuracy of the final solution.  
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A more practical approach would be to monitor the formation of auto-condensation 
and reaction products to determine optimal usage times of sugar solution stocks. The Schiff 
base and Amadori rearrangement products formed have strong ultraviolet (UV) absorptive 
and fluorescence properties. The gradual formation of these products can be monitored 
using standard 280 nm UV absorption and/or fluorescence spectroscopy with a 370 nm 
excitation wavelength and a 420 nm emission wavelength.  
Another advantage of this approach would be monitoring the glycation of the 
albumin. Currently, it is not known if glucosamine has been incorporated in the shell of 2% 
40% 15% microbubbles. Although, size distributions are noticeably different from standard 
2% 40% microbubbles, this could be a result of the changed incubation temperature, 
sonication duration, sonication output power, viscosity of the pre-sonication solution, etc. 
By washing the manufactured microbubbles to remove unbound reaction products, 
destroying them to remove buoyancy and light scattering affects and then measuring 
changes in UV absorption and fluorescence emission, it would be possible to identify 
whether glucosamine has become incorporated in the shell. 
Due to time constraints, no characterisation experiments were performed and 
instead will form the subject of future studies.  
 
221 
 
 
Figure 6.13. Typical size distribution histogram for 2% 40% microbubbles. Bin size = 0.32 µm. 
Colourless bars indicate microbubble excluded from population statistics analysis (0.5 µm < 
diameter < 10 µm). 
 
6.3. Fluorescence calibration experiments 
6.3.1. Introduction 
The purpose of producing cationic microbubbles is to see if co-localisation of plasmid 
at the sonoporation event is a contributing factor in the effectiveness of UMGT. As such, it 
must be shown that the microbubbles are both cationic and able to bind DNA. The former 
can be answered using zeta potential measurements. Zeta potential is the surface charge on 
a colloid in a solution and can give information about the stability of a colloidal solution. The 
surface charge can also be used to determine if the microbubble charge has changed by 
plasmid loading[99, 267, 326]. It is a simple experiment to perform with the appropriate 
equipment, e.g. a Zetasizer (Malvern), and only requires some knowledge of the solvent. 
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To investigate whether microbubbles can bind DNA, some form of DNA 
quantification technique must be employed. Fluorescence spectroscopy provides a sensitive 
technique that can be used for DNA quantification. Fluorescent dyes or stains bind a target 
molecule and undergo a shift in fluorescence peak and emission intensity resulting in high 
signal at precise wavelengths in the presence of the target. Dyes are typically highly specific 
to their target molecule and both DNA and protein levels can be quantified separately from 
the same sample. In this work, this will help to normalise the level of DNA bound against the 
amount of protein. Fluorescence approaches also tend to be very sensitive to low levels of 
target, due to a very low signal to noise ratio (information taken from “An introduction to 
Fluorescence Spectroscopy" by PerkinElmer Inc.). 
The drawback with fluorescence is that calibration curves of known standards have 
to be performed to quantify signal against concentrations. Some specialised systems are 
able to do this automatically with a set of standards, however these can be expensive. 
Additionally, certain contaminants can alter fluorescence emission, such as high salt 
concentrations, which necessitates careful selection of the standard. 
In this work, fluorescence was chosen as the method of choice due to relative 
simplicity once appropriate calibration curves are constructed. Two fluorescent dyes were 
selected, the DNA binding dye 4',6-diamidino-2-phenylindole (DAPI) and the Qubit™ Protein 
Assay (QPA) (Invitrogen), which utilises a proprietary protein specific fluorescent dye. DAPI 
is a DNA dye commonly used for fluorescence microscopy which binds strongly to A-T rich 
regions. It is excited at 358 nm (UV) and emits at a wavelength fluorescence emission 
maximum of 461 nm and has a ~20-fold increase in fluorescence when bound to DNA. The 
Qubit™ range of dyes are designed to be excited at approximately 485 nm and read at a 
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emission wavelength of ~585 nm, so they can be read on a single specialised fluorescence 
spectrophotometer which works only at those wavelengths. According to the manufacturer, 
it is sensitive to concentrations from 12.5 µg/mL to 5 mg/mL, with low variation between 
different proteins (information for both dyes can be found at the Invitrogen website) . 
However, the protein-DNA complex may affect the binding of dyes to either DNA or 
protein. Such electrostatic interactions can be disrupted using high salt conditions to release 
the DNA, for instance, the naturally occurring DNA-binding protein protamine will 
disassociate from DNA at sodium chloride (NaCl) concentrations of 0.5 M to 0.6 M[327]. To 
ensure accurate quantification, a 0.6 M NaCl solution will be used to disassociate the 
protein-DNA complex. 
The proposed method for measuring DNA binding capacity of microbubbles is as 
follows: 
1) Incubate fixed concentration of microbubbles with fixed concentration of 
plasmid DNA, 
2) Wash microbubbles to remove excess, unbound plasmid DNA and remnants of 
albumin and sugars left over from manufacture, 
3) Destroy microbubbles using high negative pressure, 
4) Disassociate the plasmid from protein using 0.6 M sodium chloride, 
5) Prepare separate DAPI and QPA samples, 
6) Measure fluorescence at appropriate excitation and emission wavelengths. 
 
This approach requires several calibration curves and checks. Firstly, to accurately 
quantify the concentration, standards of plasmid DNA and protein must be used for both 
DAPI and QPA respectively. The effect of the high salt concentration on fluorescence also 
needs to be examined. Additionally, the effect the non-target has on the fluorescence, e.g. 
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protein effect on DNA/DAPI fluorescence, needs to be examined. Finally, reproducibility of a 
result needs to be investigated to observe the imprecision associated with the technique 
and the F-2500 fluorescence spectrophotometer (Hitachi High Technologies Corporation). 
A preliminary experiment was performed on the 2% 40% 15% microbubbles from 
Batch 4 (Table 6.3) which had been left at room temperature for 6 days after preparation. 
The results are presented here as preliminary data demonstrating the feasibility of the 
method, not as a true result. Additionally, fluorescent microscopy images of DNA loaded 
and washed and unwashed 2% 40% 15% microbubbles from Batch 3 were also examined. 
As with the previous section on microbubble production, not all of the experiments 
were completed before the end of the project. The following results are presented with the 
caveat that the data was still relatively preliminary and required further investigation. 
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6.3.2. Methodological Particulars 
Use of DAPI involved a 1:1 dilution of the sample with 5 µg/mL DAPI and incubation 
for 10 minutes. Use of QPA involves diluting the sample 1:20 with the Qubit™ working 
solution followed by an incubation for 10 minutes. Samples were read in a Quartz cuvette 
using an Hitachi F-2500 fluorescence spectrophotometer. Fluorescence peaks were 
determined by emission scanning from 380 nm to 600 nm for DAPI and 500 nm to 700 nm 
for QPA. Excitation and emission slits of 2.5 nm, a photomultiplier of 400 V and a scan speed 
of 300 nm/min were used.  
The following standards were prepared: 
Name  Description 
IW  Injectable water (IW) 
S  0.6 M NaCl in IW 
D10  10 µg/mL pGL4.13 
D20  20 µg/mL pGL4.13 
D40  40 µg/mL pGL4.13 
D40/2  DNA40 diluted 1:1 with IW 
D40/2S  DNA40/2 with 0.6 M NaCl 
P0  Protein standard 000 ng/µL protein from Qubit™ set 
P10  Protein standard 200 ng/µL protein from Qubit™ set 
P15  PS20 diluted 3:1 with IW 
P20  Protein standard 400 ng/µL protein from Qubit™ set 
P20/2  PS20 diluted 1:1 with IW 
P20/2S  PS20/2 with 0.6 M NaCl 
P/D  PS20 diluted 1:1 with DNA40 
 
The following samples were prepared: 
Name  Description 
M  Washed and destroyed 2% 40% 15% microbubbles 
M+S  M with 0.6 M NaCl 
M+D  Plasmid loaded, washed and destroyed 2% 40% 15% microbubbles 
M+D+S  P4 with 0.6 M NaCl 
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All standards and samples were read at least once. All the following reads are from 
single experiments. Any repeats involved preparation of a fresh mix of standard or sample 
with the fluorescence dye, not a repeat measurement on the original mixed standard or 
sample. However, the standards or samples were prepared only once, and thus, the 
experiments have not been independently reproduced due to time constraints. 
After plotting the data, the wavelength fluorescence emission maximum for DAPI 
samples and standards was found to be around 452 nm compared to the recommended 461 
nm. For QPA, the wavelength fluorescence emission maximum was at 568 nm compared to 
the manufacturer’s recommended 585 nm. For DAPI, slight differences would be expected 
due to temperature or solvent differences. For QPA, the dye is designed to be used with the 
specialised Qubit™ Fluorometer which emits and detects at set wavelengths. The machine 
then calculates the relationship between fluorescence and concentration using an unknown 
curve fitting algorithm and 3 standards of known protein concentration. The manufacturer 
recommended wavelength is likely that used in the machine rather than the maximum. As 
long as the effect of contaminants is controlled for and the temperature does not undergo 
extreme fluctuations between readings, it does not matter at which wavelength the 
quantification is performed. However, logic dictates that choosing the peak maximum gives 
the greatest difference between samples, improving sensitivity. Both the average and 
recommended wavelengths are highlighted on plots. 
Fluorescence images of plasmid loaded microbubbles were also taken to indicate 
where plasmid was localised on the microbubble. Microbubbles were incubated with either 
4 mg/mL pGl4.13 or injectable water in a 3:1 ratio for 5 minutes. The samples were then 
diluted 1:1 with 500 ng/mL DAPI and incubated for a further 5 minutes. The microbubbles 
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were then washed with sterile PBS and imaged with the fluorescent microscope using the 
UV-2A filter cube. Presented images are from one experiment only. 
 
6.3.3. Calibration Results 
6.3.3.1. Control Data 
Blank control standards, IW, P0 and S, were run once using DAPI and twice using 
QPA, excluding IW. For DAPI, all three controls showed similar profiles over the scan range 
with peaks around 452 nm (Fig. 6.14). This result indicates that the DAPI concentration may 
be too high as the natural fluorescence of DAPI is being seen. 0.6 M NaCl does not change 
the fluorescence of unbound DAPI. The TE buffer and 2 mM of sodium azide of the Qubit™ 
protein standard solutions also does not change the fluorescence of unbound DAPI. 
For QPA, all blank control standards showed no fluorescence (Fig. 6.15). 
 
Figure 6.13. Fluorescence profile for blank control standards with DAPI. Peak intensity 
wavelengths for these experiments (452 nm) and from the literature (461 nm) are marked. 
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Figure 6.14. Fluorescence profile for blank control standards with QPA. Note, the control 
samples showed no background signal with QPA. Peak intensity wavelengths for these 
experiments (568 nm) and from the manufacturer (585 nm) are marked. Repeat 
measurements for a standard are shown as (1) and (2).  
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6.3.3.2. DNA and protein calibration curves 
DNA standards, D10, D20, D40 and D40/2, were run once using DAPI, except D20 
which was repeated twice using the same standard and plotted with the IW control (Fig. 
6.15). The 452 nm wavelength values were plotted as a separate calibration curve (Fig. 
6.16). There are three things to note in these plots. Firstly the repeats of D20 show excellent 
correlation, indicating the fluorescence machine has strong reproducibility. Secondly, the 
signal from D40/2 standard, which is effectively a D20 standard, at 452 nm is almost 25% 
stronger than the D20 standard which suggests that there is inaccuracy in a standard’s 
preparation. As D40/2 was only prepared and read once, it is unknown whether there was 
error in the D40/2 or D20 preparation. As such, the calibration curve may not be accurate. 
Thirdly, the D10 standard shows a lower signal than the blank IW standard at 452 nm and 
does not intersect until ~480 nm. As only 1 read of 1 standard was performed, it is unknown 
whether there was an anomaly with the reading or an issue with the standard. However, it 
is likely that there is contamination within the D10 standard which is responsible for 
quenching the fluorescence. As all DNA standards were made from a single original stock, 
the contamination may have been introduced during preparation of the fluorescence mix. 
The calibration curve shows the 452 nm values from D10, the 3 repeats of D20 and 
D40. Note that the concentration on the x-axis is the final concentration in the read 
solution, e.g. a D40 standard is 20 µg/mL when diluted 1:1 with the DAPI solution. A 
polynomial trend line has been drawn through the values by Excel (Microsoft). As the D10 
value is lower than the control, and it has been seen that D40/2 does not equal D20, the 
calibration curve is potentially not accurate and is only here for illustration of method. 
Ideally, only the linear range of fluorescence would be used for quantification purposes. 
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Protein standards, D10, D15 and D20, were run twice using QPA and plotted (Fig. 
6.17). The control is not plotted for clarity as it is zero at all wavelengths tested (Fig. 6.14). 
The repeats show good reproducibility and the different concentrations are in the correct 
order. As shown, the wavelength fluorescence emission maximum falls at around 568 nm 
compared to the 585 nm. A calibration curve plot with both wavelengths is shown with 
polynomial trend lines (Curves for…) (Fig. 6.18). As can be seen, 568 nm shows greater 
difference between values than 585 nm, improving its sensitivity. However, neither is 
showing a strongly linear phase. These Standards are made for use with the specific Qubit™ 
fluorescence spectrophotometer which has a pre-defined curve fitting algorithm which fits a 
curve to the Standard fluorescence values to create calibration curves. Excel’s polynomial 
trend line (Microsoft) fits a curve according to the values but is unlikely to exactly match the 
curve used in the Qubit™ machine. To improve upon the curve, more data points must be 
supplied, particularly in the 0 to 10 µg/mL range.  
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Figure 6.15. Fluorescence profile for DNA standards and IW control with DAPI. Peak 
intensity wavelengths for these experiments (452 nm) and from the literature (461 nm) are 
marked. Repeat measurements for a standard are shown as numbers in brackets, e.g. (X). 
 
 
Figure 6.16. Fluorescence values for DNA Standards with DAPI at 452 nm. A polynomial 
trend line curve has been added using Excel. 
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Figure 6.17. Fluorescence profile for Protein Standards with QPA. Peak intensity 
wavelengths for these experiments (568 nm) and from the manufacturer (585 nm) are 
marked. Repeat measurements for a sample are shown as (1) and (2). 
 
 
Figure 6.18. Fluorescence values for Protein Standards with QPA at 568 nm and 585 nm. 
Polynomial trend line curves have been added using Excel. 
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6.3.3.3. Effect of 0.6 M NaCl on fluorescence 
As salt is required to disassociate the DNA from the protein shell of a microbubble, 
its effect on fluorescence needs to be investigated. D40 and P20 were diluted 1:1 with 1.2 M 
NaCl to give the D40/2S and P20/2S standards respectively and run once using DAPI and 
twice using QPA, and plotted against the most appropriate standards. 
For DAPI, D40/2S was plotted against D40/2 and D20 with control standards IW and 
S (Fig. 6.19). As can be seen, the high salt content significantly alters the fluorescence from 
DAPI, increasing the fluorescence at peak by ~28%, narrowing the peak by reducing 
emission at the longer wavelengths and slightly shifting the spectra towards shorter 
wavelengths (blue-shift).  
QPA standards also show alteration of emission profile in the presence of 0.6 M 
NaCl; however the effect is relatively benign in comparison (Fig. 6.20). There is an increase 
in fluorescence of ~23% at both 568 nm and 585 nm when compared against D10, without a 
shift in peak or a noticeable narrowing in the peak. Although the effects are less severe, the 
calibration curve currently prepared is still inappropriate for microbubble samples. 
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Figure 6.19. Fluorescence profile for “20 µg/mL” standards with or without 0.6 M NaCl with 
DAPI. IW and S control standards are included for comparison. Peak intensity wavelengths 
for these experiments (452 nm) and from the literature (461 nm) are marked. Repeat 
measurements for a standard are shown as numbers in brackets, e.g. (X). 
 
 
Figure 6.20. Fluorescence profile for Protein Standards with and without 0.6 M NaCl with 
QPA. No control Standards are included. Peak intensity wavelengths for these experiments 
(568 nm) and from the manufacturer (585 nm) are marked. Repeat measurements for a 
sample are shown as (1) and (2). 
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6.3.3.4. Effect of DNA or protein contaminant on fluorescence 
As no separation between microbubble shell remnants or carried plasmid will be 
performed, it is important that neither DNA nor protein affect the other’s fluorescence 
assay. 
Protein standards, P20 and P10 were run using DAPI and plotted against the P0 and 
IW control. Both proteins standards cause a small increase in fluorescence compared to the 
controls (Fig. 6.21).  
The P/D standard was run using the QPA and plotted against P10 and P20. Unlike the 
usual QPA runs, the reproducibility for P/D was quite poor (Fig. 6.22). If averaged, the values 
match up well with P10 standard as desired, however the assumption is that one reading is 
wrong. As such, it is unknown whether DNA will increase or decrease fluorescence when 
using QPA. This does indicate that at least 3 readings with fresh samples or standards should 
be taken in case there is anomaly, although reproducibility for both DAPI and QPA has 
typically been very good. 
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Figure 6.21. Fluorescence profile for Protein Standards with DAPI. IW control standard is 
included for comparison. Peak intensity wavelengths for these experiments (452 nm) and 
from the literature (461 nm) are marked. 
 
 
Figure 6.22. Fluorescence profile for Protein Standards with and without 20 µg/mL plasmid 
with QPA. No control Standards are included. Peak intensity wavelengths for these 
experiments (568 nm) and from the manufacturer (585 nm) are marked. Repeat 
measurements for a sample are shown as (1) and (2). 
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6.3.3.5. Preliminary experiment with 2% 40% 15% microbubbles  
As is evident, a number of calibration experiments are still missing, however there is 
no evidence that the actual microbubble samples will work with this fluorescence technique 
or that a detectable difference will exist. A preliminary experiment was therefore performed 
to investigate whether microbubbles loaded with plasmid could be distinguished from 
unloaded microbubbles. Six day old, 2% 40% 15% microbubbles were loaded by 10 minute 
incubation with 4 mg/mL pGL4.13 or injectable water in a 3:1 ratio that mirrors the in vivo 
setting where 150 µL microbubbles are added to 50 µL plasmid. The microbubbles were 
then washed thrice using sterile, chilled PBS and centrifugation-aided buoyancy to remove 
excess DNA. Washed microbubbles were then destroyed in a syringe using negative 
pressure. Destroyed microbubbles were then diluted 1:1 with injectable water or 1.2 M NaCl 
to create the samples described in the Methods above. Samples were then run with DAPI 
(Fig. 6.23) and QPA (Fig. 6.24) and plotted against either a DNA and control standard, or a 
protein standard only respectively. 
The negative control samples, M and M+S, showed the same fluorescence profile as 
the IW negative control as expected for a sample without DNA. The plasmid loaded samples 
showed more interesting trends. The no salt plasmid loaded sample, M+D, was run twice 
and showed good reproducibility. At the 452 nm wavelength maximum fluorescence 
emission the values are only slightly greater than the negative controls. However, at the 
longer wavelengths the fluorescence emission is higher than control. When salt is added to 
the plasmid loaded sample the fluorescence at 452 nm doubles in comparison to M+D. 
Additionally, the expression profile shows blue shift and narrowing of the peak typical of the 
high salt plasmid standard. As such, the increase in fluorescence is likely to be an 
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overestimation. However, the difference is far greater than the ~28% seen between the 
P40/2 and P40/2S standards and does strongly suggest that plasmid was successfully loaded 
onto the microbubble initially and has been disassociated from the protein using 0.6 M 
NaCl. Without an accurate and appropriate calibration curve, it is impossible to determine 
the exact concentration of DNA in the sample, but it lies somewhere between 1 and 10 
µg/mL in the 1:1 DAPI diluted sample. 
For QPA, only salted samples were examined. The unloaded microbubble sample, 
M+S, showed less fluorescence than the P10 standard, despite the effect of the salt 
concentration, making exact quantification impossible. It is possible to say that the M+S 
sample contains between 1 and 10 µg/mL of protein.  
The plasmid loaded salt sample, M+D+S, gave two distinctly different lines for each 
read. It is uncertain whether one line is anomalous or the two repeats do contain differing 
amounts of protein. The higher line suggests a protein concentration >10 µg/mL, whilst the 
lower line falls within the same range as the M+S sample. As previously mentioned, the 
calibration curve requires a greater number of concentrations to aid exact quantification 
and a greater number of reads are required to detect anomalous readings.  
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Figure 6.23. Fluorescence profiles for microbubble samples with DAPI. IW control and D20 
standards are included for comparison. Peak intensity wavelengths for these experiments 
(452 nm) and from the literature (461 nm) are marked. Repeat measurements for a 
standard are shown as numbers in brackets, e.g. (X). 
 
 
Figure 6.24. Fluorescence profile for salted microbubble samples with and without 20 
µg/mL plasmid with QPA. P20/S standard is included for comparison. Peak intensity 
wavelengths for these experiments (568 nm) and from the manufacturer (585 nm) are 
marked. Repeat measurements for a sample are shown as (1) and (2). 
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6.3.3.6. Fluorescence microscopy results 
Plasmid loaded, freshly prepared 2% 40% 15% microbubbles (Batch 3, Table 6.3) 
were incubated with DAPI and washed. Representative fluorescent images were captured 
using the UV-2A filter cube setting on the fluorescent microscope at an exposure of 250 ms 
for the plasmid loaded microbubbles and 586 ms for the unloaded microbubbles.  
There were distinct visual differences between the unloaded and loaded 
microbubbles under bright field imaging (Fig. 6.25). Unloaded microbubbles were typically 
smaller than loaded microbubbles. Loaded microbubbles also appear to be highly clumped. 
This may be due to poor mixing during the wash steps as clumping due to plasmid has not 
been seen previously. Under UV excitation, fluorescence was seen on the outside of plasmid 
loaded microbubbles, whilst unloaded microbubbles remained dark, demonstrating that 
plasmid was successfully loaded on to the microbubble shell and does stain using DAPI. 
 
 
 
 
 
 
 
 
  
 
 0 8 16  µm 
Figure 6.25. Representative a), c) bright field and b), d) fluorescence, 40x microscope images 
of a), b) water- or c), d) pGL4.13-loaded microbubbles. Scale applies to all images.  
a) 
c) 
b) 
d) 
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6.3.4. Summary 
In this section, the fluorescence techniques to confirm and quantify plasmid loading 
onto microbubbles were examined. The first technique examined was fluorescence 
spectrophotometry, a commonly used, sensitive tool capable of accurate quantification of 
DNA and protein solutions. However, fluorescence can be sensitive to contaminants which 
affect the relationship between concentration and fluorescence signal. To fully realise the 
potential of the technique, a number of calibration experiments were required to ensure 
that under the settings it is being used, the results are reliable and quantifiable.  
Here, quantification of the DNA and protein was required so as to measure the 
plasmid loading capacity of a microbubble, normalised against the protein content of the 
microbubble. Two dyes were examined, the DNA dye DAPI and the Qubit™ Protein Assay kit. 
Firstly, these were tested against Controls and Standards of several protein and DNA 
concentrations to construct calibration curves. Contaminated Standards were prepared to 
investigate their effect on fluorescence. The contaminants tested for were the salt – used to 
disassociate plasmid from the protein shell – and protein or DNA against the other’s dye – 
as no separation between the two was to be done after disassociation. 
The experiments were relatively preliminary in nature so there is a lack of repeats 
and certain errors have not been followed up on. However, certain effects were strongly 
noticeable. For both dyes, the addition of salt caused significant shifts in the fluorescence 
profile. The QPA assay saw an increase in fluorescence of approximately 23% at 568 nm. 
Fluorescence emission for the DAPI assay was more heavily affected, with a 28% 
fluorescence increase at 452 nm, a blue shift of approximately 6 nm and a reduction in 
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fluorescence at high wavelengths. In both cases, this was expected. Fluorescence from dyes 
is a result in conformational shifts in their structure due to binding with their target. 
Changes in the local environment can strongly affect their binding to the target and 
conformational shape. Typically, increasing salt concentration will create stronger 
fluorescence signals[328].  
For instance, DAPI binds to the minor groove of DNA and resulting in an increase in 
fluorescence by displacement of water from both the DAPI molecule and the DNA. The high 
salt content is likely exacerbating this water removal from the DNA and DAPI complex 
creating a more condensed uniform structure. This will result in a more defined emission 
spectrum as seen, with a greater amount of fluorescence at the peak.  
The calibration curves created so far are therefore inappropriate for the microbubble 
samples. Without salt in the standards used to create them, the DNA amount will always be 
overestimated. The salt may also affect the shape of the calibration curve exacerbating the 
erroneous result. Additionally, as has been shown with the microbubble samples, the 
calibration curves are not sensitive enough. Protein and DNA amounts were shown to be 
lower than the lowest standard used. More points should be added to ensure better 
accuracy in quantification. Additionally, the DAPI concentration used is too high. DAPI is 
naturally fluorescent but the intensity increases ~20-fold when bound to double-stranded 
DNA. It is preferable to have a zero read for the controls to avoid having to normalise 
against background as the wavelength peak may shift when bound to DNA. Additionally, 
imprecision in the background read could affect the interpretation of the result. There is a 
trade-off however, as reducing the concentration will reduce the sensitivity. 
243 
 
The other contaminant is due to the presence of the other substance during a 
fluorescence test, e.g. protein during DNA-DAPI fluorescence and DNA during protein-QPA 
fluorescence. There are a number of methods available for removing DNA from a protein 
mix or vice versa, e.g. a DNA recovery kit, gel excision, column chromatography, etc., 
however most processes will involve some loss of the substance, and all would result in 
additional time and cost. As such, the effect of the contamination needed to be 
investigated. In these preliminary results, it is suggested that the presence of protein does 
not strongly affect DAPI fluorescence, with P20 giving only a 2 FU rise from the IW control. 
The protein standards are bovine serum albumin (BSA). There may be parts of the protein 
molecule with which DAPI could interact and be stabilised, but the effect is small. As DAPI 
will preferentially bind to DNA, it is likely to be negligible in the samples.  
However, it appears that if the DNA is still bound to the protein, there could be 
significant quenching of the signal, with M+D approximately half of M+D+S, although there 
is some effect of the salt on fluorescence. Overall, as long as the DNA is free, protein should 
not affect the read and does not need to be removed before DAPI fluorescence. 
For QPA, the results are less clear. When the DNA contaminated protein standard 
P/D was used, the two reads gave two different results. Additionally, the results were each 
above and below the P10 standard line, where it was predicted to fall if there was no effect 
on QPA. Neither result is far removed from P10 but QPA fluorescence is weaker than DAPI, 
so a small change can result in a large quantification error. It is therefore important to 
confirm whether there is or is not an effect of DNA on the QPA read. 
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The final preliminary step was to ensure that the process of quantification, and the 
methods used to reach that step, would actually work on the microbubbles. For DAPI, there 
were some clear indications that this had worked. Firstly, the no plasmid samples showed 
an expression profile that closely matched the IW control, which also tallies with the protein 
contamination experiment. Secondly, microbubbles that were loaded with plasmid 
demonstrated a clear difference in their fluorescence emission. Interestingly, for the M+D 
sample, the fluorescence at 452 nm showed only a modest 3-7% increase compared to M or 
M+S samples. However, at longer wavelengths, the emission was noticeably larger. This 
suggests that some binding between DAPI and the plasmid is occurring, but that the signal is 
being quenched by bound protein or the interaction is too disrupted to produce strong 
fluorescence at lower wavelengths. This pattern is very similar to that seen with the P10 
standard, which showed poor fluorescence in comparison to the IW at 452 nm but greater 
fluorescence at longer wavelengths. If the sample is being quenched at those wavelengths, 
yet emits at true brightness in the longer wavelengths, it may be possible to quantify 
plasmid without disassociation from protein. This would avoid the salt contamination issue, 
but sensitivity would suffer due to the reduced difference between samples off-peak. 
Thirdly, there is a clear increase in fluorescence at the 452 nm for M+D+S compared 
with M+D. Although the high salt concentration does cause an increase in fluorescence, this 
only occurs when plasmid is present, as neither M+S nor S showed an increased compared 
to M or IW respectively. Additionally, the salt appears to eliminate the quenching effect 
seen for M+S with the peak expression clearly seen at around 452 nm. This does suggest 
that DNA is disassociating from protein and becoming available for strong DAPI interaction. 
It is potentially possible that plasmid is still associated with protein and that the salt is 
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causing conformational shifts allowing DAPI to bind, however, considering the high salt 
content in use, this seems unlikely. As mentioned, protamine, a naturally occurring protein 
with a strong affinity and condensation effect on DNA, is typically disassociated from DNA at 
0.6 M NaCl solutions[327], hence the strong salt concentrations used here. Albumin glycated 
with glucosamine is unlikely to have such a strong affinity for DNA and could probably be 
made to disassociate with a lower salt concentration than has been used here. Other salts, 
such as magnesium chloride, may have a stronger disassociation effect on DNA but are also 
likely to strongly affect the fluorescence. 
As such, it has been shown that the method employed here, the loading of plasmid, 
the microbubble washing and destruction, the disassociation by sodium salt and 
quantification by DAPI will allow investigation into the loading capacity of 
albumin/glucosamine microbubbles. However, whilst this gives a DNA amount, it must be 
normalised against some characteristic of the microbubbles in the sample. Washing the 
microbubbles can cause large shifts in the size distribution and concentration (results not 
shown), making it impractical to use optical microscopy and population statistics to define 
the microbubbles. Additionally, as the microbubbles are destroyed to encourage release of 
plasmid and prevent buoyancy or light scattering effects, it could be difficult defining a 
relationship between the optical statistics and the fluorescence sample. Using protein 
concentration instead gives normalisation factor directly related to the fluorescence 
samples as the same material is used. Additionally, a protein per microbubble could be 
separately investigated using less complicated techniques such as the Lowry or Bradford 
assays, the results of which could be used to apply the DNA amount per protein amount to 
all microbubbles regardless of size. 
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Unfortunately, when the microbubble samples, M+S and M+D+S, were used in the 
QPA fluorescence assay, there were reproducibility issues. The M+S repeats were not 
strongly aligned, unlike the protein standards, and there was significant difference between 
M+D+S repeats. As only two readings were done, it is impossible to know which is accurate. 
However, considering that the QPA assay has consistently returned accurate results, it is 
likely that the reads do accurately reflect the protein content of the samples. When 
negative pressure is applied to the microbubbles, the gas core expands rapidly, rupturing 
the microbubble and escaping into the solution and eventually into the vacuum if the 
pressure is not released. This leaves behind the ruptured shell of the microbubble (Fig. 
6.26). Unlike lipid microbubbles, which will dissolve into the solution, the albumin shell is 
made of denatured protein strands with heavy cross-linking, a circumstance compounded 
by the glycation of sugar molecules. These remnants will not dissolve back into the solution, 
and will sink. If a sample is insufficiently mixed or left too long before a read, it will result in 
an erroneous reading. It is also possible that the lack of dissolution may give erroneous 
readings due to QPA reagent being unable to fully penetrate the shell remains and 
fluoresce. This may result in a difference in fluorescence due to microbubble size differences 
rather than protein content; however the two will likely be strongly linked. It is another 
avenue that needs careful exploration to be certain that the measurements recorded are 
accurate. 
Fluorescence microscopy demonstrated that plasmid is localised on the microbubble 
shell. Considering that M+D showed a low level of fluorescence at peak, it might seem 
strange that fluorescence can still be seen on these microbubbles whilst the DNA is still 
associated. The UV-2A filter cube on the fluorescence microscope uses a longpass 
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dichromatic mirror and barrier filter which only block emission light below 420 nm. As such, 
almost the entire spectrum of emitted light will be detected by the microscope. The 
intensity of the emission at any one wavelength would not likely be high enough to detect 
on the CCD in the microscope, however, the emission across the spectrum is. 
 
Figure 6.26. 40x microscope image of 2% 40% 15% microbubbles destroyed with negative 
pressure. Scale is 16 µm with a mark at 8 µm. 
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6.3.5. Discussion 
It was demonstrated that fluorescence techniques could be used to determine the 
DNA loading capacity of microbubbles and identify the loading site. There are other 
methods for quantifying DNA[329]. Two commonly used methods are UV spectrophotometry 
and gel electrophoresis. The absorption of UV light at 260 nm is directly proportional to the 
concentration of DNA; for a 1 cm path length, an optical density of 1 corresponds to 50 
µg/mL double stranded DNA[330]. It is the swiftest and simplest technique available to 
quantify nucleic acids. However, protein can also absorb UV light and a high proportion of 
protein can affect the accuracy of DNA quantification[331]. To use UV spectrophotometry, 
salt-driven disassociation of DNA from the protein would not be enough. The DNA would 
have to be extracted from the solution, increasing complexity and cost.  
UV spectroscopy has been used to measure microbubble loading in cationic lipid 
microbubbles[99, 178, 286]. In the Christiansen et al. (2003) paper, cationic lipid microbubbles 
were loaded with plasmid DNA, washed and then destroyed. UV spectroscopy was used to 
measure the DNA content of both the destroyed microbubbles and original solution. They 
found that their microbubbles were capable of loading 4 µg plasmid per 108 microbubbles; 
approximately 6700 plasmids per microbubble. Tlaxca et al. (2010) used a similar method 
and saw a loading of approximately 8 µg plasmid per 108 microbubbles, the difference being 
likely to do with the different microbubble formulations. UV spectroscopy is a viable option 
for lipids as they do not absorb UV light. There are some exceptions though; pyridinium 
cationic lipids have a cyclic carbon ring head group which is capable of absorbing UV light[51].  
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Gel electrophoresis involves size or charge separation of molecules by 
electrophoretic passage through a gel of finite pore size. As DNA is uniformly negatively 
charged, it will migrate towards the cathode in a size dependent manner. DNA can then be 
visualised by staining with a DNA binding dye, typically ethidium bromide which fluoresces 
under UV light. DAPI could also be used but equipment for UV illumination of gels typically 
use filters which block wavelengths below 575 nm[332]. For gel electrophoresis 
quantification, the sample has to be run against known concentration markers. However, 
there are potentially several issues. If the DNA is electrostatically complexed with protein, 
the normally negative charge of DNA will be altered strongly affecting its transit. 
Additionally, the large, complex size of the denatured protein shell will inhibit its transit 
through the fine pores of the gel, effectively stranding the protein-DNA complex in the 
loading well. Finally, the DNA will likely not be in its natural conformation when complexed 
with the protein, which could interfere with DNA stain binding efficiency and affect the 
quantification. Disruption of the protein-DNA complex would release DNA, potentially 
allowing its transit through the gel, whilst the protein is left in the well. However, the high 
salt concentrations would affect the mobility of the DNA in gel electrophoresis, may cause 
rapid corrosion of the metal electrodes and production of chlorine gas[267, 333, 334]. As for UV 
spectrophotometry, DNA extraction would have to be performed. Owing to the perceived 
difficulties of these approaches, fluorescence spectroscopy was used.  
Like UV spectroscopy, gel electrophoresis has been used to investigate plasmid 
loading on lipid based microbubbles[56]. In the Sun et al. (2012) paper, cationic lipid 
microbubbles were mixed with plasmid in different ratios and loaded on to a gel. As the 
cationic lipids neutralised the negative charge of DNA, only unbound plasmid was able to 
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electrophoresis. They found that their microbubbles could load plasmid at a ratio of 1:0.2 or 
1:0.3 (w/w) depending upon formulation. Gel electrophoresis has been used to investigate 
plasmid loading in albumin microbubbles as well[314]; however no detail of the method is 
given beyond describing the DNA as extracted from the protein. This does suggest that DNA 
had to be separated from the protein before gel electrophoresis but it is uncertain. It was 
shown that each microbubble carried approximately 40 pg of DNA per microbubble, 
however only 17% of the DNA was incorporated into the shell. 
A number of groups also use fluorescence although primarily in flow cytometry to 
demonstrate that their microbubbles have loaded plasmid[56, 99, 178, 286]. This is useful 
technique to examine loading across the bulk suspension of microbubbles, however it is 
difficult to quantify loading with this approach. In the Lentacker et al. (2006) paper, a similar 
fluorescence technique to here is used to quantify microbubble loading[267]. They utilised 
the PicoGreen assay (Invitrogen), a DNA specific fluorophore, to measure the level of 
unbound DNA, finding that their albumin microbubbles coated in cationic polymer could 
load 0.1 pg of DNA. This is in strong contrast with the results of Frenkel et al. (2002), which 
could be due to the different manufacture methods of their microbubbles. In Frenkel’s 
work, plasmid was added directly to the pre-sonication mixture, whereas in Lentacker’s 
work, albumin microbubbles are first made, coated in cationic polymer, and then incubated 
with DNA. It will be of interest to see how albumin/glucosamine microbubbles compare. 
Fluorescence microscopy was used in this work to demonstrate the shell loading of 
DNA onto microbubbles. This approach has been demonstrated before by other groups[99, 
267, 286, 314], using a number of different fluorescent DNA markers. Lentacker’s work also 
fluorescently labelled their polymer and albumin to provide definitive proof that all three 
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components were combined into one microbubble. Microscopy can be a powerful 
qualitative technique however it is difficult to extract quantifiable data. In this work, it has 
provided confirmation that plasmid loading does occur with the glucosamine microbubbles 
and that plasmid can persist through the washing steps. 
An investigation of the effect of co-localisation was the aim of this work, but there is 
also another effect of loading plasmid. Loaded microbubbles, like cationic polymers 
discussed in Chapter 1.1.1., have demonstrated a protective effect against nuclease 
degradation[267, 335]. Plasmids are rapidly degraded in blood due to the presence of DNA 
nucleases[336]. Protection from nucleases may improve transfection in vivo, however, as the 
treatment time is only 2 minutes, plasmid degradation may not be a significant factor.  
There is one consideration from this work; is quantification necessary? The aim of 
this experiment was to compare albumin microbubbles with or without glucosamine to 
determine whether DNA loading is a key factor in improving transfection. As this work is a 
comparison between microbubbles, it could be sufficient to calculate a ratio between the 
raw values from both the DAPI and QPA assays to give a value indicative of microbubble 
loading capacity. Comparing ratios from different microbubbles would indicate differences 
in their plasmid loading capability. As such, no calibration curves would be needed and, if 
the bubbles are treated in the same fashion, adjusting for contamination would not be an 
issue. However, this only holds true if the values fall within the linear range of fluorescence. 
For the non-linear range, fluorescence values would not scale proportionally meaning it 
would be inappropriate to ratio them. Calibration curves would still be required to ensure 
values fall within the linear range and they would need to be correctly adjusted for 
contamination. Since the calibration curve would exist, it would be trivial to quantify the 
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samples and, in doing so, linearise the scales for appropriate ratios. Additionally, having an 
actual value of mg DNA per mg protein, and eventually mg DNA per microbubble, would be 
more intuitive and allow comparison to other research in the field. 
Finally, as mentioned in Chapter 6.2.4, the discussion for the previous section, there 
is no comparison against a standard albumin/dextrose microbubble. This is a vital next step, 
as it is still unknown whether the glucosamine is incorporated in the shell and whether it 
has improved the loading capacity. If it cannot be shown that glucosamine improves loading, 
the formulation must be revisited and adjusted.  
 
6.4. Conclusion 
The aim of the work in this Chapter was to determine whether co-localisation of the 
plasmid is a key factor in UMGT. Although this has been demonstrated with lipid-based 
microbubbles, it is preferable to perform UMGT with albumin-based microbubbles which 
are more effective at transfection. To do this, a theoretically safe, microbubble formulation 
was created, and techniques investigated, that demonstrated loading of plasmid DNA. It is 
evident that this work is not complete though. The Model Protocol has not been completed 
and little else is known about the microbubble characteristics. Additionally, the most 
important data, the comparison against other microbubble formulations, is missing.  
However, the work does demonstrate a clear avenue for future potential research. 
The main outcomes of this work are new microbubble formulations and new microbubble 
characterisation techniques. Both have strong applications beyond this project and 
constitute novel research in the field.  
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7. Discussion, Future work and Conclusion 
In this final chapter, the key findings of the project are summarised and briefly 
described. Key issues from the project are discussed and future work directions are 
highlighted. Finally, the thesis is concluded.  
 
7.1. Key Findings 
This project has explored a number of potential factors involved in the process of 
UMGT. Below is a summary of the key findings: 
 Development of a model protocol able to facilitate the investigation of microbubble 
properties and transfection outcome. 
The first aim of the project was to develop a fixed protocol, in which changes could 
be investigated for their effect on both microbubble properties and transfection success. 
Currently the Model Protocol, described in Chapter 3, consists of optical examination of 
microbubble formulation to obtain population statistics and environmental stability; bulk 
suspension acoustic characterisation of the scattering, attenuation and stability behaviour 
of microbubbles; and the transfection ability of these microbubbles in vivo. Chapter 6 began 
work on adding fluorescence spectroscopy to the protocol for the purposes of investigating 
DNA loading on microbubbles. 
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 Needle gauge affects microbubble populations 
In vitro work in Chapter 4 demonstrated that the needle gauge of a syringe affects 
the microbubble population, particularly the concentration. This finding is in close 
agreement with related literature[265, 268]. 
 Needle gauge affects transfection success 
In vivo work in Chapter 4 demonstrated that the needle gauge of a syringe affects 
the transfection efficiency of UMGT. Linked with the previous finding, it was concluded that 
as a result of needle gauge driven destruction, less microbubbles are available for 
transfection reducing the effectiveness. The recommendation is to use syringes with the 
largest possible needle gauge appropriate for the model organism. The findings are also in 
agreement with previous work on concentration[97, 98], but represent a novel investigation 
into an untested parameter. 
 Albumin shell component has an effect on microbubble properties and transfection 
In Chapter 5, it was demonstrated that by changing the concentration of albumin 
used in microbubble manufacture, microbubbles with differing acoustic and stability 
properties could be produced with a resultant effect on transfection.  
 Dextrose shell component has an effect on microbubble properties and transfection 
As with the previous finding, changing the initial concentration of dextrose resulted 
in microbubbles with markedly different acoustic, stability and transfection properties. A 
link between microbubble acoustic properties and transfection has not been demonstrated 
before in the literature. 
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 Shell components of albumin dextrose microbubbles can be optimised for 
transfection 
The previous findings suggest there is significant improvement to be gained from 
optimising the initial ingredients of a microbubble formulation. The recommendation from 
this work is to produce stable microbubbles with strong acoustic properties, which appear 
to be important for transfection success. It is suggested from this work that this can be done 
with an increase of dextrose and a decrease of albumin. 
 Fluorescence spectroscopy can be used to determine plasmid loading 
In Chapter 6, it was demonstrated that fluorescence techniques can be used to 
identify and quantify plasmid loading. The work is still preliminary and requires further 
calibration experiments to get fully quantitative information, but it should integrate with 
the Model Protocol and provide another tool for microbubble characterisation. 
 A novel microbubble produced from albumin, dextrose and glucosamine 
In Chapter 6, a novel microbubble was produced using two sugar moieties, dextrose 
and glucosamine. To the author’s knowledge, the use of multiple sugars in an albumin 
microbubble has not been demonstrated before in the literature. The microbubble has also 
been shown to be capable of DNA loading. 
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7.2. Key Discussions 
The primary aim of this project was to identify key factors affecting UMGT. In 
Chapter 3, a Model Protocol was described which could accomplish this task. It combined 
acoustic interrogation with optically measured population statistics of microbubbles, and 
attempted to link these characteristics with in vivo transfection success, using a fixed UMGT 
model. In the past, focus on microbubble acoustics has been primarily designed to address 
the method of transfection; stable cavitation or inertial cavitation[85, 142, 337]. These studies 
have focused on adjusting the acoustics required to elicit a particular microbubble response, 
rather than investigating the response of a microbubble at a particular frequency. The 
importance of these studies should not be dismissed though; understanding the mechanism 
of transfection has had important consequences regarding the choice of acoustic setup and 
further optimisation. However, by not investigating the microbubble acoustic differences, 
other important factors might have been missed. Some groups do now include some 
acoustic characterisation work as part of their investigations into novel microbubble 
formulations, particularly the polymeric microbubble groups[190, 267, 315]. The work conducted 
in the Netherlands using the Brandaris 128 camera has also encouraged the collection of 
acoustic data which can be directly correlated with microbubble behaviour at diagnostically 
relevant ultrasound frequencies[92, 194, 208, 338]. However, acoustic characterisation, even of 
novel formulations, is still not the norm[56, 171, 308]. 
However, there are practical considerations that might prevent such an endeavour. 
Setting up an acoustic rig to investigate acoustic behaviour is not a trivial task and requires 
considerable expense. The acoustic machines used for transfection may not be appropriate 
for acoustic work due to being incapable of either collecting scatter data, e.g. the Sonitron 
257 
 
range (Artison Corp., Inola, OK, USA), or providing raw data, e.g. Acuson Sequoia (Siemens). 
An understanding of the physics is also necessary to obtain the most from any acoustic 
setup, particularly in the design of the interrogation pulse. In instances where such facilities 
are not available, collaboration should be considered. Again, the Netherlands group is worth 
mentioning as several different research groups have used their existing high speed camera 
and acoustic set up for interrogation of microbubbles. Our own group has also been 
involved in collaborations with other London based groups, providing our expertise and 
protocols for use with novel microbubble formulations[339, 340]. As shown by this project, 
there are benefits to acoustic characterisation; in Chapter 5, a link was demonstrated 
between the acoustic attenuation of a microbubble and its transfection performance. 
Optimisation of the acoustic characteristics of a microbubble is typically done to improve 
imaging strategies[213, 227, 341]. It is possible that the results from previous imaging 
optimisation studies could be applied in future for transfection optimisation. 
There are limitations to the bulk acoustic set up though. In Chapter 5, the 
microbubble formulations being compared did not have the same size distributions. The size 
of a microbubble has a strong effect on its acoustic properties[263, 342, 343]. The variation in 
size distribution therefore makes it difficult to interpret the bulk acoustics. As discussed in 
Chapter 3, methods to minimise this effect included gas concentration normalisation and 
broadband pulses. This has given us results which are likely related to shell material 
properties only, however a further way to confirm these differences is using single bubble 
acoustics. The high speed camera set up used by the Netherlands group is of this type[344] 
and is useful for investigating microbubble behaviour[92, 194, 208, 338]. Other set ups have also 
been investigated[343]. This type of setup is also non-trivial and suffers from a low signal to 
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noise ratio due to the relatively weak acoustic signature of a single microbubble, however 
the effect of microbubble size can be isolated, allowing the material properties to be 
examined[190, 208]. The addition of this technique to the Model Protocol is further discussed 
below, in Future Directions. 
In Chapter 4, it was demonstrated that needle gauge has a significant effect on 
transfection with SonoVue microbubbles. The suggested cause was a decrease in 
microbubble concentration after needle passage due to shear stress. Shear stresses and 
their effects on microbubbles are commonly discussed in the literature, however this is 
primarily concerning adherent microbubbles in flow conditions or the effect on cells by 
microbubbles[140, 325, 345]. The effect of shear stress on microbubbles in a needle environment 
is discussed in the two publications[265, 268]. In the Barrack and Stride (2008) paper, the shear 
stresses are modelled in a similar manner to the work presented in the discussion of 
Chapter 4, and are hypothesised to be the primary cause of destruction during microbubble 
administration. The authors also recommended that “current procedures should be 
reviewed, particularly for therapeutic applications.” The Talu et al. (2008) paper also ends 
with a warning that “researchers… should pay specific attention to the injection conditions… 
to avoid deleterious effects on the microbubble contrast agents and to maintain 
experimental consistency.” 
However, descriptions of the needle gauge used to deliver microbubbles systemically 
is rare in the literature and it is unlikely that much consideration is given to the choice[99, 232, 
241, 244]. It should be said though, that guidelines for tail vein injections in mice recommend 
the use of needles of less than 26G for animal welfare reasons (information from the 
National Cancer Institute IV Injection Recommendations in Mice). Insulin or Tuberculin 
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syringes are popular due to their integrated needle design, small volume (<1 mL) and high 
gauge (27G or 29G)[90, 231, 299]. As demonstrated by the work in this project, this can cause a 
reduction in transfection. The progression of UMGT to clinical relevance is hampered by low 
transfection efficiencies and this simple improvement to a design would be trivial to 
integrate into any set up using preclinical mouse models. It is the recommendation of this 
work that investigators should strongly consider their injection protocol for both imaging 
and therapeutic strategies. 
It is here that a UK researcher may run into difficulties. The Terumo SurSaver 25G 
syringe used in this project is, at present, not marketed in Europe and was provided only as 
a sample pack from Terumo Europe upon request. Currently there is only one syringe with 
an integrated 25G needle available in the UK; the VanishPoint™ syringe marketed by G+N 
Medical. These, however, have a needle retraction system and a larger dead-space than a 
typical integrated needle system, which may make them impractical to implement in a 
UMGT set up. In the USA, integrated 25G needle syringes are purchasable and would be a 
simple improvement in any UMGT set up.  
In Chapter 6, a novel microbubble formulation which binds plasmid DNA was 
developed to investigate the effect of co-localisation of plasmid at the treatment site. 
Alteration of albumin microbubbles is occasionally performed to improve their stability or 
imaging performance[213, 219, 227], however only one previous attempt has been made to 
improve the DNA loading capacity[267]. In that study, a cationic polymer was first loaded onto 
the negatively charged microbubble, followed by loading of the negatively charged plasmid, 
effectively making a multi-layered microbubble. While loading appeared improved over 
non-cationic microbubbles, the polymer used was non-biodegradable raising safety 
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concerns. Additionally, the polymer could become “unstuck” from the microbubble yet 
remain complexed with DNA under certain conditions, nullifying the point of the loaded 
microbubble. To physically disrupt the complex, 5 M NaCl had to be used. As transfection 
experiments were not performed it is difficult to be sure that the plasmid would be 
effectively released after entering the target cell.  
The proposed microbubble in this project should not have such issues. Firstly, 
glucosamine is a dietary sugar with no safety indications and is biodegradable. Secondly, the 
interaction between glucosamine and DNA is not as strong; in our work, only 0.6 M NaCl 
was required to disassociate DNA from the microbubble shell and this is likely to undergo 
optimisation to reduce fluorescence artefacts. Thirdly, it is anticipated that glucosamine will 
react with albumin to form covalent bonds. This should prevent glucosamine from detaching 
from the shell, ensuring that plasmid remains complexed with the microbubble. As cationic 
lipid microbubbles tend to show improved transfection profiles compared to neutral 
microbubbles[286], an improvement in albumin microbubble transfection is expected in 
future experiments. Plasmid loading in albumin microbubbles has never been tested in vivo 
and should highlight another key factor in transfection. 
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7.3. Future Directions 
The work in this project has helped to highlight certain microbubble parameters and 
methodological practices which have a strong effect on transfection, but there still exist a 
number of potential factors which may affect UMGT success. 
Chapter 3 includes a lengthy discussion about the potential sources of variation in 
the Model Protocol and their effect on transfection. Whilst some are specific to the set up 
used here, there are a number which could be applicable across the field. For instance, it 
was seen in this project that the angles of the syringe prior to passage had a noticeable 
effect on the degree of destruction seen in microbubble formulations. In Chapter 4.3.1., 
data is presented which demonstrated how microbubbles are destroyed by needle passage 
when the syringe is handled in a similar manner to the in vivo experiments. The preliminary 
experiments investigating this lacked the handling step and involved aspiration of the 
solution immediately followed by ejection over 5 to 10 seconds. Following this method, the 
microbubbles showed very little change in concentration or size distribution. Syringe 
handling prior to injection appears to be an important factor in microbubble destruction. 
Although larger gauges appeared to mitigate this effect in vitro, the experiments followed a 
strict timing protocol. For in vivo experimentation, timing is dependent upon the physical 
conditions associated with each mouse, e.g. time to remove air bubbles from syringe, 
placement of needle into tail vein, etc., which will likely have some effect on transfection. A 
thorough investigation into how syringe handling affects microbubbles may not perhaps be 
ground breaking science, but the results could be vital in improving transfection and, most 
importantly, reducing variation. 
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It was also noticed in Chapter 4.3 that passage through 27G needles caused no 
significant damage to microbubbles, yet resulted in a decrease, albeit not significant, in 
transfection. It was hypothesised that other forces present during an in vivo injection may 
be causing further destruction or that stability of the microbubble was affected but not 
observed under optical examination. To investigate the effect on stability, microbubbles 
could be examined at multiple time points after needle passage to determine if there is an 
effect on microbubble collapse over time which may also be responsible for lowered 
transfection. It is also possible that needle passage affects a microbubble’s response to 
ultrasound, which could affect its transfection performance. The current acoustic 
characterisation techniques used in the Model Protocol could be used to check for any 
changes in acoustic behaviour after needle passage. 
Checking for other forces present during an in vivo injection is more complex. To the 
author’s knowledge there are no appropriate simulation models for the intravenous 
injection environment, although there may be an applicable and adaptable model for 
industrial applications and situations, e.g. fuel injection, gas assisted injection moulding, etc. 
To test such a model, a phantom could be constructed using cellulose tubes of size similar to 
that of the tail vein of a mouse (~500 µm) using a syringe pump to provide flow. Needle 
injections of a microbubble solution into the tubes could be performed and flow collected to 
determine needle-driven microbubble destruction during injection. To account for dilution 
by flow, a second measurable inert compound, e.g. plasmid or a coloured dye, could be co-
injected for normalisation of microbubble destruction. To account for microbubble 
destruction caused by the tube, control experiments without injections could be performed 
using a flow with added microbubbles to measure destruction caused by flow through the 
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tube. This phantom set up could be used to investigate the effect of tube size, flow velocity, 
syringe handling and injection speed on microbubble dose. It would also provide 
experimental results to validate any computer model. 
The notable unfinished part of this work is the DNA loading investigation. The 
preliminary experiments demonstrated that a novel microbubble formulation could be 
produced from albumin, dextrose and glucosamine. However, the formulation had poor 
batch control with high variability between samples. As discussed in Chapter 6, 
improvements in the maintenance of the sugar stock solution were needed, along with a 
monitoring system to check solution stability. Once completed, the microbubble can then be 
investigated under the Model Protocol. However, most importantly, its DNA loading 
capacity versus a non-glucosamine microbubble needs to be investigated. If there is no 
difference between the loading capacities then further refinement of the microbubble 
formulation is required to produce an increased loading effect. There is also interest in 
utilising the DNA-loading protocol to investigate differences between commercial 
formulations, where differences in transfection have been previously noted[98, 148, 157]. 
One previously identified desirable microbubble characteristic is stability[98]. In this 
project a similar trend was identified; stable microbubbles were required for effective 
transfection (Chapter 5.3.). Increasing dextrose concentration appeared to be the simplest 
method to improving transfection, however there may be safety considerations if 
transferred to a clinical setting. Although it is hypothesised that the sugar is incorporated 
into the shell of the microbubble, there will likely be some left in the solution. High dextrose 
solutions are hypertonic and can be irritating to blood vessels when injected systemically[346] 
(personal correspondence Dr R. Malik), and are currently used for prolotherapy to cause 
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minor damage in muscle to encourage repair or strengthening[347, 348]. Additionally, in vivo 
degradation and removal pathways for glycated albumin may not be able to cope with the 
amount and degree of denaturation of the microbubble shells[349, 350]. For polymer based 
microbubbles, current focus is on the use of the biodegradable fluorinated poly(L-lactic acid) 
(PLLA)[190]. Fluorination is achieved by capping the PLLA compound with pentadecafluoro-1-
octanol (PFO) which increases the hydrophobicity of the shell, improving stability and 
resistance to water penetration[194]. Albumin can be electrostatically complexed with similar 
fluorinated compounds[351], which may improve the stability of the microbubble without 
having to use increased dextrose. However, the compound used, perfluorooctanoic acid, is 
known to be toxic and carcinogenic to rodents, although there is little data for its effect on 
humans and there is currently no regulatory limit on human exposure[352, 353]. A preliminary 
study to investigate its effect on albumin microbubble stability might be of benefit in 
determining its potential usefulness in UMGT. 
Microbubble acoustic behaviour was identified in this project as a key factor on 
UMGT success. Increases in a microbubble’s bulk attenuation and scattering behaviour 
correlated with an increase in transfection. However, these findings have not been 
optimised, as this was not the primary aim of this project. Additionally, with only two 
sample groups per condition, there may be other factors at work which are not evident. 
Further alteration of the dextrose and albumin content of a microbubble could help further 
identify any other key factors and confirm the finding that the microbubble bulk acoustic 
properties are key factors in transfection. This would also help optimise the 
albumin/dextrose microbubble, potentially creating a microbubble with clinically relevant 
transfection efficiency. 
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The acoustic behaviour could also be investigated more thoroughly using a single 
bubble acoustic approach. As microbubbles are typically used as a bulk suspension for 
imaging or transfection, measuring the acoustic response of a bulk suspension is an 
appropriate method to investigate their acoustic behaviour. However, other properties 
which may be of interest, such as material properties, or resonant size, are difficult to 
extract from these bulk measurements due to the size distribution of the microbubble 
suspension. As seen in Chapter 5, comparison between formulations is complicated when 
there is variation in size distribution. Single microbubble acoustics interrogates individual, 
sized microbubbles. This allows analysis of the how the material properties of different 
formulations affect acoustic properties independent of size distribution. However, single 
microbubbles have very weak acoustic signature, requiring a sensitive setup which will 
suffer from a poor signal to noise ratio. Results can also be highly variable, requiring a large 
number of repeats to provide accuracy. Still, a single microbubble acoustic approach would 
be useful to confirm the differences between the albumin/dextrose formulations in Chapter 
5 and could be implemented within the Model Protocol when size distribution variation is 
an issue for novel formulations.  
There are a couple of further points to make regarding the future of the field. The 
first is a point about clarity. Currently there is no uniform title for the technique. In this 
work, I have referred to the technique as ultrasound and microbubble mediated gene 
transfection, giving the UMGT acronym. Others refer to the technology as microbubble 
ultrasound (MBUS) or ultrasound targeted microbubble destruction (UTMD). Sonoporation 
is also still occasionally used and ultrasound-mediated microbubble destruction has been 
seen. The Wikipedia article titles the technique as Acoustic Targeted Drug Delivery (ATDD), 
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although this appears to apply primarily to non-microbubble applications and all the cited 
sources and images are from a single research team. Instead of transfection, others use the 
term gene transfer, gene delivery or gene therapy to describe the process. None of these 
terms are technically wrong and this may be a trivial issue, but the multitude of terms and 
names does weaken the field by hampering research efforts and understanding, particularly 
for non-specialists. Other ultrasound techniques are typically described by one term making 
it simple for clinicians to explain and for patients to research, e.g. high intensity focused 
ultrasound (HIFU), lithotripsy, etc. This issue may be resolved when the technique reaches 
clinical relevance but it would be advantageous to finalise a term sooner rather than later. 
The second point is an opinion on the field. As mentioned several times throughout 
this thesis, knowledge of the key factors and their optimisation is lacking. Unfortunately, 
addressing this issue still does not seem to be paramount. There are still papers coming out 
which have taken the technology and applied it directly to treatment of a preclinical model. 
This work should not be dismissed as unhelpful as it does provide further demonstration of 
the potential of the technique, however the potential of the technique has been shown; it 
now needs proper controlled optimisation and an understanding of the mechanism of 
improvement.  
There are areas of the field that are driven strongly by optimisation. The 
development of targeted contrast agents is a rapidly advancing area with research focused 
on improvement by tweaking of formulations, targeting ligands, imaging strategies, etc. This 
may be in part due to commercial interests, particularly from Bracco and VisualSonics, or 
perhaps recognition that clinical relevance is attainable; a feeling undoubtedly reinforced by 
the recent phase 0 clinical trial of a targeted agent.  
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Fortunately, interest in UMGT is still strong and its potential for safe, targeted 
treatment of genetic disorders is undiminished. Clinical relevance will be achieved through 
increased understanding and optimisation of the technique. 
 
7.4. Conclusion 
In this project, I have attempted to identify key factors involved in UMGT that are 
currently hindering the progression to clinical relevance. To do so, I have designed a Model 
Protocol capable of characterising several properties of a microbubble formulation; their 
acoustic properties, their population statistics, their stability, and their transfection ability. 
By introducing changes to the procedure, several key factors have been identified. Firstly, 
the needle gauge used in preclinical transfection experiments has a significant impact upon 
the microbubble population during injection, causing a reduced microbubble dose and 
reduced transfection. Secondly, the formulation of an albumin microbubble has a strong 
effect on its acoustic and transfection properties. Thirdly, there is a strong link between the 
attenuation property of a microbubble and its transfection efficiency. Fourthly, novel 
microbubble formulations with an affinity for DNA can be produced without potential 
toxicity or safety issues. Finally, the Model Protocol can be easily improved with new 
techniques, increasing its potential as a tool for future work. 
The key factors identified here are simple to either implement or optimise. It is my 
hope that this work will help other groups in this field to improve their own setups, increase 
the interest in the field, provide some reasoning behind low transfection efficiencies, and 
ultimately speed up the transition of this technique to clinical relevance.  
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9. Appendix 
9.1. Characterisation of 15L8 linear array probe 
9.1.1. Introduction 
A microbubble’s behaviour under the influence of ultrasound is strongly determined 
by the frequency and amplitude of the acoustic wave. It is therefore important to know the 
“true” acoustic wave being transmitted. In many diagnostic systems, there is often a 
mismatch between the settings chosen by the user and what the machine actually 
transmits. This is done in part for simplicity, as the beam forming performed by a diagnostic 
machine from their multiple element arrays cannot always be simply described; and safety, 
with the indices of TI and MI being overestimated as the values displayed are based on 
formulas which may not take into account any tissue specific issues, e.g. bone or air-filled 
spaces. Whilst this is accepted practise for diagnostic purposes, knowing the exact 
parameters of the transmitted wave is important in determining the response of a 
microbubble and its transfection potential. 
The transducer probe used in this work, the 15L8 linear array of the Acuson Sequoia, 
has previously been characterised by Dr Julia Alete and published in the literature as part of 
her thesis[123]. As such, characterisation of the probe was not performed in this project. 
Instead, parts of her work have been selected and presented here to provide details about 
the probe used in this project. The transmitted power and frequency were characterised to 
determine the true MI of the probe, in comparison to the value set on the machine. 
Additionally, the individual pulses were examined to calculate the duty cycle, i.e. the time 
the ultrasound is transmitting compared to the time the ultrasound is off. 
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9.1.2. Methodological Particulars 
In a water bath, the 15L8 ultrasound transducer of the Siemens Acuson Sequoia 
ultrasound scanner and a membrane hydrophone (Marconi Research Centre, UK) were 
aligned 1 cm apart. The focus of the ultrasound beam was set at 1 cm. Ultrasound pulses 
transmitted by the scanner were detected using the hydrophone and data was recorded 
using a digital oscilloscope (TDS7154, Tektronix, Beaverton, Oregon, USA). Data was 
recorded as mean peak frequency and transmitted pressure. 
As mentioned, this work was performed by Dr Julia Alete. The above is a description 
of the method she employed. It should be noted that the ultrasound settings used are 
specific to her work and some differences exist between them and the work presented in 
this thesis. In particular, the ultrasound beam was set to a focal depth of 0.75 cm in this 
project, compared to the 1 cm used in Dr Alete’s work. This affects the maximum MI 
transmitted by the machine, with a 0.75 cm focal depth allowing a maximum of 1.6 MI only, 
in comparison to 1.8 MI for 1 cm.  
Table 9.1. Measurements of the frequency (f) and peak negative pressure (PNP) of the 15L8 
linear array probe as measured by a membrane hydrophone placed 1 cm away. Adapted 
with permission from Alete (2008)[123] 
Set MI Mean f (MHz) PNP (MPa) Measured MI 
0.47 6.1 0.38 0.16 
1.00 6.1 0.93 0.38 
1.6 6.1 1.54 0.63 
1.8 6.1 1.73 0.71 
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9.1.3. Results 
As expected, the measured values of frequency and power result in an MI which is 
significantly different to the value described by the machine (Table 9.1). At a machine 
setting of 1.6 MI, the peak negative pressure was 1.54 MPa at a frequency of 6.1 MHz, 
resulting in a “true” MI of 0.63; less than 40% of the stated value.  
On a diagnostic ultrasound machine, a B-mode image is constructed out of multiple 
pulses swept over the region of ultrasound insonation. Due to beam forming, a region of 
interest is struck by a series of pulses of different amplitudes to form a single image. Dr 
Alete determined that each sweep contained 6 individual pulses with a transmit amplitude 
over 50% of the maximum (Fig. 9.1A). Each of the 6 pulses had an amplitude greater than 
50% of the maximum for 0.5 µs (Fig. 9.1B). The scanner itself has an image refresh rate of 70 
Hz, i.e. a new image is produced 70 times a second. Using these numbers it is possible to 
calculate the duty cycle of the pulse using the following equation: 
                        
Equation 9.1 
Where     is the number of pulses per sweep with greater than 50% total 
amplitude,     is the length of time a pulse has greater than 50% total amplitude, and   is 
the sweep repetition frequency. The duty cycle for the ultrasound machine at 1.8 MI is 
0.021%, i.e. the pulse is over 50% total amplitude for 210 µs every second. 
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a)  
b)  
Figure 9.1. Oscilloscope screen captures of ultrasound pulses from the Siemens Acuson 
Sequoia as detected by a membrane hydrophone, showing a) ultrasound pulses transmitted 
during one image forming sweep at 1.8 MI and b) a close up of a single pulse from a). 
Arrows indicate positions of 50% maximum amplitude applied for the measurements of 
number of pulses and time of an individual pulse. Reprinted with permission from Alete 
(2008)[123]. 
304 
 
9.1.4. Discussion 
The results obtained by Dr Alete show that the settings chosen by the user on the 
Acuson Sequoia do not necessarily relate to the actual transmitted pulse. As mentioned, this 
is a common occurrence on diagnostic ultrasound machines for reasons of simplicity and 
safety however, these factors become important when considering the use of microbubbles. 
Microbubble behaviour is strongly dependent on the frequency and power of an acoustic 
pulse[186, 261, 274] so knowing exactly what is transmitted from the transducer can be of use in 
determining the bubble response. 
There are some differences between the ultrasound settings used for 
characterisation of the transducer and the UMGT procedure in this project. The change in 
focal depth affects the maximum output power of the transducer. At a focal depth of 0.75 
cm, the maximum power output according to the Sequoia is 1.6 MI, compared to 1.8 MI at a 
focal depth of 1 cm. It is possible that a setting of 1.6 MI, the transducer transmits a 
different “true” peak negative pressure depending upon the set focal depth. However, if 
there is a difference, it is likely to be quite small, as the 1.6 MI will be related to a PNP value 
approximately similar to that measured for a 1 cm focal depth. Additionally, the ultrasound 
settings used throughout this project have remained constant so a slight discrepancy from 
the true value is not important. Finally, these values have been measured in a water bath. 
They are likely to be very different from the pressures experienced in vivo at the focal depth 
due to attenuation from overlaying tissue and microbubbles. As such, these values are 
primarily here an indication of what the approximate MI of the transmitted wave could be, 
in comparison to what is displayed by the ultrasound machine.  
